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Inflammatory markers are non-specific blood tests including C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR) and plasma viscosity (PV). These 
tests are commonly used by general practitioners (GPs) as an aid to the diagnosis 
and monitoring of inflammatory conditions including infections, autoimmune 
conditions, and cancers. Previous research into inflammatory markers has mostly 
been based in secondary care and explored relationships with single disease 
outcomes. This means it is less useful for GPs, who often use inflammatory 
markers in patients with undifferentiated symptoms who have multiple possible 
disease outcomes. There is also a lack of information about how GPs 
communicate the rationale for testing and the meaning of results with patients. 
My research addresses these evidence gaps.  
Firstly, I conducted a series of quantitative studies using electronic health records 
of nearly 200,000 patients from the Clinical Practice Research Datalink (CPRD). 
The aim was determine the epidemiology and diagnostic utility of inflammatory 
marker tests in primary care for relevant disease: defined as any infection, 
autoimmune disease or cancer. Secondly, I conducted a qualitative study, 
completing a total of 80 interviews with patients before and after receiving 
inflammatory marker results, and with the GPs who requested these tests. The 
aim was to explore the meaning of inflammatory markers for doctors and 
patients.  
I have shown that, contrary to GPs perceptions, inflammatory markers are not a 
useful ‘rule-out’ test: in fact they miss around half of relevant disease in primary 
care. Testing more than one inflammatory marker simultaneously does not 
increase diagnostic accuracy. Although these tests are often used for reassurance, 
patients with ongoing symptoms perceived that normal results were unhelpful. I 
identified a lack of shared understanding and multiple barriers to shared 
decision-making. Results will be of interest to patients, GPs and commissioners 
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CHAPTER 1.  BACKGROUND 
 Introduction 
This thesis explores the diagnostic utility and clinical practice of inflammatory 
marker testing in primary care, using a mixed methods approach. Inflammatory 
markers are non-specific tests which are commonly used in primary care as an 
aid to the diagnosis and monitoring of inflammatory conditions including 
infections, autoimmune conditions, and cancers.  
My interest in this research area has arisen from my own clinical experiences as a 
General Practitioner (GP), and the challenges I have experienced when using 
inflammatory marker tests, including uncertainty about when to test, how to 
interpret results, and how to share these with patients. In 2012 I was first author 
of a British Medical Journal (BMJ) review article on inflammatory marker testing; 
whilst I found many studies of inflammatory marker tests from secondary care, I 
was surprised by the lack of research in primary care settings.(1) Most of the 
published research focussed on single disease outcomes, which did not reflect 
the reality of my experience in primary care, where patients with 
undifferentiated symptoms had multiple possible disease outcomes. To explore 
the way inflammatory markers were really being used in primary care, I 
conducted a qualitative research project, interviewing primary care clinicians 
about their experiences of inflammatory marker testing in primary care, during 
my pre-doctoral Academic Clinical Fellowship.(2) The issues arising from these 
qualitative interviews were used to help generate the research questions for this 
thesis. In particular, GPs described using inflammatory markers in patients with 
non-specific symptoms as a generic test to rule-out serious underlying disease 
and to provide reassurance to patients and GPs. This practice was largely 
unsupported by evidence and guidelines. GPs perceived that normal 
inflammatory markers were useful for reassurance, but there was a lack of 
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evidence on patients’ perspectives of testing. GPs described their decision-
making for inflammatory marker testing as encompassing multiple non-medical 
reasons for testing, and their accounts of diagnostic decision-making and 
information sharing did not reflect the ideals of shared decision-making. 
I therefore set out to look at inflammatory marker testing using a different 
approach to previous researchers. Firstly, I wanted to explore the diagnostic 
accuracy of inflammatory markers for overall relevant disease including 
infections, autoimmune conditions, and cancers, to determine their utility as a 
non-specific ‘rule-out’. Secondly, I wanted to use qualitative methods to explore 
the communication and shared understanding of inflammatory marker tests 
between doctors and patients.  
 
 What are inflammatory markers? 
Inflammatory markers are blood tests which are commonly used in clinical 
practice to detect inflammation in the body, which may occur due to infections, 
autoimmune conditions, or some cancers. The three main inflammatory markers 
used in primary care are C reactive protein (CRP), erythrocyte sedimentation rate 
(ESR) and plasma viscosity (PV). Procalcitonin is a newer inflammatory marker, 
which is now used routinely in hospital and A+E settings, but has yet to be 
introduced to routine primary care in the UK. For the purposes of this thesis, I 
focus on the three main inflammatory markers: CRP, ESR and PV.  
The ESR is the oldest of these three inflammatory markers and is measured as the 
distance in millimetres that erythrocytes settle in anticoagulated whole blood in 
one hour. Therefore, it is not a measure of a single acute phase protein, and is 
dependent on a number of other factors, including anaemia or polycythaemia, 
delays between sample taking and lab processing, medications (e.g. oral 
contraceptive pill and heparin), sex, age, pregnancy, ethnicity and obesity.(3) As 
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a result of these limitations, many laboratories and guidelines are moving away 
from the use of ESR, except in a limited number of specific conditions.(4)  
Plasma viscosity is measured by calculating the force needed to send plasma 
down a thin tube in a given time, which is associated with the amount of protein 
in the blood. Thus, it is raised with elevations in acute phase proteins and with 
increased paraproteins in the blood produced by certain tumours. It can be 
considered technically superior to ESR, being unaffected by anaemia or 
polycythaemia, or by delays between sampling and measurement, and has 
results which are independent of age or sex.(5) However it can be technically 
challenging to perform and is only offered by some laboratories in the UK. Many 
of the factors that determine ESR and plasma viscosity have long half-lives, so 
elevated results may be due to an event which happened weeks to months 
previously and may have resolved at the time of measurement. This makes them 
less suitable for assessing acute changes and monitoring response to treatment 
and means that results may be difficult to interpret.   
CRP is a pentameric protein molecule first described in 1930, which is produced 
by hepatocytes, and named due to its reaction with pneumococcal C-
polysaccharide.(6) CRP binds with phosphocholine, then interacts with antibody 
receptors on phagocytic cells to facilitate phagocytosis. CRP therefore has a role 
in clearing pathogens in infection, plus damaged, necrotic or apoptotic cells from 
other types of inflammatory response. CRP has a more rapid response and 
shorter half-life than ESR and plasma viscosity, allowing it to be used to detect 
and monitor the progress of systemic inflammation in the body.(7) In ostensibly 
healthy subjects, CRP tends to increase slightly with age,(8) and is also increased 
with obesity.(9)  
Most inflammatory marker tests are performed on venous blood samples in 
laboratory settings; however, CRP tests are also available as point of care tests, 
using finger-prick blood samples. Point of care CRP tests are increasingly 
available in the UK, and offer the potential to provide rapid feedback, allowing 
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test results to inform immediate clinical decision-making within a general 
practice consultation.  
 
 Epidemiology of inflammatory marker 
testing 
 Temporal trends in inflammatory marker 
testing rates 
Rates of inflammatory marker testing in primary care are rising in the UK. A 
recent paper by O’Sullivan et al analysed all tests conducted between April 2000 
and March 2016 in the Clinical Practice Research Datalink (CPRD), a large 
database covering about 7% of the UK population.(10) They found primary care 
CRP testing rates showed a consistent linear increase from 2000-2015 from 91.6 
tests per 10,000 age and sex adjusted person years in 2000 to 924.4 tests per 10,000 
person-years in 2015, an average increase of 16.5% per annum. Only five blood 
tests - vitamin D, ferritin, troponin, folate and B12 - had higher annual increases 
than CRP. Use of ESR also increased, though less steeply, from 501.1 tests per 
10,000 person years in 2000 to 1027.2 per 10,000 in 2015, an average annual 
increase of 4.7%. Use of plasma viscosity was not examined in this study, 
although another smaller study using CPRD did examine plasma viscosity, 
which increased by 31% from 129 to 170 tests per 10,000 person years between 
2005 and 2009.(11)  
These large increases in testing rates seen over time have not been matched by 
concomitant rises in rates of diagnosis of disease. Presumably therefore testing is 




 Variation in inflammatory marker testing rates 
Variation in rates of inflammatory marker testing between GP practices was 
examined in a linked paper by O’Sullivan et al, using a subset of the same 
dataset.(12) They calculated a co-efficient of variation for 44 primary care tests to 
identify variation in testing rates between GP practices. CRP was one of only 
seven tests which showed both high variation in testing rates and high use. The 
observed differences could potentially reflect different rates of pathology in 
different practices, which could warrant different levels of testing. However, the 
differences persisted after adjustment for practice level age distribution, sex and 
deprivation. Residual confounding due to unmeasured differences between 
practices could be an issue, however it seems unlikely that this accounts for all 
the remaining variation seen. Some of this variation is therefore likely to reflect 
differences in clinicians’ habits and thresholds for testing. This is in keeping with 
my pre-doctoral qualitative research, in which clinicians reported they felt 
uncertain when to test inflammatory markers, with decisions about testing based 
on experience and habit rather than guidelines or evidence:(2)   
With GPs, a lot of things are oh well it is what I do and it’s what I have always 
done and erm it seems to work, so yeah I’ll just do it a bit more … so what we 
end up doing is kind of making it up.   
Another paper described the variation in the proportion of abnormal CRP and 
ESR test results, across practices in Oxfordshire in 2016.(13) This showed that the 
annual unadjusted proportion of abnormal CRP tests per practice varied from 
22% to 42%. For ESR the variation in proportion of abnormal results was greater 
still, varying from 12% to 41%. After adjustment for practice list size, age, sex and 
gender and index of multiple deprivation, twelve (17%) and seven (10%) 
practices were greater than 3 standard deviations below the mean proportion of 
abnormal test results for CRP and ESR respectively. This suggests that not only 
do rates of testing vary, but thresholds for testing vary between practices, with 
some practices testing behaviour yielding fewer abnormal results. This is in 
keeping with the hypothesis that high testing rates in some practices cannot 
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solely be explained by differences in rates of pathology. Similar variation in rates 
of inflammatory marker testing rates have been found in studies in Spain(14, 15) 
and Sweden.(16)  
 
 Potential harms of inappropriate testing 
A major limitation of the research described above is that none of it directly 
explores the ‘appropriateness’ of testing, by measuring reasons for testing and 
outcomes of testing. There is a long history of using geographical variation and 
between practice variation to highlight potential overuse and underuse of 
healthcare resources,(17) for example the NHS Atlas of Variation.(18, 19) Within 
this wider literature, factors predicting variation in testing rates have been 
extensively studied, both at GP practice level,(20) and also by looking at 
characteristics of clinicians which are associated with higher or lower rates of 
testing.(21) This is often interpreted as ‘unwarranted’ variation, however this 
evidence must be interpreted with caution, particularly if used for feedback to 
individual practices or clinicians, as there may be good reasons for variation in 
testing rates which are not measured or measurable. Nonetheless, the 
triangulation of evidence showing rising testing rates, variation in rates of testing 
and variation in rates of abnormal results, combined with qualitative evidence 
demonstrating uncertainty surrounding inflammatory marker testing,(2) all 
points to potential inappropriate use of inflammatory marker tests. 
If tests are used inappropriately, either through over-testing or undertesting, this 
influences the interpretation, and usefulness, of the results. This is because tests 
work in a Bayesian fashion. This means that the interpretation of any test 
depends on two things: the performance characteristics of the test itself and the 
subgroup of people it is performed on (the prior odds or pre-test probability of 
disease).  
No test is perfect - test accuracy is measured by two parameters: sensitivity or 
true positive rate, and specificity or true negative rate. These measures are 
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relatively stable. However, the clinically more important parameters - positive 
predictive value and negative predictive value, vary depending on pre-test 
probability.  
This can have counter-intuitive implications: for example – studies have shown 
that people with normal test results have an increased risk of cancer.(22) This is 
because the mere fact that a test has been conducted predicts cancer and this 
additional risk is only partly eliminated by a negative test result. The higher the 
pre-test probability of disease, the more likely it is that these false negatives will 
occur. Missed diagnosis of cancer is a particular concern, with much of the UK’s 
poor record in cancer outcomes blamed on diagnostic delays. If raised 
inflammatory markers are not investigated appropriately this may represent a 
missed opportunity for early diagnosis of cancer or other serious disease. 
However, conversely, if inflammatory markers have low sensitivity for cancer, 
and are used on those at high risk of disease, it is equally possible that false 
negatives could lead to false reassurance.  
Given the rising rates of testing, the opposite problem over-testing and false 
positives is more likely to be a concern.(23, 24) As testing rates increase, in lower 
risk populations, this leads to a reduction in the signal-to-noise ratio, leading to 
lower positive predictive values and increased false positives. These false 
positives may cause anxiety for patients, and may lead to further tests, 
appointments and referrals, in what Deyo has called the ‘cascade effect of 
medical technology’.(25) Recent estimates have suggested that more than half of 
abnormal results from laboratory tests ordered by family physicians could be 
false positives.(26) Although this concept of cascade testing has been around for 
decades,(25) it is rarely measured,(27) and the overall frequency and implications 
of cascade testing on primary care workload is unknown. My qualitative 
research showed that GPs perceive cascade testing to be a particular issue with 
inflammatory markers, because of the non-specific nature of these tests.(2) As 
well as patient harms, this could lead to increased workload for GPs(28) who are 
already overstretched.(29) The carbon footprint of pathology testing is also 
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significant,(30) and an increasing priority, given current targets for reducing 
waste in healthcare(31) and the NHS target to achieve net zero emissions by 
2040.(32)  
Although the unit cost of inflammatory marker tests is relatively low, overall 
costs of testing are considerable; in 2014 at North Bristol NHS Trust over 120,000 
primary care requests for inflammatory markers were performed at a cost of 
£177,000, for a population of 500,000. These costs do not include the substantial 
additional costs of phlebotomists’, GPs’ and patients’ time and the potential costs 
generated by further cascades of tests and follow up appointments.  
 
 Quantitative evidence of inflammatory 
marker test accuracy 
 Reasons for inflammatory marker testing 
Inflammatory markers are non-specific tests which detect inflammation in the 
blood but do not indicate the cause of this inflammation. Diseases with 
prominent activation of the inflammatory response fall into three main groups: 
infections, autoimmune conditions and some malignancies.  
Inflammatory markers can be measured by primary care clinicians for four main 
possible reasons:  
• Diagnosis of specific disease (see 1.4.2) 
• Monitoring of disease progression or treatment response (see 1.4.3) 
• Non-specific testing for systemic disease (see 1.4.4) 
• Testing to predict future outcomes or prognosis (see 1.4.5) 
Several studies, now decades old, have looked at the reasons for general 
practitioners using inflammatory markers. They found that inflammatory 
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markers were used for a range of indications, with about 44-47% requested for 
specific diagnostic purposes, 27-33% for monitoring disease, and 14-28% for non-
specific diagnostic purposes. (33, 34) Testing to predict future outcomes is mostly 
of research interest rather than having direct clinical implications but may have 
future implications for inflammatory marker testing rates and is therefore 
discussed briefly in section 1.4.5.  
 
 Testing for diagnosis of specific diseases 
I was first author of a literature review published in the BMJ in 2012 which 
summarised the evidence for using inflammatory marker tests in diagnosis.(1) 
Since this was published there has been a significant amount of further research, 
so I have updated the summary table from my BMJ paper to include more recent 
systematic reviews of the accuracy of inflammatory markers for diagnosis (Table 
1). Most of this evidence focuses on single disease outcomes, mostly infections, 
and the majority is based in secondary care; positive predictive values will be 
lower in primary care where disease prevalence is lower. I will consider this 
evidence in more depth in relation to the three main categories of disease below: 
infections, autoimmune conditions and cancers. These three categories of disease 
have been chosen as they were the main disease groups identified by my 
literature review of inflammatory marker testing.(1) The combination of 
infection, autoimmune conditions or cancers will be referred to throughout this 
thesis as ‘relevant disease’.  
 
Infections 
Most inflammatory marker research into infections uses CRP as the index test for 
detecting and monitoring acute infections, due to its shorter half-life compared to 
PV and ESR. In secondary care settings CRP has been studied as a diagnostic aid 
for multiple types of infection including endocarditis, meningitis, peritonitis, 
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sepsis, bone and joint infections, chorioamnionitis, post-operative infections, and 
more recently SARS-CoV-2 infections (Table 1). Many of these infective 
outcomes are relatively rare in primary care settings.  
Research in primary care settings has mostly focussed on the utility of CRP tests 
for the diagnosis of acute respiratory infection. Systematic reviews of diagnostic 
accuracy studies in primary care settings have been published for community 
acquired pneumonia (35) and acute sinusitis.(36) Inflammatory markers have 
also been studied in primary care settings to assess their diagnostic utility in 
predicting serious infection in children with a fever,(37) and to predict infective 
exacerbations of chronic obstructive pulmonary disease.(38) 
In these clinical scenarios, CRP has been found to have only modest diagnostic 
accuracy, which is generally insufficient to safely rule acute infection either in or 
out. As a result there has been significant interest in developing clinical 
prediction rules incorporating CRP test results with relevant clinical features, 
including prediction rules for serious infection in children with fever,(39) and 
community acquired pneumonia.(40) Clinical prediction rules for the diagnosis 
of community acquired pneumonia have been extensively investigated, with 
meta-analysis of individual patient data demonstrating improved discrimination 
using CRP tests in addition to symptoms and signs as measured by the area 
under curve (AUC).(41) The delay in obtaining the results of inflammatory 
marker test results if the specimen requires analysis off site contributes to slow 
uptake of these clinical decision rules in mainstream UK clinical practice. With 
point of care (POC) testing widespread in Europe, and entering clinical practice 
in primary care in the UK, this may lead to changes in the use of inflammatory 
markers in the future. 
The research into the diagnostic accuracy of CRP for community acquired 
pneumonia mostly uses radiological changes on chest x-ray as the reference 
standard; however clinical prognosis of acute respiratory infection is arguably 
more important, as antibiotics should ideally be targeted to those with the 
highest risk of complications, which may not correspond to radiological 
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features.(42) To address this, Bruyndonckx et al developed a clinical prediction 
rule for adverse outcome (defined as re-attendance in primary care or hospital 
admission) using symptoms, signs and tests in six European countries; the 
addition of CRP to the model based on symptoms and signs did not improve 
prediction.(43)   
Despite this, there has been significant interest in the utility of POC CRP tests to 
reduce primary care antibiotic prescribing rates, driven by concerns about rising 
rates of antimicrobial resistance. Multiple randomised controlled trials (RCTs) 
have been performed, with a 2014 Cochrane review concluding that use of POC 
CRP tests leads to overall reduction in antibiotic prescribing for suspected lower 
respiratory tract infections.(44) Similar reductions in antibiotic prescribing have 
also been demonstrated for infective exacerbations of chronic obstructive 
pulmonary disease.(45) The apparent contradiction between RCTs findings and 
diagnostic test accuracy studies may reflect the fact that point of care CRP tests 
exert some of their effect as a behavioural intervention to improve patients’ and 
doctors’ confidence in prescribing decisions. Longer term follow up of some 
RCTs has shown that this reduction in antibiotic prescribing with POC CRP 
testing wanes with time.(46) Qualitative studies have demonstrated a number of 
barriers to implementation(47) which may explain the lack of use of POC CRP 
testing in UK primary care, despite UK National Institute for Health and Care 
Excellence (NICE) guidelines suggesting GPs ‘consider’ their use in suspected 
community acquired pneumonia.(48)  
This thesis focuses on the overall utility of inflammatory markers for overall 
relevant disease, rather than strengthening this evidence base for specific 
infective indications. However, if (or when) point-of-care CRP tests become 
widely available in the UK they could end up being used for indications beyond 
those for which they have been evaluated. This has been demonstrated in 
Norway where GPs have been found to use point-of-care CRP tests for skin, 
digestive, ear, eye and ‘general unspecified’ symptoms.(49) Further research to 
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determine an optimal evidence-based approach to the interpretation and 
management of raised inflammatory markers is therefore timely. 
 
Autoimmune conditions 
Inflammatory markers are established first-line tests for a small number of 
autoimmune diseases. The classic conditions are polymyalgia rheumatica or 
giant cell arteritis. There are no specific serological tests for these conditions, so 
diagnosis is generally made on the basis of symptoms and signs of myalgia, 
headache and systemic features, alongside a raised inflammatory marker.(50, 51) 
Evidence mostly comes from secondary care settings, and generally requires a 
temporal artery biopsy as the reference standard, so patients evaluated would be 
likely to have more severe disease than primary care populations.(50, 51) Studies 
show that both ESR and CRP can sometimes be normal in polymyalgia and giant 
cell arteritis;(52, 53) UK guidelines therefore recommend both tests for 
diagnosis.(54) 
Diagnosis of inflammatory arthritis is another common clinical reason for 
inflammatory marker testing. NICE guidelines state that urgent referral of 
patients with clinical evidence of rheumatoid arthritis should not be delayed 
even if inflammatory marker tests are normal:(55) this is based on evidence that 
35% to 45% of patients with rheumatoid arthritis have normal inflammatory 
markers at diagnosis.(56)  
Inflammatory markers have been studied as an aid to diagnosis of inflammatory 
bowel disease; however, the newer test, faecal calprotectin, has largely 
superseded inflammatory marker blood testing in the diagnosis of inflammatory 
bowel disease and is now recommended as a first line test by NICE.(57) The 
NICE diagnostics guidance for faecal calprotectin concludes that CRP and ESR 
have poor sensitivity for inflammatory bowel disease and states ‘there therefore 





Cancer diagnosis in primary care can be challenging; many of the early 
symptoms are non-specific and can be difficult to differentiate from the 
symptoms of common benign conditions. GPs need to triage patients with low-
risk symptoms to identify those needing further investigations, using additional 
‘clues’ from history, examination and investigations.(58) One triaging tool 
increasingly used in clinical practice is inflammatory marker testing. These are 
often performed as a ‘rule-out’ test by clinicians trying to exclude serious 
underlying disease, including cancer.(2) This practice is largely unsupported by 
evidence and inflammatory markers are not recognised within current guidelines 
for cancer diagnosis. The main exception to this is multiple myeloma, with a 
recent large case-control study in primary care confirming the diagnostic utility 
of ESR and PV; CRP had lower diagnostic accuracy and was therefore not 
recommended by the authors.(59) This is reflected in the NICE cancer guidelines, 
which recommend ESR or PV as first line tests for suspected myeloma. Evidence 
for inflammatory marker testing in primary care for other types of cancer is 
limited, with case-control studies for pancreatic cancer,(60) bladder cancer,(61) 
renal cancer(62) and non-Hodgkin’s lymphoma,(63) showing associations, but 
with positive predictive values <1%; too small to be clinically useful. Cohort 
studies in the general population (irrespective of symptoms) have shown an 
association between CRP and risk of future cancer,(64) although not strong 
enough to be clinically useful for identification of symptomatic cancer. There 
have been no previous primary care studies to measure the predictive value of 
inflammatory markers for overall cancer diagnosis. Current NICE guidelines 
recommend urgent referral or investigations for anyone with a cancer risk of 
≥3%,(65) so even relatively low predictive values could potentially be clinically 





Table 1: Systematic reviews of the accuracy of inflammatory markers for 
diagnosis of specific conditions 
Target condition 
(test) 




and ENT clinics 
Systematic review (4 
reports of CRP/ESR; 789 
patients) 
CRP summary sensitivity 0.34 (0.21 to 
0.51), specificity 0.88 (0.79 to 0.94). ESR 
summary sensitivity 0.43 (0.29 to 0.58), 
specificity 0.83 (0.70 to 0.92) (36) 
Bacterial chest 






Systematic review (8 
reports; 1230 patients) 
Likelihood ratio of raised CRP 2.1 (1.8 to 
2.4); negative likelihood ratio 0.33 (0.25 
to 0.43).(35) Similar results in an earlier 
review (66) and a subsequent study.(67)  
Bacterial chest 




Systematic review (8 
reports; 1230 patients) 
Pooled odds ratio for raised CRP and 
bacterial infection 2.6 (1.2 to 5.6) (68)  
Infective exacerbations 
in patients with COPD 
Secondary 
care 
Systematic review (59 
reports investigating 134 
biomarkers; 28 reports of 
CRP) 
Due to heterogeneity of studies no 
meta-analysis performed.(69)  
Infective exacerbation 
in patients with cystic 
fibrosis (CRP, ESR) 
Secondary 
care 
Systematic review (18 
reports of 35 biomarkers; 
9 reports of CRP; 3 reports 
of ESR)  






Systematic review (9 
reports; 1793 patients) 
Sensitivity 0.93 (0.88 to 0.98) specificity 
0.60 (0.40-0.75) among out-patients (71) 
Appendicitis in children 






Systematic review (5 
studies of CRP, 1 of ESR; 
730 and 162 children 
respectively).  
Likelihood ratio for CRP>35mg/L 5.2 (1.7 
to 16). For ESR>20mm/h, 3.8 (1.8 to 
8.1)(72) 
Appendicitis in adults 





Systematic review (7 
studies; 1011 patients) 
 
Summary sensitivity 0.57 (0.39 to 0.73), 
specificity 0.87 (0.58 to 0.97).(73) 
 
Serious conditions in 





Systematic review (3 
studies, 2961 patients) 
Sensitivity 0.77 (0.74 to 0.79), specificity 
0.61 (0.59 to 0.64) at cut-off 
CRP>10mg/L (74) 
Intra-abdominal 





Systematic review (11 
studies, 2692 patients) 
Pooled sensitivity 0.75 (0.69 to 0.81), 
specificity 0.72 (0.70 to 0.74).(75) Similar 
findings in one other study  (76) 
Bacterial peritonitis in 






with CRP (7 reports of 
CRP; 499 patients) 
Pooled sensitivity 0.76 (0.58 to 0.88), 
specificity 0.81 (0.63 to 0.92) (77) 






Systematic review (7 
studies; 1986 patients) 
Summary sensitivity 68%, specificity 
72%. (79) Similar findings in two other 
reviews (80) (81) 
Sepsis in adults (CRP) Secondary 
care 
Systematic review (9 
reports; 495 sepsis 
patients, 873 non-sepsis 
patients) 
Pooled sensitivity 0.80 (0.63 to 0.90) 
specificity 0.61 (0.50 to 0.72). (82)  
Neonatal sepsis (CRP) Secondary 
care 
Systematic review (28 
reports; 2661 patients) 
Pooled sensitivity 0.71 (0.63 to 0.78) 
specificity 0.88 (0.80 to 0.93)(83) 
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Late onset infection in 




review (20 reports; 1615 
infants) 
At median specificity (0.74), sensitivity 
was 0.62 (0.50 to 0.73) (84) 




Systematic review (8 
studies, 616 patients) 
Pooled sensitivity 0.70 (0.64 to 0.76), 
pooled specificity 0.83 (0.79 to 0.87) (85)  




Systematic review of 
procalcitonin versus CRP 
(7 studies of CRP; 635 
patients)  
Pooled sensitivity 0.92 (0.75 to 0.88) 
specificity 0.81 (0.77 to 0.84). (86) 
Bacterial infection in 




Systematic review (13 
studies; 1712 patients) 
Pooled sensitivity 0.77 (0.62 to 0.87), 
specificity 0.58 (0.44 to 0.71) (87) 
Adverse outcomes in 
febrile neutropenic 




Systematic review (7 
studies; 731 episodes) 
Pooled sensitivity 0.65 (0.41 to 0.84), 
specificity 0.73 (0.63 to 0.82). (88) 
Updated study showed procalcitonin 
may have better discriminatory ability. 
(89) 
Pyelonephritis in 




review (16 reports, 1895 
children for CRP; 8 
studies, 1910 children for 
ESR)  
Summary sensitivity 0.93 (0.86 to 0.96) 
for CRP>20mg/L; 0.83 (0.71 to 0.91) for 
ESR>30mm/h. Summary specificity 0.37 
(0.24 to 0.53) for CRP; 0.57 (0.41 to 
0.72) for ESR. (90) 
Serious infection in 




Systematic review (5 
reports of CRP; 1379 
children. 1 report of ESR) 
Pooled positive likelihood ratio of raised 
CRP 3.2 (95% CI 2.7 to 3.7) negative 
likelihood ratio 0.33 (0.23 to 0.49).(91) 
Similar results in 2 other reviews (92, 93) 




Systematic review (7 
reports with 583 patients 
in total, of which 3 reports 
of CRP) 
Pooled sensitivity 0.85 (0.72 to 0.94), 
specificity 0.37 (0.27 to 0.47). (94)  






Systematic review (4 
reports of CRP; 11 reports 
of ESR) 
CRP sensitivity varied from 0.44 to 0.91, 
specificity 0.15 to 0.85; ESR sensitivity 
varied from 0.18 to 0.95, specificity 0.11 
to 0.94, no meta-analysis performed due 
to heterogeneity. (95) Similar findings in 
another study (96) 
Osteomyelitis of the 




Systematic review (8 
reports, 7 reporting ESR, 
351 patients, 2 reporting 
CRP, 404 patients)  
ESR pooled sensitivity 0.81 (0.71 to 0.88) 





Systematic review (25 
studies) 
Pooled sensitivity 0.82 (0.80 to 0.84), 
specificity 0.77 (0.76 to 0.79).(98) Similar 
findings in a previous study which also 






Systematic review (23 
reports; 1717 patients) 
 
Sensitivity 0.59 (0.48 to 0.69) specificity 
0.83 (0.74 to 0.89) for CRP >20mg/L 
(100) 
Bacterial infection in 







with CRP (7 studies; 803 
patients)  
Pooled sensitivity 0.78 (0.52 to 0.92) 







Systematic review (6 
reports; 1344 patients) 
Pooled sensitivity 0.80 (0.54 to 0.93) 




in adults (CRP) 
Secondary 
care 
Systematic review (6 
reports; 1006 patients) 
Pooled sensitivity 0.75 (0.62 to 0.85) 
specificity 0.73 (0.61 to 0.82) (103)  
Excluding inflammatory 
bowel disease in adults 
with IBS (CRP, ESR) 
Secondary 
care 
Systematic review (4 
reports of CRP, 823 
patients; 4 reports of ESR, 
616 patients) 
CRP <0.5 gives a <1% probability of 
having IBD. No level of ESR was 
predictive of IBD. Sensitivity/specificity 
not reported (104) 
Inflammatory bowel 






Systematic review (4 
reports of CRP, 3 reports 
of ESR) 
CRP sensitivity range 0.55 to 1.0, 
specificity 0.42 to 0.90. ESR sensitivity 
range 0.56 to 0.78, specificity 0.75 to 
0.96. No meta-analysis performed due 
to heterogeneity. (105)  
Inflammatory bowel 




Systematic review (9 
studies; 1146 patients) 
Pooled sensitivity 0.63 (0.51-0.73) 
specificity 0.88 (0.80-0.93).(106)  
Bacterial infection in 





Systematic review (8 
reports; 668 patients)  
Pooled sensitivity 0.81 (0.75 to 0.86) 






review (14 studies; 997 
cases/1284 non-cases) 
Pooled sensitivity 0.66 (0.55 to 0.75), 
specificity 0.44 (very low certainty 
evidence). (108) 
*Where possible results are presented as pooled sensitivities and specificities to enable 
comparisons between studies 
 
 Testing for monitoring of disease progression or 
treatment response 
As well as diagnosis of specific diseases, inflammatory markers can be used for 
monitoring in patients who have inflammatory disease which has already been 
diagnosed. NICE guidelines suggest measuring CRP ‘regularly’ in people with 
rheumatoid arthritis, and ‘monthly’ for those with active disease, to inform 
decision-making about increasing treatment to control disease, or decreasing 
treatment when disease is well controlled.(109)  
For infections, CRP monitoring can be used as a marker of treatment response, 
potentially helping to guide antibiotic therapy, particularly for infections which 
can be difficult to fully eradicate such as osteomyelitis.(110) Other inflammatory 
markers such as viscosity and ESR are less suitable for this purpose due to the 
long half-life and delayed response.  
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Some research has also evaluated the use of inflammatory markers for 
monitoring and assessing prognosis in diagnosed cancer.(111, 112) This tends to 
be done in secondary care. This thesis focuses on the diagnostic utility of 
inflammatory markers in primary care, so further discussion of their utility in 
disease monitoring is out with the scope of this research.   
 
 Non-specific testing for systemic disease 
A third use of inflammatory markers is as a tool to differentiate between the 
presence or absence of disease. This can either be as a screening tool in 
asymptomatic patients; for example, as part of a ‘health check’, offered by the 
NHS or by private companies (the ‘essential health screen’ offered by 
citydoc.org.uk is one example). Alternatively, inflammatory markers may be 
used by GPs for patients with non-specific or undifferentiated symptoms as a 
way of trying to detect or rule-out serious underlying systemic disease. Examples 
of this in clinical practice include recommendations from the medical education 
organisation ‘GP Update’ to use CRP as a ‘rule-out’ test to exclude secondary 
causes of hypertension(113) or for patients with newly diagnosed memory 
problems prior to memory clinic referral.(114) Inflammatory marker testing is 
also recommended by NICE as part of the diagnostic process for chronic 
fatigue(115) and irritable bowel syndrome.(116) As there are no specific 
serological tests for these conditions, the inflammatory marker is used as a ‘rule-
out’, with the aim of excluding other potential causes of tiredness or abdominal 
pains before making the diagnosis of a functional disorder.  
One of the commonest non-specific symptoms seen in primary care is tiredness, 
and inflammatory markers are often used in primary care for these patients. 
Only one trial appears to have studied the appropriateness of primary care blood 
tests for patients with tiredness: the VAMPIRE trial. This randomised controlled 
trial compared immediate or postponed blood test ordering, with either limited 
or expanded sets of blood tests.(117) In this study the ‘limited’ set of blood tests 
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included an ESR, although it is unclear what additional diagnostic yield this test 
provided. Results supported restricting the number of tests ordered to this 
‘limited’ set and have led to several guidelines recommending the use of 
inflammatory markers as part of the first line of investigations for patients 
presenting to their general practitioner with tiredness or fatigue, including the 
UK Clinical Knowledge Summary guidelines.(115) 
Several small studies, now decades old, have evaluated the utility of 
inflammatory markers as a non-specific screening test. Table 2 summarises these 
studies; this table was produced for my BMJ review of inflammatory marker 
testing(1) and updated to include a small number of more recent studies. 
Generally, when general practitioners test inflammatory markers for non-specific 
purposes the results are afterwards seen as being of little or no clinical value.(33) 
If the pre-test probability of disease is low then there is a higher probability that a 
raised result may represent a false positive. The wide range of differential 
diagnoses in patients without localising symptoms or signs makes interpreting 
‘incidental’ abnormalities more difficult; this may potentially lead to ‘cascade 
testing’ (118) which may be costly or lead to patient anxiety. It is unclear based 
on current evidence how frequently inflammatory markers are used as a non-
specific screening test in clinical practice, and what the diagnostic yield of these 




Table 2: Community and primary care studies investigating the diagnostic role of 
inflammatory markers as diagnostic or screening tools for non-specific disease. 




study, 15 year 
follow-up(119) 
1000 healthy men aged 
18-33 years: yearly ESR 
measurement 
44 had persistently raised ESR; of these 10 
subsequently developed diseases (4 myocardial 
infarctions, 3 ankylosing spondylitis, and one 
each of inflammatory bowel disease, psoriasis 
and benign monoclonal gammopathy) 
Community 
study of 






100 healthy men and 
women aged over 70 
years 
9 subjects had an ESR >30 mm/h for ≥6 
months; a previously undiagnosed illness was 
identified in 4 of these (2 polymyalgia, 1 









362 patients presenting 
with a new complaint 
for which the general 
practitioner considered 
ESR to be indicated 
ESR values were on average higher in those 
with malignancy or inflammatory diseases. 
Almost all diagnoses ‘revealed’ by the raised 
ESR had been suspected at the initial 






439 patients over 70 
presenting to primary 
care 
58 had ESR >40 and were thoroughly 
investigated; of these nine new diagnoses were 
found and three patients could be offered 








where an ESR was 
performed 
In 60% of the consultations the test exerted its 
influence mainly by supporting or reinforcing 
the doctor’s clinical opinion. In 11% the results 
were unexpected and forced the doctor to 
reconsider. In 22% the results were felt to be 
of little or no clinical consequence. 
Community 
setting in US 
(ESR and CRP) 
Prospective 
study (124) 
101 elderly men and 
women living in 
residential and nursing 
homes 
CRP and ESR were significantly higher in those 
with infections and/or inflammatory 
conditions.  
 
Despite the very limited evidence to support this practice, my pre-doctoral 
qualitative interviews with GPs suggest this type of testing is common in clinical 
practice:(2) 
I'm fishing really.  So it's, a lot of our work is early presentation of 
undifferentiated disease and I get, essentially buying time I get very strongly 
reassured, rightly or wrongly, by negative inflammatory markers. 
Clinicians talked about a fear of ‘missing something’, and many used 
inflammatory markers as a way of dealing with diagnostic uncertainty and to 
help reassure themselves that there was ‘nothing serious going on’. Clinicians 
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often had the expectation that results were going to be normal and used the test 
to help ‘rule-out’ serious pathology:(2) 
So, if we had a test that, a single blood test, that doctors could do which 
would reassure the patient there was nothing bloody wrong at all, then that 
would be a very popular test. We'll have the “nothing wrong at all” test for 
you, sir… You know, all the other tests are, well, you might have this 
specifically wrong with you or you might have this…  But the CRP is probably 
the closest thing that we've got to a “nothing wrong at all” test.  
 
 Inflammatory markers as a predictor of future 
disease 
Another area of research interest is the utility of inflammatory markers as a 
predictor of the risk of future disease, including cardiovascular disease,(125) 
diabetes,(126) atrial fibrillation,(127) cancers,(128-130) dementia, (131) 
schizophrenia,(132) depression(133) and overall mortality.(134) At present this is 
mostly of research interest and has not yet entered mainstream clinical practice, 
however it has potential to lead to significant changes in testing rates in future. 
In primary care, the main potential areas of clinical interest are the identification 
of patients at increased risk of mortality and those at increased risk of hospital 
admission, particularly given the context of an ageing population and rising 
multimorbidity. Predictive tools could help inform the planning and delivery of 
services including advanced care planning, and interventions to reduce hospital 
admissions. An inflammatory marker test (ESR) is included as part of 
QAdmissions, a tool for predicting hospital admissions in primary care 
populations.(135) Several mortality risk tools exist: none in current use includes 
an inflammatory marker test.(136, 137) There is evidence for an association 
between inflammatory markers and mortality in secondary care,(138) and 
evidence of a small association over the long term from population based cohort 
studies.(139) The association in a primary care population, and over the shorter 
term, is unknown.   
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The role of inflammation in the susceptibility and pathogenesis of cardiovascular 
disease has also received much attention. A wide variety of inflammatory 
biomarkers have been studied, and high-sensitivity C-reactive protein (hs-CRP) 
has been examined for its potential role in risk stratification. The hs-CRP test 
measures the same plasma protein as the ‘standard’ CRP test, but has a lower 
limit of detection for the assay. A number of professional societies have 
produced guidelines or recommendations for hs-CRP testing for cardiovascular 
risk profiling. (140, 141) This has not yet entered mainstream clinical practice in 
the UK.  
If hs-CRP is incorporated into mainstream clinical practice for cardiovascular risk 
profiling it will lead to increased testing of asymptomatic patients; inevitably a 
proportion of them will be found to have unexpected abnormalities. When 
results are in the peri-normal range, they can be used for cardiovascular risk 
profiling; however there has been a lack of attention paid to the issue of how to 
best manage the patients who are found incidentally to have raised CPR results. 
In asymptomatic patients with a low pre-test probability of disease, there is a 
higher probability that abnormal results represent false positives.  Present 
guidelines offer relatively little advice for clinicians, for example; ‘because hs-CRP 
can be elevated during acute illness, clinical judgment should be exercised in the 
interpretation of any single measurement of hs-CRP’(140) and ‘further assessment of 
patients with highly elevated hs-CRP (>10 mg/L) for non-cardiovascular causes of 
inflammation was also endorsed.’(142)  
Further research to determine an optimal evidence-based approach to the 
interpretation and management of raised inflammatory markers is therefore 
timely. However, as this thesis focuses on the diagnostic utility of raised 
inflammatory markers, further discussion of their role in cardiovascular risk 




 Comparative diagnostic accuracy of 
inflammatory markers 
Comparison of the accuracy of CRP versus ESR was examined in a recent 
systematic review.(143) A total of 29 studies were identified; 16 measuring 
accuracy of ESR versus CRP for orthopaedic infections, 3 for rheumatic disease 
and 10 ‘other’ diseases; all studies were based in secondary care settings. CRP 
did not appear to have a superior diagnostic accuracy to ESR for orthopaedic 
infections, with area under summary receiver operating curve (SAUC) 0.80 for 
ESR versus 0.81 for CRP. Despite high heterogeneity in the ‘other’ category 
(which included pyelonephritis, pneumonia, sepsis, meningitis and 
epididymitis), meta-analysis for this group was performed, with higher SAUC 
for CRP (0.86) compared with ESR (0.75) leading the authors to conclude, on 
limited evidence, that CRP had superior diagnostic accuracy.  
Another recent comprehensive systematic review aimed to determine when it is 
appropriate to concurrently test ESR and CRP (as opposed to testing only ESR or 
CRP) to help diagnose inflammatory disease or serious infection.(144) Evidence 
for single versus multiple inflammatory marker tests was identified for a limited 
number of conditions; suspected periprosthetic joint infections, paediatric 
orthopaedic infections, giant cell arteritis and inflammatory bowel disease. Most 
of the evidence was from secondary care and was assessed as being at high risk 
of bias. Due to the limited number of direct comparisons between ESR and CRP 
which could be made within studies, the authors also made indirect comparisons 
of the accuracy of CRP and ESR across studies with the same disease condition. 
As a result of the limited evidence identified the authors were unable to make 
any clear recommendations about preferred choice of tests.(144)  
Limited published evidence comparing the diagnostic accuracy of PV versus 
CRP and ESR is available, including a small study on periprosthetic joint 
infections,(145) a case-control study on multiple myeloma(59) and a systematic 
review (without meta-analysis) on inflammatory arthritis.(146)  
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In summary there is very limited evidence comparing the diagnostic accuracy of 
inflammatory markers in primary care, and a lack of evidence to determine the 
added benefit of testing multiple inflammatory markers simultaneously. Due to 
the lack of guidelines and uncertainty regarding which inflammatory marker to 
use, clinicians interviewed in my pre-doctoral qualitative research reported 
frequently using two inflammatory markers simultaneously:(2) 
I probably tend to do both [CRP and PV], actually, which is probably more out 
of just making sure I caught everything.  
 
 Interpretation of inflammatory marker tests 
results 
The interpretation of a raised inflammatory marker should be relatively 
straightforward if there is a clear pre-test hypothesis against which the test result 
can be evaluated – for example assessing the likelihood of pneumonia in a 
patient with a cough. This was demonstrated by a Dutch study of patients in 
whom the raised ESR seemed to confirm an initial diagnosis as opposed to 
revealing unexpected disease.(121, 122) The difficulty lies in interpreting an 
‘incidental’ finding, when no specific disease is suspected. Markedly raised 
inflammatory markers (such as an ESR >100mm/h or CRP>100mg/L) have been 
shown to have a high likelihood of disease. The conditions found depend on the 
setting, but include infection (33-60%), inflammatory disease (14-30%) and 
malignancy (5-28%)(147-152). In my pre-doctoral qualitative research, GPs I 
interviewed identified interpretation of a raised inflammatory marker in primary 
care as a particular challenge, which could lead to lead to uncertainty, follow up 
GP consultations and further testing:(2)  
‘Then you think suddenly, well should I be looking further and further and 
further, but that could mean more and more random investigations until you 
get the point where you goes, oh, I’ll just do a whole body CT scan to see if 




 Qualitative research and inflammatory 
marker testing 
Given the large numbers of quantitative research studies exploring inflammatory 
marker testing summarised above, it is perhaps surprising that relatively little 
qualitative research has been done. To address this lack of qualitative research 
into inflammatory marker testing I conducted interviews with GPs about these 
tests in my pre-doctoral Academic Clinical Fellowship.(2)  
Further qualitative research to address both doctors’ and patients’ perspectives is 
important for several reasons. Firstly, qualitative research can be used to explore 
the psychosocial reasons driving use of tests from both doctors’ and patients’ 
perspective. This is important because understanding the diagnostic accuracy of 
a test is necessary but not sufficient; to improve test usage non-medical drivers 
for testing must be understood and addressed. This was summarised in 1998 by 
Little et al who said: ‘If psycho-social agendas are important in ordering investigations, 
then clinical guidelines which discuss only medical criteria may not be effective in 
reducing ‘inappropriate’ investigations’. (153) Despite this, the vast majority of 
guidelines and interventions to ‘optimise’ use of blood tests still focus on medical 
reasons for testing.(154) 
Secondly, qualitative research is important because tests in themselves do not 
make people better - unless actions based on the test result lead to either a 
change in patient management or reassurance. Both of these are dependent on 
test result communication. A systematic review of US studies quantifying 
failures in test result follow up has shown that between 6.8% and 62% of 
laboratory tests are not followed-up; no relevant UK research was 
identified.(155) Surveys and qualitative studies have shown that UK general 
practices generally rely on patients contacting the practice to obtain their test 
result, with a lack of fail-safe mechanisms.(156-158) Errors associated with filing, 
communicating and actioning of abnormal results could lead to delayed and 
missed diagnoses;(159) conversely if normal results are not adequately 
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communicated patients are unlikely to be reassured by testing. Improving the 
use of tests therefore requires improved communication around testing.   
Finally, shared decision-making has been described as ‘the pinnacle of patient-
centred care’,(160) yet most research into shared decision-making focuses on 
treatment decisions rather than diagnostic testing.(161) If shared decision-
making between clinician and patient is to be achieved it is crucial that doctors 
and patients have a shared understanding of why inflammatory marker tests are 
being done and the meaning of the results.  
 
 Doctors’ perspectives of blood tests 
Studies exploring doctors’ reasons for testing have been reviewed by Whiting et 
al and classified into several key groupings: diagnostic factors, therapeutic and 
prognostic factors, patient-related factors, doctor-related factors and policy and 
organisation related factors.(162) From this it is clear that diagnostic factors, 
which can be modelled mathematically in terms of Bayesian pre-test and post-
test probabilities, are only one factor in a complex decision-making process. A 
telephone survey of 300 physicians in the US indicated that most do not use 
formal recommended quantitative methods for appraising a diagnostic test, with 
only 3% reporting that they use formal Bayesian calculations.(163) In my pre-
doctoral qualitative work I explored these non-medical motives for testing by 
looking at the question ‘what do tests do for doctors?’.(164) I found that doctors 
viewed tests as a way to manage uncertainty within the context of increased 
litigation, risk aversion and reduced continuity of care. They could also be used 
as part of the social interaction as a ‘gift’ for the patient, and a way to be seen to 
be ‘doing something’, within the social context of time pressures and perceived 
patient pressures. A recent realist review by Duddy et al explored clinicians’ 
decision-making in relation to laboratory testing, and found that workload and 
time pressures tend to promote the use of tests, with clinicians prioritising 




 Patients’ perspectives of blood tests 
There are a smaller number of studies looking at patients’ perceptions of blood 
testing, with none specifically focussed on inflammatory marker testing. One 
qualitative study interviewed patients recruited via GP practice waiting rooms, 
and found that patients tended to overestimate the qualities of blood tests, which 
were seen as almost ‘magic’ and regarded as providing diagnostic certainty.(166) 
This is in keeping with a systematic review of quantitative studies measuring 
patient expectations of tests and treatments; the majority showed patients tend to 
overestimate benefits and underestimate harms.(167) Studies exploring whether 
patients are reassured by normal test results have shown some evidence of short 
term reductions in anxiety and GP visits, for example with neuroimaging in 
chronic daily headaches.(168) However, systematic reviews have shown that 
overall normal diagnostic tests do little to reassure patients, decrease anxiety or 
resolve their symptoms.(169, 170)  
Comparisons between doctors’ and patients’ perspectives are important to 
highlight potential areas of misunderstanding, which can impact on decision-
making. Qualitative studies into antibiotic prescribing have shown that patients 
and doctors can sometimes be talking at cross purposes about the ‘seriousness’ of 
the illness, with patients’ expressions of anxiety misinterpreted as a pressure for 
antibiotics.(171) Similarly, one study measured patients’ expectations in general 
practice and found that patients have less desire for ‘tests and diagnosis’ and a 
greater desire for ‘explanation of the problem’.(172) It is therefore possible that 




 Shared decision-making and informed 
consent 
The General Medical Council published guidelines in 2020 for decision-making 
and informed consent which recommend that doctors and patients should ‘reach 
a shared understanding of the expectations and limitations of the available options’.(173) 
The legal framework underpinning these guidelines comes from Montgomery v 
Lanarkshire (2015), which state that ‘consent must be obtained before treatment 
interfering with bodily integrity is undertaken’, with doctors obliged to ensure 
patients are aware of risks and benefits of each course of action that are 
meaningful to the particular person.(174) The amount of information sharing 
required for blood tests is unclear, although there have been cases of complaints 
and litigation in primary care, for example, patient who was not informed that 
they were having liver function tests done alongside cholesterol screening 
bloods.(175)  
Shared decision-making goes above and beyond this legal framework for 
informed consent and shared understanding, seeking not only to inform but to 
actively involve and engage patients in decision-making. Shared decision-
making has been defined as ‘a collaborative process that involves a person and their 
healthcare professional working together to reach a joint decision about care’.(176) 
Evidence for the benefits of shared decision-making is mostly based around 
treatment decisions; (161) however, draft NICE guidelines are not limited to 
treatment decisions and recommend shared decision-making ‘to choose tests, 
treatments, management or support packages, based on evidence and informed personal 
preferences, health beliefs and values’.(176)  
Evidence for shared decision-making around blood testing is limited, although 
specific tests such as prostate specific antigen (PSA),(177) genetic testing(178) and 
screening tests(179) have received much attention, and some decision aids are 
available.(180) It is unclear whether the same principles are applicable to blood 
tests such as inflammatory marker tests. Observational research using video-
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recorded GP consultations in UK primary care has demonstrated that the reality 
of decision-making around blood testing does not reflect the ideals of shared 
decision-making, with most decisions being doctor-led, with a lack of 
information-sharing and shared decision-making.(181, 182)  
 
 Gaps in current evidence base 
Despite the large numbers of studies evaluating inflammatory markers 
summarised in section 1.4, there is a lack of clinically relevant research for 
general practice. Most research on inflammatory markers comes from a 
secondary care setting, where disease prevalence is higher. This evidence cannot 
be extrapolated to a low-prevalence primary care setting, due to the variation in 
test performance seen amongst different population subgroups, which is known 
as the spectrum effect.(183) The impact of this spectrum effect is that tests 
developed in high prevalence settings (e.g. secondary care) will typically have a 
lower sensitivity and higher specificity when applied in a population with lower 
disease prevalence (e.g. primary care).(183)  
Additionally, most studies measure accuracy for single disease outcomes; 
however, this does not reflect the clinical experience of general practitioners who 
are faced with a test result and often need to weigh up the risks of a wide range 
of possible disease outcomes, to decide on the most appropriate further tests and 
treatments required. In clinical practice this leads to uncertainty and anxiety for 
clinicians. They describe a tension between not wanting to ‘miss anything’, and, 
on the other hand, being wary of picking up borderline abnormalities which can 
lead to cascades of further tests.(2) Whilst clinicians commonly use inflammatory 
markers as a ‘rule-out’ or ‘nothing wrong at all’ test, there is a lack of evidence to 
support this practice. There is therefore uncertainty within the current research 
literature about when to use inflammatory markers and how to interpret results.   
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Another limitation of the current inflammatory marker literature is that 
diagnostic test accuracy (DTA) studies generally present results in terms of 
sensitivity and specificity, which have been shown to be poorly understood by 
clinicians and patients, are difficult to interpret and rarely used in clinical 
practice.(163) Research suggests that natural frequencies are easier to understand 
than sensitivities and specificities, and methods of presenting DTA studies using 
natural frequencies have been developed.(184)  
Additionally, current DTA study methodologies use a binary model of test 
positive versus test negative. This ignores those with indeterminate test results 
which can be the most challenging to manage in primary care, and may lead to 
overestimation of the probability of disease in patients who have borderline 
abnormal results, and underestimation in those with significant abnormalities. 
My qualitative research highlighted that this was perceived as a problem with 
inflammatory marker testing:(2)  
So, I think that if they’re very normal that’s good, if they’re very abnormal 
that’s helpful. I think that probably where the problem lies is if you get like a 
mildly raised viscosity and you wonder is that, how significant is that? 
Finally, there is a lack of evidence addressing patients’ perspectives of testing. 
Although shared decision-making is increasingly promoted as best practice, 
there is also a lack of research exploring shared decision-making in the context of 
diagnostic decisions.  
In this thesis I set out to address some of these limitations. I use routine data 
from UK primary care to explore how tests are used in clinical practice, and to 
measure the diagnostic accuracy for a combined disease outcome of any 
infection, autoimmune disease or cancer (‘relevant disease’). The results are 
presented in a variety of ways including natural frequencies to aid 
understanding and applicability. As well as disease outcomes, I measure process 
outcomes including rates of consultations, blood test and referral after 
inflammatory marker testing to quantify the cascade effect. Additionally, as well 
as looking at a binary model of test positive versus test negative, I also explore 
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the dose-response relationship between test results as a continuous variable and 
disease incidence. Finally, by incorporating qualitative methods I explore 
patients’ and doctors’ perspectives and generate finding to help doctors and 
patients develop a shared understanding of testing.  
 
 Ontological and epistemological position 
Ontological and epistemological beliefs influence how research questions and 
methods are shaped and interpreted. Both are philosophical concepts – ontology 
relates to our knowledge and understanding of the world; epistemology relates 
to the methods, validity and scope of our knowledge. My thesis incorporates 
quantitative and qualitative methods which come from different epistemological 
positions. Quantitative research is generally grounded in the positivist paradigm, 
which recognizes only that which can be scientifically measured and verified 
with empirical data or which is capable of logical or mathematical proof. This is 
in keeping with my background as a doctor and my training in evidence-based 
medicine and the biomedical model of disease. The focus of the quantitative 
component of my thesis, to measure the diagnostic accuracy of inflammatory 
marker tests, is in keeping with this positivist paradigm.  
The qualitative component of my thesis however aligns more with an 
interpretivist paradigm, in which the way the world is experienced and 
understood is socially constructed and depends on how people interpret and 
make sense of their experiences.(185) This is in keeping with my training and 
experience as a general practitioner, in which patients’ experience of illness is not 
solely explained by biomedical pathology, but influenced by their beliefs, 
experiences, social interactions and psychology.   
My overall epistemological approach is therefore one of methodological 
pragmatism:(186) I believe that in order to understand the clinical practice of 
inflammatory marker testing, both qualitative and quantitative methods are 
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needed. My priority has been to ensure that the research questions and the 
results of my research are relevant to clinicians and patients. I believe a 
pragmatic approach is needed to choose optimal methods to achieve this, even 
though this means being flexible and willing to switch between paradigms. I feel 
comfortable switching between positivist and interpretivist paradigms as a GP, 
as this reflects my daily clinical practice of medicine. In my clinical practice I 
draw on my biomedical knowledge, from a positivist perspective, to interpret 
symptoms, signs and test results and to recommend evidence-based treatments. 
At the same time, I also explore patients’ ideas, concerns and expectations, which 
brings an interpretivist approach to understanding and exploring their problems. 
My clinical experience has taught me that a biomedical understanding of disease 
is necessary but not sufficient. Holistic care of patients requires integration of 
biomedical knowledge with psychosocial factors which influence patients’ 
experience of illness. In the same way, my research experience has shown me 
that different types of knowledge, from both positivist and interpretivist 
paradigms, bring important insights which can be used to shed light on research 
questions.    
 
 Aims and Objectives 
 Overall aims 
The overall aim of this thesis is to explore the diagnostic utility and clinical 
practice of inflammatory marker testing in primary care, including how results 
are shared with patients, using a mixed methods approach. This will inform 
policies and clinical practice to optimise the use of inflammatory marker tests in 




 Quantitative aims and objectives 
For the quantitative component of my thesis, I use a cohort of 160,000 patients 
from the Clinical Practice Research Datalink (CPRD) who had inflammatory 
marker blood tests in 2014, and 40,000 matched untested patients. The overall 
aim is to determine the diagnostic utility of inflammatory marker tests in 
primary care for relevant disease, including infections, autoimmune disease and 
cancer. The results will be of relevance for a general practitioner deciding when 
to use inflammatory markers and how to interpret results.   
Specific objectives for the quantitative phase of the thesis are: 
1) To describe the baseline characteristics in terms of age, gender, 
socioeconomic status and ethnicity of patients having inflammatory 
marker tests in primary care. 
2) To determine the diagnostic accuracy of CRP, ESR and PV, singly and in 
combination, for relevant disease (infections, autoimmune conditions or 
cancer) in primary care, and to compare disease incidence in tested versus 
untested populations.  
3) To determine the symptomatology of patients with inflammatory marker 
testing in primary care and measure the consequences of testing in terms 
of numbers of consultations, blood tests and referrals.  
4) To determine the diagnostic accuracy of inflammatory markers 
specifically for cancer in primary care, including stratification by age, 
gender, inflammatory marker level and cancer type.  
5) To explore the association between inflammatory markers and one-year 




 Qualitative aims and objectives 
The second component of the thesis is a qualitative study, involving interviews 
with patients who had recent inflammatory marker tests at two time points: (a) at 
or soon after their blood tests and (b) after they received their test results. I also 
interview the GPs who requested these tests. The overall aim is to explore the 
meaning of inflammatory marker tests for doctors and patients in primary care.  
The specific objectives of this qualitative component are:  
1) To explore to what extent doctors and patients have a shared 
understanding of the use of inflammatory marker blood tests. 
2) To provide in-depth exploration of patients’ experience of testing - from 
GP consultation to results. 
3) To identify barriers and facilitators to communication and shared 
understanding, in order to inform improved communication in future.  
 
 Outline of chapters 
In the next chapter I will describe the methods of the quantitative component of 
my thesis, in chapter three I will then describe the results. Chapter four describes 
the methods of the qualitative component of the thesis and chapter five describes 
the results. Finally, in chapter six I will discuss and synthesise the findings of 
both the qualitative and quantitative components of my thesis, considering the 
strengths and limitations of the methods chosen, comparisons with existing 




CHAPTER 2.  QUANTITATIVE 
METHODS 
 Chapter overview 
This chapter describes the methods used for the quantitative study. The 
overarching aim was to determine the diagnostic utility of inflammatory markers 
in primary care populations for relevant disease, including infections, 
autoimmune disease and cancer. The specific objectives are described in section 
1.9.2.  
To achieve these objectives, I used a cohort of 160,000 patients from the Clinical 
Practice Research Datalink (CPRD) who had an inflammatory marker blood test 
in 2014, and 40,000 matched untested patients, and measured the incidence of 
relevant disease following testing.   
In this chapter I first provide an overview of the study design and sources of 
data. Then I describe the methods of code-list development, stages of data 
manipulation, variables created, and finally the statistical methods and analyses 
used.  
 
 Study design 
This was a diagnostic cohort study to measure the accuracy of inflammatory 
marker tests in primary care using electronic health record data from CPRD. The 
index test was defined as any inflammatory marker blood test (CRP, ESR or PV) 
performed in 2014. The target condition was any relevant disease defined as 
diagnosis of one or more of inflammatory conditions including infection, 
autoimmune disease, or cancer. The reference standard for diagnostic accuracy 
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research is usually defined as the best available method for classifying whether 
people have the target condition or not. In this study one-year incidence of 
cancer and autoimmune disease and one-month incidence of infection was used 
as a proxy measure for presence of disease at the time of testing; thus, the 
reference standard is based on GP diagnosis and coding of disease. This was 
chosen as a reasonable compromise between identifying all the conditions 
related to the raised inflammatory marker yet reducing the chance of identifying 
unrelated conditions.  
 
 Sources of data 
The CPRD is a government run database containing anonymised routinely 
collected data from primary care electronic health records. It contains coded 
information about patient demographics, diagnoses, symptoms, prescriptions, 
referrals, and test results. It also offers linkages to data sources outside primary 
care including to data recorded by the Office for National Statistics (ONS), the 
National Cancer Registration Service (NCRS) and Hospital Episode Statistics 
(HES), although not all patients are linked to all datasets.  
At the time of analysis, CPRD GOLD included over 11.3 million patients from GP 
practices using Vision® software, of whom 4.4 million were active (alive and 
currently registered) and meeting quality standards. This comprised 
approximately 6.9% of the UK population, and has been shown to be 
representative of the UK general population in terms of gender, age and 
ethnicity.(187) More recently CPRD Aurum has been developed, containing data 
from practices using EMIS Web® software; this was not available at the time of 




 Study population 
Eligibility criteria for the study were as follows: 
• Aged 18 or over in 2014. 
• Defined as ‘up to standard’ according to CPRD criteria. 
• Had inflammatory marker blood test (CRP, ESR or PV) performed 
between 01/01/2014 and 31/12/2014 (identified using the code-list in 
Appendix A).  
At the time of extraction (23rd June 2017), 463,304 patients fulfilled these 
eligibility criteria, of whom 160,000 patients were chosen at random by CPRD. A 
comparison sample of 40,000 untested patients were selected by CPRD – these 
were patients who had no inflammatory marker test in 2014, although they could 
have had testing at other dates. These were matched by age (in 5-year bands), sex 
and practice, to a random subset of 40,000 patients from the inflammatory 
marker test group. No exclusion criteria were applied, in order to maximise 
generalisability.   
 
 Rationale for the untested comparison group 
The untested comparison group allowed me to quantify the disease risk 
associated with inflammatory marker testing, as well as the risk associated with 
test results. This is important as diagnostic testing is a two-step Bayesian process. 
The first step is the clinicians’ decision to perform an inflammatory marker test 
on a patient, based on the pattern of symptoms, signs and risk factors in an 
individual, which clinicians use to generate an overall ‘gestalt’ judgement. The 
second step is the test result which is used to refine this judgement. Comparing 
the incidence of disease in the tested versus untested populations, gives an 
indication of the diagnostic accuracy of clinicians’ gestalt judgement.  If the 
excess disease risk associated with testing is not fully eliminated by a negative 
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result, those with normal inflammatory marker test results could have increased 
disease risk compared to untested. This has been demonstrated with other tests, 
for example male primary care patients with a normal platelet count 
(<400x109/l) have a one-year cancer risk of 4.1%; above the NICE threshold for 
urgent referral.(189) This is particularly important, as clinicians tend to use 
inflammatory markers as a ‘rule-out’ test. 
Matching was required for this comparison group as we know that age and sex 
are strong determinants of disease, and because different practices have different 
recording and testing styles. The alternative of requesting a comparison group 
never to have had an inflammatory marker test would introduce a bias by 
including patients with particularly good health, as nearly 25% of potentially 
eligible patients aged >18 in CPRD have had an inflammatory marker test at 
some time.  
 
 Index tests, target conditions and co-variables 
The index tests were inflammatory marker blood tests: CRP, ESR and PV. The 
index date was defined as the date of the first inflammatory marker blood test 
performed in 2014. Controls were allocated the same index date as their matched 
case. 
The overall target condition was ‘any relevant disease’, defined as any cancer or 
autoimmune conditions coded within 1 year, or infection within 1 month of the 
index date. A secondary outcome of cancer incidence at 2-years after 
inflammatory marker testing was measured, to detect any late effect. As well as 
examining the overall diagnostic accuracy for ‘any relevant disease’ I also 
calculated measures of diagnostic accuracy for infections, autoimmune 
conditions and cancers separately.  
Age, gender and socioeconomic status were examined as co-variates. I also 
analysed symptomatology at the time of testing by measuring the top 20 
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symptoms in the 28 days before testing in the tested and untested groups, to give 
an indication of the reasons GPs are ordering the tests. Process outcomes of 
repeat GP consultations, additional blood tests and referrals, were identified, in 
order to quantify the cascade effects of testing.    
 
 Sample size calculation 
I performed a sample size calculation based on estimating the 12-month 
condition incidence amongst those with raised inflammatory marker. CPRD 
feasibility data indicated that roughly one third of inflammatory marker tests in 
2014 were above the laboratory normal range. Using this assumption of a 2:1 
ratio of test negative: test positive, I calculated that a total sample size of 77,577 
would achieve an 80% power to detect a 0.2% increase in the incidence of a 
condition in the test positive compared with the test negative group, assuming a 
baseline (test negative group) condition incidence of 0.8% and with a type II error 
rate of 5%. This is realistic given that previous studies have shown that the 
positive predictive value of a raised inflammatory marker for myeloma is 0.2 
(Ref: NICE Cancer guidelines); for multiple cancers I would expect this to be 
higher. I rounded this to a sample size of 80,000 to allow for dropouts once those 
with pre-existing relevant disease were excluded from analyses.  
As well as examining the three inflammatory markers combined, I also wanted to 
look at diagnostic accuracy of each of the three tests individually. Of the three, 
plasma viscosity was the least used, comprising 8% of the total tests, or 6,400 out 
of the 80,000 total sample size. After exclusions I would expect to have over 4977 
plasma viscosity tests. This sample size achieves an 80% power to detect (with a 
type II error rate of 5%) a difference of 2% disease incidence in the test positive 
group, versus 1% in the test negative group; ample power for the more common 
outcomes. 
A comparison group of 20,000 matched untested patients was requested from 
CPRD. I opted for a smaller sample size in this group to ensure maximum power 
57 
 
in the main study, as this comparator group was not used for the majority of the 
analyses, and no subgroup analyses were done on this group. Based on the 
assumption of a condition incidence of 0.8% in the inflammatory marker test 
group (as above), in order to detect a condition incidence in the untested group 
of 0.6% with a 4:1 ratio (allowing for the proposed smaller sample size of the 
comparison group) requires 65,772 in the inflammatory marker tested group, and 
16,443 in the untested comparator group for an 80% power; rounded to 20,000 to 
accommodate exclusions.    
Following feedback from the CPRD the sample size was increased to 200,000 
(160,000 tested and 40,000 untested cohorts). They suggested that this was within 
the same costing envelope and would increase the power to detect rarer 
outcomes such as cancers and autoimmune conditions.  
 
Sensitivity analysis to check sample size 
As my primary objective was to measure the diagnostic accuracy of 
inflammatory marker tests, I did additional sensitivity analyses to check my 
proposed sample size (Table 3).  I used the following formula to check the likely 
standard error for my proposed sample size under a variety of assumptions for 
prevalence and sensitivities:  
SE = √( p(1-p) /k) 
k = expected number of cases (sample size x prevalence) 
p = sensitivity 











0.25% 0.5% 1% 2% 5% 10% 
50% 2.5% 1.8% 1.3% 0.9% 0.6% 0.4% 
60% 2.5% 1.7% 1.2% 0.9% 0.5% 0.4% 
70% 2.3% 1.6% 1.1% 0.8% 0.5% 0.3% 
80% 2.0% 1.4% 1.0% 0.7% 0.4% 0.3% 
90% 1.5% 1.1% 0.75% 0.5% 0.3% 0.2% 
 
This demonstrates that my sample should give sufficient power to detect rare 
outcomes such as cancer and autoimmune conditions down to prevalence rates 
<1% with test sensitivities of up to 90%.  
 
 Ethics approvals 
Approval for this study was obtained from the Independent Scientific Advisory 
Committee (ISAC) approval reference number 17_003.  
 
 Reporting 
The reporting of this study conforms to the STARD(190) and RECORD(191) 
statements.   
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 Code-list development 
The methods of code-list development described below have been published in 
the following Open Access article distributed in accordance with the terms of the 
Creative Commons Attribution (CC BY 4.0) license: 
• Watson J, Nicholson BD, Hamilton W, & Price S. (2017) Identifying clinical 
features in primary care electronic health record studies: methods for 
codelist development. BMJ Open 7(11) https://doi.org/10.1136/bmjopen-
2017-019637    
Code-list development is an important first step for most research using 
electronic health records. This apparently simple task is made complex by the 
fact that methods for developing code-lists are not standardised and are often 
poorly reported. In order to improve transparency, replicability and rigor in 
code-list development I published a standardised method for code-list 
development, based on methods used by my supervisor Professor Willie 
Hamilton and his team.(192) This method involves three stages, summarised in 





Figure 1: The method for code-list collation consists of three steps 
 
 Step 1: clearly defining the target condition 
To identify the target condition, the first stage was to collate lists of codes 
pertaining to infections, autoimmune conditions, and cancers. To achieve this, I 
first needed to clearly define the diseases of interest and inclusion and exclusion 
criteria. Appendix A contains a summary of the disease outcomes for infections 
and autoimmune conditions which were studied. Pre-existing cancer code-lists 
were available (see 2.3.4) so this process was not repeated for cancers.   
Reliable sources of clinical information were used to define each disease outcome 
including: 
• International Classification of Primary Care (ICPC) 
• National Institute for Health and Care Excellence (NICE) Clinical 
Knowledge Summaries (CKS) 
• ICD-10 
• GP notebook 
Step 1: Clearly define the clinical feature of interest
a. With reference to a wide range of reliable resources
b. Generate a list of search terms to use in Step 2
Step 2: Assemble a short list of potential codes
a. Extract a long list of codes using an algorithm based in statistical 
software (e.g. Stata)
b. Manually exclude bogus codes to produce a short list  for Step 3
Step 3: Selection of final list by consensus process
a. Round one: review of codes independently by members of the 
clinical panel
b. Round two: collation of the final selection by panel chair
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 Step 2: assemble a list of potential codes 
The second stage consisted of identifying all potential codes that might be used 
by GPs to record the target condition defined in Step 1 and collating them into a 
list. This was done using Stata to search the lookup file (medical.txt) provided by 
CPRD. This contains the alphanumeric ‘Read code’ which is used in GP 
electronic health records for storing coded information, the CPRD’s ‘medcode’ 
(which is simply a numeric equivalent of the Read code) and a text description 
(‘desc’) which is common to both the readcode and the medcode. 
Using the resources listed in Step 1, I developed an exhaustive list of synonyms 
for each disease of interest. Using Stata, I created a variable for the disease 
outcome of interest and set this to zero. I then used Stata to search the description 
of each code, and set this new variable to 1 if it contains any of the synonyms. 





import delimited “medical.txt", clear 
 
*generate a binary variable for SLE and set its value to zero 
g autoimmune_SLE=0 
 
*search the description of the medcode and change the value of variable 
autoimmune_SLE from 0 to 1 if it contains words that suggest the code might be 
related to the diagnosis of SLE 
 
replace autoimmune_SLE=1 if regexm(desc, "SLE") 
replace autoimmune_SLE=1 if regexm(desc, "[Ll]upus|LUPUS") 
replace autoimmune_SLE=1 if regexm(desc, "[Ll]ibman|LIBMAN") 




*manual check for bogus codes – manually change to autoimmune_SLE=0 if the code 
is clearly inappropriate 
 
*drop bogus codes 
drop if autoimmune_SLE==0 
 
*retain the variables of interest 
Keep medcode readcode desc autoimmune_SLE 
 
*save the file as a library 
save  "Autoimmune_SLE.dta", replace 
 
*export as an excel file for step 3 (see below) 
Export excel using “autoimmune_SLE”, replace 
Figure 2: Example syntax used to identify medcodes for SLE 
 
To cross reference and validate this, the same Stata do-file was used to search an 
additional file which contained ICD-10 codes cross-referenced to Read code and 
medcodes. As well as the text ‘description’ this file also contained a variable ‘ICD 
description’; both were searched for synonyms representing the disease of 
interest. Additionally, the code-list was then sorted by ICD-10 codes, which 
allowed relevant sections of ICD-10 to be visually inspected to ensure that no 
additional missing codes had been omitted. In some cases, this cross-check 
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helped to generate additional synonyms for searching in an iterative process. 
Unfortunately, this file is no longer provided by CPRD so was not fully up to 
date; however, using the latest CPRD lookup file (‘medical.txt’) ensured that 
newer codes were not omitted. 
Once a complete list of potential codes had been produced this was manually 
inspected for any bogus codes which were clearly inappropriate. This manual 
check for bogus codes erred on the side of caution, only rejecting codes that were 
clearly inappropriate according to predefined inclusion and exclusion criteria. 
Common reasons for exclusion were codes indicating a family history of a 
condition, absence of a condition, or screening for a condition rather than 
presence of a condition.  
The output from Step 2 was then exported to Excel as a list of potential codes for 
clinical review (Step 3).  
 
 Step 3: selection of final list by consensus 
process 
Each code-list was reviewed by me, plus at least one other GP from a panel of six 
using a modified nominal group technique.(193) Each GP independently 
categorised the list, ranking each Read code/medcode using a 3-point scale as 
follows: 
1 =  Definitely include - the code accurately defines the clinical feature of interest, and 
GPs would definitely use it. 
2 =  Uncertain – it remains unclear whether the code accurately reflects the clinical 
feature of interest, or whether GPs would use it. 
3 =  Definitely exclude – the code does not define the clinical feature of interest, and 
GPs definitely would not use it. 
Panel members were encouraged to add comments to explain the reasons for 
their inclusion/exclusion. This was shared with the panel chair and helped in 
cases of uncertainty to clarify whether disagreements reflected 
misunderstandings or problems with definition or inclusion/exclusion criteria, 
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or whether the uncertainty reflected the inherent variability in clinical coding 
between clinicians.  
Codes were retained in the final list if they were ranked as ‘1=definitely include’ 
by both reviewers. Codes ranked as ‘3=definitely exclude’ by both reviewers 
were dropped. Remaining codes were discussed with my supervisor Professor 
Willie Hamilton, a GP with significant experience of code-list collation, and final 
decisions regarding inclusion/exclusion was made by consensus.  
Full code-lists for infections and autoimmune conditions are published on the 
University of Bristol Research Data storage repository.(194) Table 4 shows the 
complete results of the consensus review for the example of SLE.   
 
Table 4: List of potential codes for inclusion to identify patients with SLE  
(1: definitely include, 2: uncertain, 3: definitely exclude) 











erythematosus 1 3 1 
As discoid lupus is 
autoimmune, we 
clarified the definition 
of the disease outcome 
to include this 
4125 Lupus erythematosus 1 1 1  
7522 Lupus erythematosus NOS 1 1 1  
7871 
Systemic lupus 










pericarditis 1 1 1 
 
16367 Tuberculosis - lupus vulgaris 2 3 0 






erythematosus 1 1 1 
 
22205 Lupus nephritis 1 1 1  
22205 Lupus nephritis 1 1 1  




28952 Lupus pernio 2 3 0 




erythematosus with organ 
or sys involv 1 1 1 
 
31564 
Lung disease with systemic 
lupus erythematosus 1 1 1 
 
31564 
Lung disease with systemic 








lupus erythematosus 1 1 1 
 
37492 Tuberculosis - lupus NOS 1 3 0 Included in infections 
40797 
Lupus erythematosus 



































profundus 1 3 1 
 
46675 Lupus - tuberculous 1 3 0 Infection 
47047 
BILAG - British Isles lupus 
assessment group score 1 1 1 
 
47672 
Nephrotic syndrome in 
systemic lupus 
erythematosus 1 1 1 
 
47672 
Nephrotic syndrome in 
systemic lupus 
erythematosus 1 1 1 
 
51798 
Systemic lupus activity 
measure 1 1 1 
 
57675 Libman-Sacks disease 1 1 1  
57675 Libman-Sacks disease 1 1 1  





SLEDAI-Sys lup ery dis act 








nodularis 1 1 1 
 
67637 
Tuberculosis - lupus 
exedens 1 3 0 
Infection 
94751 
Eyelid discoid lupus 
erythematosus 1 3 1 
Discoid lupus included 
as autoimmune – see 
above 
103784 
Lupus insensitive activated 




anticoagulant index 3 3 0 
 
14478 Lupus anticoagulant screen 3 3 0  
107468 
Lupus anticoagulant 




positive 3 3 0 
 
38264 Lupus inhibitor activity 3 3 0  
30919 
Lupus anticoagulant 




erythematosus 3 3 0 
 
101433 Cerebral lupus 1 1 1  
106086 
SLAM - Systemic lupus 
activity measure 1 1 1 
 
 
 Cancer code-list 
A pre-existing, validated list of 2,120 cancer-related medcodes was used to 
identify cancer diagnoses. These were developed by my supervisor Professor 
Willie Hamilton using the methods outlined in section 2.3 above for the 
Diagnosis of Symptomatic Cancer Optimally (DISCO) studies,(195) and updated 
by Dr Sarah Bailey for the CanTest collaborative.(196) These codes are mapped 
onto ICD-10 and collated into 20 common cancer sites: bladder, breast, cervix, 
head and neck, kidney, leukaemia, lymphoma, myeloma, oesophagus, pancreas, 
stomach, testis, uterus, brain, colorectal, lung, ovary, oral, melanoma, prostate 




 Autoimmune code-lists 
A full list of autoimmune conditions was developed using the Mackay and Rose 
Textbook ‘The Autoimmune Diseases’ (fifth edition).(197) This was cross checked 
against the American Autoimmune Related Diseases Association list of 
autoimmune diseases.(198) The list was developed with the aim of optimising 
sensitivity and inclusivity, with a total of 829 autoimmune-related medcodes 
identified. However, as there was a lack of clear evidence from the literature 
about which autoimmune conditions were associated with a raised inflammatory 
marker,(197) I used a data-driven approach to determine which codes to include 
in the final list of autoimmune disease. I used the full code-list of 829 medcodes 
subdivided into 22 autoimmune conditions to develop a binary variable for each 
of these 22 autoimmune conditions. I then used Chi2 testing to look for 
associations between having a code for any of these autoimmune conditions in 
the two years before or two years after testing and having a raised inflammatory 
marker at the index date. No associations between raised inflammatory marker 
and autoimmune skin conditions, psoriasis, coeliac disease, autoimmune 
neurological disorders, or autoimmune thyroid disease were found. This was 
also felt to be clinically plausible, as clinicians would be unlikely to use 
inflammatory marker testing in these conditions. A shortened code-list 
containing only autoimmune conditions with some evidence of an association 
with raised inflammatory markers was therefore produced, with 679 medcodes, 
categorised into 17 subtypes: rheumatoid arthritis, seronegative arthritis, lupus, 
vasculitis, polymyalgia rheumatica, dermatomyositis, scleroderma, sarcoid, 
inflammatory bowel disease, cardiovascular autoimmune diseases, type 1 
diabetes, haematological autoimmune diseases, Addison’s disease, liver 
autoimmune diseases, pemphigus & pemphigoid, renal autoimmune diseases 




 Infection code-lists 
A total of 2,671 medcodes associated with infection were identified and 
categorised into 16 sites: bacterial upper respiratory tract infections, viral upper 
respiratory tract infections, lower respiratory tract infections, lower urinary tract 
infections, pyelonephritis, gastrointestinal infections, diverticulitis, liver 
infections, biliary infections, genital tract infections, puerperal infections, 
cardiovascular infections, neurological infections, bone infections, skin infections 
and ‘other’. Subcategories were retained to allow sub-analyses of the types of 
infection diagnosed subsequent to inflammatory marker testing. I aimed to make 
this list inclusive, in order to maximise sensitivity, as both viral and bacterial 
infections were felt to be potentially clinically relevant in the context of a raised 
inflammatory marker. Definitions of each subtype of infection are shown in 
Appendix A.  
Chronic infections were defined as a separate subcategory (overlapping with 
several infection sites above); this included tuberculosis, HIV, Lyme disease and 
syphilis. This distinction was made on the basis that these could cause chronic 
inflammation, and therefore the cut-off for excluding those with pre-existing 
chronic infections needed to be longer (see section 2.4.5). 
 
 Data manipulation 
 Raw Data received from CPRD 
Raw data files were received from the CPRD and imported into Stata 15 for 
analysis. These included the following files: 
• Patient file; containing basic demographic and patient registration details.  
• Practice file; containing details of each practice.  
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• Clinical and referral file; these contain all events in the patients’ medical 
history including symptoms, referrals, measurements, and the date that 
these were recorded, stored as medcodes. 
• Consultation file; containing information on the type of consultation.   
• Test file; containing all blood tests, reference ranges and dates of testing. 
• Therapy file; containing all prescriptions on the GP system.  
• Matching file; containing the details of which cases match which controls. 
• Case file; containing the index date defined as the date of the first 
inflammatory marker test in 2014.  
The complete dataset contained 199,928 patients: 160,000 patients with 
inflammatory marker testing in 2014 and 39,928 matched controls. This is 
because, of the 40,000 randomly selected cases for matching, 72 were unmatched 
(no suitable age, gender and practice matched patient available in CPRD).  
 
 Linked data provided by CPRD 
Linked data provided included Cancer Registry Data, ONS Death Data, Basic 
Hospital Episode Statistics (HES) and patient level Index of Multiple Deprivation 
(IMD). Of the 199,928 patients identified in CPRD; 88,250 were eligible for 
linkage to all of these datasets. I did not solely study participants with data 
linkage in case this introduced bias; for example, limiting to patients eligible for 
HES linkage would exclude those who had not attended hospital and could 
therefore introduce bias towards higher rates of disease in the cohort.   
 
Cancer Registry Data 
Of the 199,928 patients identified in the CPRD, 110,245 were eligible for linkage 
to the cancer registry data; of these, 15,399 were identified in the cancer registry 
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data. Patients in whom it was not possible to obtain linked data were resident 
outside England, lacked a valid NHS identifier, were registered at a GP practice 
which had not consented to linkage or were individuals who had personally 
dissented from linkage. One file was obtained from the cancer registry. This 
contained the ‘epatid’; the encrypted identifier given to patients in CPRD GOLD. 
It also contained the date of diagnosis and the site of cancer, defined using ICD-
10.  
   
ONS Death Registration Data 
This data comes from death certification, which is a legal requirement in England 
and Wales, and therefore provides the most complete source for mortality 
statistics. ONS Death Registration contains death information for patients 
registered at a subset of English practices which participate in the CPRD linkage 
scheme; this linkage was available for 109,966 patients in our cohort. One file was 
obtained from ONS Death Registry containing the epatid (the encrypted patient 
identifier) and the date of death.  
 
Index of Multiple Deprivation 
Linked data for patient level index of multiple deprivation was available for 
110,181 patients. The Index of Multiple Deprivation (IMD) is a composite score, 
based on patients’ postcode, categorised into five equally sized quintiles, where 1 
corresponds to the least deprived, and 5 the most deprived. Not all patients in 
CPRD are eligible for linkage. To be eligible for inclusion patients must be 
registered in a practice which has consented to take part in the CPRD-linkage 
scheme (which is currently restricted to practices in England). They also must 
have a full postcode recorded in their electronic records, and have no record 





Basic Hospital Episode Statistics 
HES linked data was available for 93,923 patients. HES linkage is only available 
in England and only for patients who are admitted to hospital, attend accident 
and emergency departments or outpatient clinic appointments. Hospital episode 
statistics (HES) were used to obtain data on ethnicity of the sample, for 
descriptive purposes. Ethnicity data was therefore only available for the minority 
of patients who had been to hospital. Ethnicity is coded as white, black 
Caribbean, black African, black other, Indian, Pakistani, Bangladeshi, other 
Asian, Chinese, Mixed, other or unknown.  
 
 Variables generated – participant characteristics 
Raw variables used included ‘epatid’ which is the unique identifier given to each 
patient in CPRD. Several new variables were generated to allow analysis. The 
matching file was used to generate a categorical ‘case-control’ variable defined as 
follows: 
1- Matched controls: 39,928 controls without inflammatory marker testing in 2014, 
matched by age, sex and practice to a random sample of cases. 
2- Matched cases: 39,928 cases with inflammatory marker testing in 2014 with 
matched controls. 
3- Unmatched cases: 72 cases, of the 40,000 randomly selected for matching, who 
could not be matched to a control.  
4- Cohort only: 120,000 patients with inflammatory marker tests in 2014, without a 
matched control.  
A matching variable was generated to enable case-control pairs to be identified. 
All date variables were converted into ‘elapsed dates’ (calculated as the number 
of days from January 1st, 1960) which allows Stata to calculate time periods by 
adding and subtracting dates.  
CPRD provides year of birth, but not month or day of birth. In order to generate 
an age variable as a continuous variable day and month of birth were set to 1st 
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July for all patients. This allowed date of birth to be converted into ‘elapsed 
dates’ (calculated as the number of days from January 1, 1960) then subtracted 
from the index date, in order to impute age at testing. Age was then categorised 
into 10-year bands (<30, 30-39, 40-49, 50-59, 60-69, 70-79, >80).  
 
 Variables generated - index tests 
The test file was used to identify all inflammatory marker tests in the sample, 
based on the following entity types: CRP=280, ESR=273, PV=374. The first 
inflammatory marker test in 2014 was defined as the index test. Controls who did 
not have any inflammatory marker testing done were allocated the same index 
date as their matched case. Inflammatory markers were defined as raised if the 
test result (‘data2’ in CPRD) was above the mean upper limit of normal from 
laboratories within our CPRD sample (‘data6’ in CPRD). For CRP the mean 
upper limit of normal was 6.8mg/l, for ease of clinical interpretation this was 
rounded to 7mg/l; for PV this was 1.72mPa.s. For ESR this was stratified by 
gender and age (see Appendix B).  
I chose to use a set threshold for defining a raised inflammatory marker, to 
increase the clinical applicability of the findings. To explore the impact of 
differences in laboratory assays I retained a second variable defining a raised 
inflammatory marker based on an individual laboratories upper limit of normal 
to allow sensitivity analyses (see 2.5.6). As well as retaining these categorical 
variables, the continuous test results for each index test, CRP, ESR and PV 
(‘data6’ in CPRD) were retained.  
For those who had the same inflammatory marker test coded more than once on 
the same day (n=231), the highest value was retained. In most cases the duplicate 
tests were identical suggesting duplicate coding of one test.  
For those who had more than one type of inflammatory marker test done on the 
index date a binary variable for ‘any raised inflammatory marker’ was produced, 
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which was positive if either CRP, PV or ESR was raised (even if the others were 
normal).  
For patients with subsequent repeat inflammatory markers, I generated a 
categorical variable to measure the trend in CRP, ESR and PV tests (‘CRP trend’, 
‘ESR trend’ and ‘PV trend’). This measured the trend in CRP, ESR and PV in the 
first repeat test in the 3 months after the index date. For simplicity I only 
examined the first repeat test, I did not look at patterns of change over 3rd or 4th 
repeat tests. Three months was chosen as a pragmatic cut-off after discussions 
with my clinical supervisors; we felt that tests done more than three months after 
initial testing were unlikely to be related to the same clinical episode, yet a 
shorter time-period could miss relevant tests due to potential delay in organising 
follow up inflammatory marker tests. This categorical variable (‘CRP/ESR/PV 
trend’) was defined as follows: 
1 – index test in the normal range, and no repeat test done 
2 – index test normal and repeat test normal 
3 – index test normal and repeat raised 
4 – index test raised, no repeat test 
5 – index test raised, repeat test normal 
6 – index test raised, repeat test stable or lower than index, but still above the normal 
range 
7 – index test raised, repeat test rising 
To simplify the analysis for those having several tests (CRP, ESR, PV) at two 
time-intervals I created a simplified variable ‘Repeat IM trend’. This was 
categorised as follows: 
0- Normal inflammatory markers at index date 
1- One or more index test raised, no repeat test done  
2- One or more index test raised, all repeat inflammatory markers normal 
3- One or more index test raised, one or more repeat inflammatory markers raised 
 
 
 Variables generated – target condition 
The target condition was defined as any new cancer, infection or autoimmune 
conditions (combined and individually), diagnosed following inflammatory 





All cancer diagnoses, other than non-melanomatous skin cancer, were identified 
by searching the CPRD clinical and referral files for any of 2,120 cancer-related 
medcodes (see 2.3.4). Ascertainment of cancer diagnosis was improved by 
additionally using linked Cancer Registry Data. A variable ‘date difference’ was 
generated to record the time elapsed between the index date and the first dated 
record of cancer in either CPRD or Cancer Registry Data.  
A binary variable for pre-existing cancer, ‘cancer_old’ was created. Participants 
were defined as having pre-existing cancer if they had any record of cancer in 
CPRD or cancer registry in the two years prior to the index date. Historic cancers 
which had not been coded in the medical record for more than 2 years were felt 
to be unlikely to be relevant to the index inflammatory marker test, so these were 
not included in the pre-existing cancer category. Patients with undated diagnosis 
of cancer were included as having pre-existing cancer, as these undated disease 
codes tend to represent significant past history of disease. 
A binary variable for newly diagnosed cancer was created, which was positive 
for participants without pre-existing cancer, who had a record of cancer in CPRD 
or cancer registry in the 1 year after the index date. A second binary variable for 
new cancers diagnosed in the 2 years after the index date was also generated. For 
those with more than one diagnosis of cancer in the two years after the index 
date, only the first was retained. A categorical variable for cancer site was 
generated and defined as 1-21 for the following cancer sites: bladder, breast, 
cervix, head and neck, kidney, leukaemia, lymphoma, myeloma, oesophagus, 
pancreas, stomach, testis, uterus, brain, colorectal, lung, ovary, oral, melanoma, 





Autoimmune diagnoses were identified by searching the clinical and referral 
files of the CPRD records for any of the 679 autoimmune related medcodes.  
A binary variable for pre-existing autoimmune conditions was defined as 
positive if any of these pre-existing autoimmune conditions were coded in the 
two-year period before the index date. Patients with undated diagnosis of 
autoimmune conditions were also defined as having pre-existing autoimmune 
disease, as these undated disease codes tend to represent significant past history 
of disease.      
A binary variable for ‘new autoimmune conditions’ was generated for those 
without pre-existing autoimmune disease, who had one of these autoimmune 
conditions coded in the 1 year after the index date. A second variable for new 
autoimmune conditions diagnosed in 2 years was also produced. A categorical 
variable ‘new autoimmune site’ was created and defined as 1-17 for the following 
autoimmune conditions; rheumatoid arthritis, seronegative arthritis, lupus, 
vasculitis, polymyalgia rheumatica, dermatomyositis, scleroderma, sarcoid, 
inflammatory bowel disease, cardiovascular autoimmune conditions, type I 
diabetes, haematological autoimmune diseases, Addison’s, liver autoimmune 
diseases, pemphigus & pemphigoid, renal autoimmune diseases and respiratory 
autoimmune diseases.  
A variable ‘date difference’ was generated to record the time elapsed between 
the index date of testing, and the first record of an autoimmune condition in 
CPRD. For those with more than one diagnosis of autoimmune conditions in the 
two years after the index date, only the first was retained. 
 
Infections 
Infections were identified by searching the clinical and referral file for any of the 
2,671 infection-related medcodes.  
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A binary variable for pre-existing infections was generated and defined as 
positive if patients were coded as having an infection in the 30 days prior to the 
index date, on the basis that this could represent monitoring rather than new 
diagnosis of infection. A shorter time period for pre-existing infections compared 
to cancer and autoimmune conditions was chosen on the basis that patients 
could have multiple infections within a one-year time period. Patients with 
chronic systemic infections (TB, HIV, Lyme and syphilis) in the 2 years before the 
index date were also defined as having pre-existing infection. A binary variable 
indicating a new diagnosis of infection was generated for patients without pre-
existing infection who had a new infection diagnosis on or in the 30 days after 
the index date of testing.  
A variable ‘date difference’ was generated to record the time period between the 
index date of testing and the first coding of the diagnosis of an infection. For 
those with more than one diagnosis of infection in the 30 days after the index 
date, only the first was retained.  
 
Mortality 
I used two sources of data on death: CPRD recorded death date and ONS Death 
Registry Data. I generated a categorical variable for death which was positive if 
the patient was recorded as dead within 1 year of the index date according to 
either CPRD or ONS. A second variable for death within 2 years of the index date 
was also generated. Date of death was defined as the earliest of ONS and CPRD 
date of death. I generated a continuous variable of death interval which was 





Any relevant disease  
A single binary variable for ‘any relevant disease’ was generated which was 
positive if the participant had either a new diagnosis of cancer or autoimmune 
disease within 1 year of the index date, or an infection in 30 days of the index 
date.  
 
 Additional variables generated 
Patient symptoms 
In order to identify the main symptoms associated with inflammatory marker 
testing I searched the clinical and referral file for all medcodes in the 28 days 
prior to and including the index date. I retained the top 200 medcodes most 
frequently recorded in this period in patients with raised inflammatory markers, 
the top 200 medcodes in patients with normal inflammatory markers and the top 
200 medcodes in the 40,000 untested control group. The untested group were 
included as a comparator, to determine whether symptoms were at a higher 
frequency in the tested group.  
These three lists were merged and manually reviewed. All medcodes which did 
not represent symptoms were dropped, including administrative codes and non-
specific codes such as ‘had a chat to patient’. This left a total of 57 medcodes, 
representing the most commonly coded symptoms before the index date. Several 
of these were very closely overlapping (e.g., ‘Tiredness symptom’ and ‘Tired all 
the time’). The International Classification of Primary Care (ICPC) was used to 
categorise these 57 medcodes into 45 distinct symptoms. ICPC provides lists of 
symptoms and diagnoses, provides synonyms for each symptom, and most 
importantly, lists what should be excluded from the definition of each symptom. 
Frequency counts were used to determine the 20 symptoms most frequently 
occurring in the 28 days before the index date in the total dataset from this list of 
45 symptoms. I then used the methods described in section 2.3 to generate 
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complete code-lists for each of these symptoms. Existing code-lists developed by 
Dr Sarah Bailey using the same ICPC definitions were used as a starting point. 
Finally, these symptom code-lists were applied to the full dataset to create a 
binary variable to signify the presence or absence of each of the 20 symptoms in 
the 28 days prior to the index date.  
 
Process outcomes: frequency of appointments, referrals and 
blood tests after inflammatory marker testing 
Variables were generated to count the frequency of blood tests, phlebotomy 
appointments and referrals following inflammatory marker testing.  
The CPRD consultation file was used to generate a variable to record the number 
of consultations in the 6 months after the index date. The consultation file 
contains a variable ‘constype’ which defines the type of consultation. All 
administrative consultations were dropped, as were consultations with a 
duration of 0 minutes, which were assumed to be bogus. Telephone 
consultations, face to face consultations and home visits were retained. A date 
difference variable was generated to measure the elapsed dates between the 
consultation and index date; those in the 6-month period after the index date 
were retained. A new variable ‘consultation count’ was generated which counted 
the number of consultations in this 6-month period. The same process was 
followed using the referral file, to count the number of referrals in the 6 months 
following testing.  
Finally, the test file was used to count the number of blood tests in the 6 months 
following the index date. Two variables were created here; the first counted the 
number of phlebotomy appointments by counting the number of new test dates 
per patient in the 6 months following the index date. The second counted the 




 Statistical methods and analysis 
The statistical methods are mapped to each of the objectives listed in section 
1.9.2. Analysis was performed using Stata15.(199)  
 
 Objective 1: Epidemiology of inflammatory 
marker testing 
Objective 1 was to describe the baseline characteristics in terms of age, gender, 
socioeconomic status and ethnicity of patients having inflammatory marker tests 
in primary care. 
Summary statistics were calculated using Stata to describe the epidemiology of 
inflammatory marker testing in terms of the age, gender, ethnicity and 
socioeconomic status of the tested population. Logistic regression was used to 
calculate the odds of a raised inflammatory marker by age group, gender and 
socioeconomic status. Continuous test results were explored using histograms. 
Scatterplots were used to explore associations between inflammatory markers 
where more than one test was performed simultaneously.  
 
 Objective 2: Inflammatory markers and overall 
disease outcomes 
Objective 2 was to determine the diagnostic accuracy of CRP, ESR and PV, singly 
and in combination, for relevant disease (infections, autoimmune conditions or 
cancer) in primary care, and to compare disease incidence in tested versus 
untested populations. 
This objective was further broken down as follows: 
80 
 
2a) To determine the incidence of disease following inflammatory marker 
testing in primary care 
2b) To determine the association between inflammatory marker level and 
disease incidence 
2c) To determine the comparative diagnostic accuracy of CRP, ESR and PV 
for relevant disease in primary care  
2d) To determine whether measuring two inflammatory markers 
simultaneously increases diagnostic accuracy  
 
Objective 2a + 2b: Incidence of disease 
Participants with pre-existing disease were excluded from analysis of disease 
outcomes, including 4,489 with cancers, 11,129 autoimmune conditions and 9,148 
infections. This is because I was interested in the utility of inflammatory markers 
for diagnosis, not the utility of tests for monitoring purposes or in those with 
known inflammatory conditions.  
In the remaining 174,500 participants, the overall incidence of relevant diseases, 
including infections, autoimmune diseases and cancers (combined and 
individually), was calculated in patients with raised inflammatory markers 
versus those with normal inflammatory markers, and in tested versus untested 
controls. The incidence of disease in the test positive/raised inflammatory 
marker group is equivalent to the positive predictive value (PPV).  
To aid interpretation and clinical utility, test results and disease outcomes were 
presented using a test consequences graphic based on a nominal primary care 
tested population of 1000 people.(184) 
For those with multiple inflammatory marker tests performed simultaneously, 
disease incidence was calculated in three subgroups: those with multiple raised 
inflammatory markers, those with discordant results (one raised, one normal), 
and those with multiple normal results.  
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For those with a raised inflammatory marker at the index date, disease incidence 
was calculated in three subgroups: those with no repeat inflammatory marker 
tests done in the subsequent 3 months, those with normal repeat inflammatory 
markers, and those with one or more persistently raised inflammatory marker.  
Continuous test results for CRP, PV and ESR were categorised into quintiles, and 
incidence of infections, autoimmune conditions and cancers calculated in each 
subgroup in order to explore the dose-response relationship between disease 
incidence and inflammatory marker levels.  
 
Objective 2c: Diagnostic accuracy  
For each of the three tests (CRP, ESR and PV), dichotomised test results were 
cross classified with the target condition ‘any relevant disease’, allowing 
sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) to be calculated using the formulae listed in Figure 3. The STATA 
module DIAGT(200) was used to generate 2x2 tables and calculate measures of 
diagnostic accuracy. Logistic regression was used to calculate diagnostic odds 
ratios, with and without adjustment for age and gender. As well as looking at 
‘any relevant disease’ I also calculated measures of diagnostic accuracy 
separately for each of the three disease subtypes: infection, autoimmune 







True positives People with relevant disease who have a positive IM test result  TP 
True negatives People without relevant disease who have a negative IM test result  TN 
False positives People without relevant disease who have a positive IM test result  FP 
False negatives People with relevant disease who have a negative IM test result  FN 
Sensitivity Proportion of patients with relevant disease who have a positive IM 
test result 
TP/(TP + FN)  
Specificity Proportion of patients without relevant disease who have a negative 
IM test result 
TN/(FP+ TN)  
Positive predictive 
value (PPV) 





Probability that a patient with a negative IM test result does not have 
relevant disease 
TN/(FN+TN) 
Figure 3: 2x2 table showing the cross-classification of index test and reference 
standard results and overview of measures of accuracy that can be calculated from 
these data (adapted from Whiting et al (201)) 
 
To address potential concerns that differences in patient mix could lead to biased 
estimates (for example CRP used preferentially in patients with suspected 
infection), sensitivity analyses were done on the subgroup of participants who 
had two tests performed simultaneously to allow head-to-head comparison of 
diagnostic test accuracy.  
Test results were also treated as continuous variables on a log scale (due to their 
skewed distribution) to assess their predictive value in a logistic regression 
model, with and without age and gender as additional explanatory variables, 
calculating the area under curve (AUC), otherwise known as the c-statistic. Sub-




Objective 2d: Accuracy of test results in combination 
I examined the accuracy of two combinations of inflammatory markers: CRP plus 
ESR (n=43,820) and CRP plus PV (n=9,575). Only 111 patients had ESR plus PV 
and 306 had all three tests so I did not examine these test combinations. Where 
two inflammatory markers were performed simultaneously, I calculated 
measures of diagnostic accuracy (sensitivity/specificity/PPV/NPV) for two 
alternative definitions of an overall positive result: 
• Both inflammatory markers raised (denoted, for example, as CRP + ESR or CRP 
+ PV)  
o Defined as a combined test where both inflammatory markers tested 
were positive. 
• Either inflammatory marker raised (denoted, for example, as CRP|ESR or 
CRP|PV)  
o Defined as a combined test where either of the inflammatory markers 
tested were positive. 
 
The AUC for test combinations were calculated using a logistic regression model 
with log transformed test values, including age and gender as co-variates. An 
interaction term was used in the model due to the associations between 
inflammatory marker test results. The AUCs for CRP and ESR combined was 
compared to the better of the two individual tests using the DeLong method(202) 
generating confidence intervals and p-values. The AUC for CRP and PV 




 Objective 3: Symptoms and cascade testing 
Objective 3 was to determine the symptomatology of patients with inflammatory 
marker testing in primary care and measure the consequences of testing in terms 
of numbers of consultations, blood tests and referrals.  
Frequency counts were used to measure frequency of symptoms in the 28 days 
up to and including the index date in three subgroups: those with normal 
inflammatory markers, those with raised inflammatory markers and untested 
controls. This allowed measurement of the symptoms triggering testing, and 
exploration of which symptoms were more commonly associated with a positive 
test result.  
Frequency counts were used to measure the number of appointments, referrals 
and blood tests in the 6 months after testing in five subgroups: true positives, 
false positives, true negatives, false negatives and untested controls. 
Comparisons were made between true positives and false negatives and between 
false positives and true negatives using t test to calculate p-values.  
 
 Objective 4: Inflammatory markers and cancer 
Objective 4 was to determine the diagnostic accuracy of inflammatory markers 
for cancer diagnosis in primary care, including stratification by age, gender, 
inflammatory marker level and cancer type.  
This objective was further broken down as follows:  
4a) What is the diagnostic accuracy of inflammatory markers, singly and in 
combination for cancer?  
4b) How does this vary by age and gender? 
4c) What is the association between inflammatory marker level and cancer? 
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4d) Which types of cancer are diagnosed following inflammatory marker 
testing? 
The primary analysis reported the one-year cancer incidence (hereafter referred 
to as ‘cancer incidence’) for patients with raised versus normal inflammatory 
markers, and versus untested patients.  
I also stratified analysis according to whether multiple inflammatory markers 
showed concordant or discordant results, whether repeat inflammatory markers 
were normal or abnormal, and according to symptoms recorded in CPRD in the 
28 days prior to testing.  
The effect of age and gender on the incidence of disease was examined using a 
stratified analysis with sub-groups defined by gender and age at index date. The 
incidence of any relevant disease and corresponding 95% confidence intervals 
were estimated separately for men and women in each age group, for patients 
with raised inflammatory markers, normal inflammatory markers and untested 
controls.  
I used logistic regression to examine the dose-response relationship between 
CRP, ESR and PV test results as continuous variables, and cancer diagnosis as a 
binary variable, also generating a receiver-operating characteristic (ROC curve). 
Logistic regression was also used to generate diagnostic odds ratios (DOR), 
which were adjusted for age and gender.  
A fractional polynomial model was used to model the relationship between 
cancer incidence and inflammatory markers as a continuous predictor, in order 
to accommodate the non-linearity in the relationship. These analyses were 
performed separately for men and women.  
Frequency count was used to measure the types of cancer diagnosed following 




 Objective 5: Inflammatory markers and 
mortality 
Objective 5 was to explore the association between inflammatory markers and 
one-year mortality in primary care.  
This objective was further broken down as follows:  
5a) What is the predictive value of inflammatory markers, singly and in 
combination for one-year mortality? 
5b) How does this vary by age and gender? 
5c) What is the association between inflammatory marker level and 
mortality? 
5c) What is the cause of death in patients with a raised inflammatory 
marker? 
The index date was defined as the first date of inflammatory marker testing in 
2014, with one-year mortality defined as death within one year of this index date. 
Date of death was defined as the earlier date of recorded death in either CPRD or 
ONS death registry. Cause of death was available from death certification data in 
3,141 out of 5,512 deaths where ONS linkage was available.  
The primary analysis reported the one-year mortality (hereafter referred to as 
‘mortality’), stratified by age and gender, for patients with raised versus normal 
inflammatory markers, and versus untested patients. Sub-analyses were 
stratified according to whether multiple inflammatory markers showed 
concordant or discordant results, and whether repeat inflammatory markers 
were normal or abnormal. I used logistic regression to examine the dose-
response relationship between CRP, ESR and PV test results as continuous 
variables, and mortality as a binary variable, also generating a receiver-operating 
characteristic (ROC curve). Logistic regression was also used to generate 
diagnostic odds ratios (DOR), with and without adjustment for age and gender.  
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A fractional polynomial model was used to model the relationship between 
mortality and inflammatory markers as a continuous predictor, in order to 
accommodate the non-linearity in the relationship.  
Frequency count was used to measure cause of death in those with ONS registry 
linkage in three groups: untested controls, normal inflammatory markers and 
raised inflammatory markers.  
 
 Sensitivity analyses 
Several sensitivity analyses for overall disease outcomes were performed; 
excluding those with less than one year follow up in CPRD (for example patients 
moving practice), using the laboratory’s own upper limit of normal rather than 
our own derived thresholds and finally restricting analysis only to those patients 
eligible for linkages. 
 
 Summary 
In this chapter I have outlined the methods of the CPRD study, including the 
aims and objectives, study design, sources of data, methods of code-list 
development, stages of data manipulation and finally statistical methods and 
analyses used. In the next chapter I will present the results of this study, and in 
the final discussion chapter I will explore the strengths and weaknesses, and 





CHAPTER 3.  QUANTITATIVE 
RESULTS 
 Chapter overview 
The overall aim of this chapter is to describe the diagnostic utility of 
inflammatory markers in primary care for relevant disease, including infection, 
autoimmune disease, and cancer. The results are mapped onto the quantitative 
objectives which were listed in section 1.9.2. Detailed methodology has been 
described in Chapter 2.  
 
 Objective 1: Epidemiology of 
inflammatory marker testing 
Objective 1 was to describe the baseline characteristics in terms of age, gender, 
socioeconomic status, and ethnicity of patients having inflammatory marker tests 
in primary care. 
 
 Study sample 
From 12,905,266 potentially eligible patients aged >18 in CPRD GOLD in 2014, 
3,197,446 (24.8%) have had an inflammatory marker test at some point, of these 
463,304 (3.6%) had one or more inflammatory marker test in 2014. Of these 
160,000 were selected at random by CPRD. Patients with missing inflammatory 
marker test results were excluded from the analysis (n=673) as well as 2 patients 
with test results so abnormal they were considered spurious, leaving 159,375 





Baseline characteristics of the cohort are shown in Table 5. The overall cohort 
was 61.6% female with a median age of 55.4 years (interquartile range 41.1 - 69.9 
years). Compared to the UK adult population, the tested cohort was more likely 
to be female (62.0% versus 51.3%), of white ethnicity (87.8% versus 85.4%), and 
from the most affluent socioeconomic quintile (23.1% versus 20.0%).    
 
Table 5: Characteristics of the tested cohort, compared to the UK population(203) 
and compared to the population attending GP practices(204) 
Patient 
Characteristic 








Gender: (159,325) (39,928) * ** 
Male 38.0% 38.2% 48.7% 39.8% 
Female 62.0% 61.8% 51.3% 60.2% 
Age Group: (159,325) (39,928) * ** 
18-29 10.9% 10.8% 20.2% 12.5% 
30-39 11.4% 11.5% 16.4% 13.7% 
40-49 15.9% 15.8% 17.8% 14.7% 
50-59 17.6% 17.7% 16.3% 14.1% 
60-69 17.7% 17.3% 13.9% 16.3% 
70-79 15.1% 15.4% 9.4% 15.5% 




(87,839) (22,063)   
1 (least deprived) 23.1% 23.9% 20.0%  
2 21.9% 22.2% 20.0%  
3 21.6% 21.4% 20.0%  
4 19.1% 19.0% 20.0%  
5 (most deprived) 14.2% 13.6% 20.0%  
Ethnicity*: (75,802) (17,868) **  
White 87.8% 87.7% 85.4%  
Non-white 12.3% 12.4% 14.6%  
*IMD linkage and ethnicity data was not available for the complete dataset, hence a lower 




 Tests requested 
Figure 4 shows the tests requested; 114,198 (71.7%) had a CRP test, 92,325 (58.0%) 
had an ESR and 15,994 (10.0%) had a PV test. Of those tested, 96,536 (60.6%) had 
a single inflammatory marker at the index date, and 62,790 (39.4%) had more 
than one inflammatory marker; mostly CRP and ESR (51,949), followed by CRP 
and PV (11,107). Four hundred and three had all three inflammatory markers 
tested simultaneously.  
 
 
Figure 4: Inflammatory marker tests requested by GPs in the cohort 
 
 Test results 
Of the overall tested cohort, 47,797 (30.0%) had at least one raised inflammatory 
marker; 25.5% of CRP tests were raised, 25.1% of ESR tests were raised and 28.6% 
of PV tests were raised. In those with a single inflammatory marker tested, 25.9% 
had a raised inflammatory marker. In comparison, 36.3% of those with multiple 
simultaneous tests done had one or more raised inflammatory marker; 14.4% had 
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concordant raised values and 22.0% had discordant results (one raised, one 
normal).  
Figure 5 shows a scatter plot showing the association between CRP and ESR test 
results for those who had these two tests performed simultaneously. Whilst an 
association was seen, the R-squared was only 0.285, meaning that only 28% of the 
movement in the independent variable can be explained by the dependent 
variable. Figure 6 shows a similar association between CRP and PV test results, 
this time the R-squared was only 0.194. This demonstrates that, whilst there is an 
association between these inflammatory markers, they are not closely correlated.  
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Figure 6: Scatterplot of CRP against PV test results with fitted linear regression 
line 
 
Mean unadjusted test results by age, gender and index of multiple deprivation 
are shown in Table 6. For all three tests the mean test result increased with 
increasing age. Mean CRP test results were higher in men, ESR test results were 
higher in women, for PV no gender difference was seen. Higher mean ESR test 
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Table 7 shows the overall odds of a raised inflammatory marker according to 
demographic characteristics, with and without adjustment. Raised inflammatory 
markers were more common amongst the most deprived socioeconomic quintile 
(adjusted OR 1.39, 95% CI 1.32–1.46, p<0.001), more common amongst women 
(adjusted OR 1.13, CI 1.10-1.17, p<0.001) and more common with increasing age.   
 
 
Table 6: Mean test results according to age, gender, socioeconomic status and 
ethnicity (unadjusted) 
 Mean test result (SD) 
Patient Characteristic CRP ESR PV 
Gender:    
Male 12.4 (30.7) 12.0 (17.0) 1.68 (0.16) 
Female 9.9 (27.7) 15.1 (16.2) 1.68 (0.14) 
Age Group:    
18-29 7.7 (20.9) 8.3 (10.0) 1.64 (0.11) 
30-39 7.7 (20.8) 9.5 (11.3) 1.66 (0.17) 
40-49 7.7 (21.6) 10.7 (12.6) 1.66 (0.13) 
50-59 8.9 (23.6) 12.7 (14.3) 1.68 (0.13) 
60-69 11.6 (29.6) 15.4 (17.6) 1.69 (0.14) 
70-79 14.6 (33.4) 18.6 (19.8) 1.70 (0.18) 
≥80 18.7 (37.6) 22.9 (22.7) 1.71 (0.16) 
IMD Socioeconomic 
Status: 
   
1 (least deprived) 10.2 (27.1) 13.2 (16.2) 1.67 (0.12) 
2 10.5 (27.4) 13.8 (16.4) 1.68 (0.17) 
3 10.6 (27.9) 13.9 (16.9) 1.68 (0.14) 
4 11.0 (28.1) 14.0 (16.2) 1.69 (0.13) 
5 (most deprived) 11.4 (29.2) 14.1 (16.6) 1.69 (0.14) 
Ethnicity***:    
White 11.6 (29.8) 14.4 (15.8) 1.68 (0.14) 





Table 7: Odds of any raised inflammatory marker (CRP, ESR or PV) by age 
group, gender, ethnicity and socioeconomic status 
 Unadjusted model Adjusted* 
 OR 95% CI OR 95% CI 
Gender:  
Male 1.0  1.0  
Female 1.15 1.13 to 1.18 1.13 1.10 to 1.17 
Age Group:  
18-30 1.00  1.0  
30-39 1.21 1.15 to 1.27 1.19 1.11 to 1.29 
40-49 1.25 1.19 to 1.31 1.24 1.16 to 1.33 
50-59 1.47 1.41 to 1.54 1.47 1.38 to 1.58 
60-69 1.83 1.76 to 1.92 1.83 1.72 to 1.96 
70-79 2.15 2.05 to 2.25 2.13 1.99 to 2.28 




1 (least deprived) 1.00  1.0  
2 1.10 1.05 to 1.14 1.10 1.05 to 1.15 
3 1.15 1.10 to 1.20 1.17 1.11 to 1.22 
4 1.23 1.18 to 1.29 1.30 1.24 to 1.37 
5 (most deprived) 1.28 1.22 to 1.35 1.39 1.32 to 1.46 
Ethnicity:  
White 1.0  1.0  
Non-White 1.00 0.96 to 1.05† 1.12 1.07 to 1.18 
   *Adjusted for gender, age group, IMD socioeconomic status, and ethnicity 
 
 Repeat testing 
The overall mean number of repeat inflammatory marker tests performed in the 
12 months following the index date was 1.09 (ranging from 0 to 104 repeat tests). 
This figure counts each additional CRP, ESR or PV test performed 
simultaneously or sequentially after the index date as one repeat test. For those 
with normal inflammatory markers at the index date the mean number of repeat 
tests was 0.80, for those with a single raised inflammatory marker at the index 
date this increased to 1.32, with discordant inflammatory markers (one raised 
one normal) this was 1.84 and with multiple raised inflammatory markers there 
was an average of 2.91 repeat tests. The majority of these repeat tests were done 
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in the first 3 months after the index date (see Figure 7). This shows that raised 
inflammatory markers are associated with repeat inflammatory marker testing, 
usually within 3 months of the first test.  
 
Figure 7: Histogram showing the number of days between the index and the first 
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 Objective 2: Inflammatory markers and 
overall disease outcomes 
Objective 2 was to determine the diagnostic accuracy of CRP, ESR and PV, singly 
and in combination, for relevant disease (infections, autoimmune conditions or 
cancer) in primary care, and to compare disease incidence in tested versus 
untested populations. 
This objective was further broken down as follows: 
2a) To determine the incidence of disease following inflammatory marker 
testing in primary care. This is covered in section 3.3.2 to 3.3.4. 
2b) To determine the association between inflammatory marker level and 
disease incidence. This is covered in section 3.3.5. 
2c) To determine the comparative diagnostic accuracy of CRP, ESR and PV 
for relevant disease in primary care. This is covered in section 3.3.6 and 
3.3.8 
2d) To determine whether measuring two inflammatory markers 
simultaneously increases diagnostic accuracy. This is covered in section 
3.3.7 and 3.3.9 
The results described below have been published in the following Open Access 
articles distributed in accordance with the terms of the Creative Commons 
Attribution (CC BY 4.0) license: 
• Watson J, Salisbury C, Whiting P, Banks J, Pyne Y, & Hamilton W. (2019). 
Added value and cascade effects of inflammatory marker tests in UK 
primary care: a cohort study from the Clinical Practice Research Datalink. 
British Journal of General Practice, 69(684), e470-e478. 
https://doi.org/10.3399/bjgp19X704321   
• Watson J, Jones H, Banks J, Whiting P, Salisbury C, & Hamilton W. (2019). 
Use of multiple inflammatory marker tests in primary care: using Clinical 
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Practice Research Datalink to evaluate accuracy. British Journal of General 
Practice, 69(684), e462-e469. https://doi.org/10.3399/bjgp19X704309  
 
 Study sample 
As the aim of this analysis was to explore new diagnosis of infection, 
autoimmune disease, or cancer, those with pre-existing disease were excluded 
(4,489 cancers, 11,129 autoimmune conditions, 9,148 infections) as well as 660 
with missing test results and 2 with test results so abnormal they were 
considered spurious, leaving 136,961 in the final cohort (see Figure 8).  
 
 
Figure 8: Flowchart showing exclusions 
*Matched untested consists of 39,928 because of the 40,000 from the cohort who were 




 Overall disease incidence 
The overall disease incidence in the tested cohort was 8.49%: 3.88% infections, 
2.75% autoimmune conditions, 2.12% cancers. This compares to 3.44% disease 
incidence in the untested comparison cohort; 2.02% infections, 0.53% 
autoimmune conditions and 0.94% cancer. This demonstrates an increased 
disease incidence in the population selected for inflammatory marker testing. 
When the tested population were subdivided according to test results, the overall 
incidence of disease in patients with a raised inflammatory marker (PPV) was 
15.0%: 6.3% infections, 5.6% autoimmune conditions, 3.7% cancers (Table 8). In 
comparison, in those with normal inflammatory markers overall disease 
incidence was 6.0%: 2.9% infections, 1.7% autoimmune disease and 1.5% cancers. 
The disease incidence in those with normal inflammatory markers is lower than 
the raised inflammatory marker group, but higher than the untested comparison 
cohort (Table 8).  
Types of infection and autoimmune disease diagnosed in those with raised 
inflammatory markers are shown in Table 9 and Table 10, cancer types are 
shown in Table 24. The most frequent types of infection diagnosed following a 
raised inflammatory marker were pneumonia, urinary tract infections, upper 
respiratory tract infections and cellulitis. The most frequent types of autoimmune 
condition diagnosed following a raised inflammatory marker were polymyalgia 














































*All inflammatory marker tests normal **one or more inflammatory markers raised 
 
 
Table 9: Types of infection diagnosed following a raised inflammatory marker test 
Type of infection  Frequency % 
Pneumonia 640 26.6% 
Urinary tract infection 529 22.0% 
Viral upper respiratory tract 
infections* 
316 13.1% 
Cellulitis 212 8.81% 
Bacterial upper respiratory tract 
infections** 
181 7.52% 
Hepatobiliary infections 72 3.00% 
Diverticulitis 54 2.24% 
Other gastrointestinal infections 53 2.20% 
Pyelonephritis 31 1.29% 
Genital infections 28 1.16% 
Other*** 291 12.1% 
Total 2,407 100% 
*including laryngitis, pharyngitis, influenza and common cold ** Including mastoiditis, 
streptococcal pharyngitis, otitis media, tracheitis, tonsillitis, sinusitis ***Infections occurring in 
<1% merged into ‘other’ including bone and joint infections, cardiovascular infections, 





Table 10: Types of autoimmune disease diagnosed following a raised 
inflammatory marker test 
Type of autoimmune 
disease 
Frequency % 
Polymyalgia rheumatica 862 33.5% 
Rheumatoid arthritis 716 27.8% 
Inflammatory bowel disease 298 11.6% 







Renal autoimmune diseases* 46 1.79% 
Sarcoidosis 43 1.67% 
Scleroderma 43 1.67% 
Liver autoimmune diseases 29 1.13 
Lupus 26 1.01% 
Other** 165 6.4% 
Total 2,574 100% 
*For definitions see Appendix A: Autoimmune diseases and infections included in analysis 
**autoimmune conditions comprising <1% merged into ‘other’ 
  
Figure 9 and Figure 10 show the test consequences in terms of test results and 
disease outcomes, simplified to a nominal population of 1000 tested patients, 
using natural frequencies to aid interpretation and clinical utility. Figure 9 uses 
the graphic developed by Whiting et al,(184) Figure 10 presents the same data 
using a modified Cates plot. Of those with a positive test result, 85.0% had no 
evidence of infection, autoimmune condition or cancer (‘false positives’).  
 
 




Figure 10: Test consequences graphic using a modified cates plot
 
 Disease incidence and multiple simultaneous 
inflammatory marker tests  
Table 11 shows the incidence of disease for those with a single inflammatory 
marker on the index date, in comparison to those with multiple simultaneous 
inflammatory markers on the index date. Overall disease incidence was 8.17% in 
the single tested group compared to 8.98% in the double tested group. In the 
double tested group, disease incidence was higher in the group with concordant 
raised values (22.6%), compared to those with a single raised value (10.4%) 
(Table 11). The negative predictive value for any single normal inflammatory 
marker was 94.0%, compared to 94.1% with multiple normal tests. 
 
Table 11: Overall disease incidence for single versus double tested patients 
















































































*This includes patients with two and three inflammatory marker tests. If two or more tests were 
raised patients were included in the ‘multiple raised inflammatory markers’; those with only one 
raised inflammatory marker were included in the ‘discordant results’ category.  
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 Disease incidence and repeat testing  
Of those with one or more raised inflammatory marker (n=38,010), incidence of 
disease was highest amongst those with persistently raised inflammatory 
markers on repeat testing, lower in those with normal inflammatory markers on 
repeat testing, and lowest amongst those without repeat testing in the next 90 
days (Table 12). Cancer was the notable exception; those with a normal repeat 
test had a lower disease risk (2.11%) than those without repeat testing (3.57%).  
 
 
Table 12: Disease incidence according to repeat inflammatory marker test results 
in those with one or more raised inflammatory marker at the index date 
(n=38,010) 







No repeat inflammatory 
markers done (n= 27,874) 






Repeat inflammatory markers 
normal (n=3,314) 






One or more raised 
inflammatory marker on 
repeat testing (n=6,822) 








 Disease incidence and inflammatory marker 
levels 
Incidence of disease increased with rising inflammatory marker levels in a dose-
response relationship (Figure 11). With CRP ≥100mg/L (n=1552), 501 (32.3%) 
developed one or more relevant diseases: 109 (7.02%) cancers, 99 (6.38%) 
autoimmune conditions and 317 (20.2%) infections. With ESR ≥100mm/h 
(n=389), 141 (36.3%) developed one or more relevant diseases: 59 (15.2%) cancers, 
60 (15.4%) autoimmune conditions and 36 (9.25%) infections. With PV ≥2mPas 
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(n=276), 81 (29.4%) developed one or more relevant diseases: 30 (10.9%) 
developed cancer, 38 (13.8%) developed autoimmune conditions and 15 (5.43%) 
developed infections.  
 
 
Figure 11: Incidence of relevant disease in relation to test result for CRP, ESR and PV 
























































 Diagnostic accuracy of single inflammatory 
marker tests: sensitivity, specificity, PPV, NPV 
Table 13 summarises the detailed performance characteristics of each of the three 
tests (CRP, ESR, PV) for the primary outcome of any relevant disease as well as 
for each of the three disease outcomes separately. All three tests had sensitivities 
below 50% for any relevant disease. CRP, ESR and PV were broadly similar in 
terms of sensitivity, specificity, PPV and NPV. 
In order to address the issue of confounding by indication, sensitivity analyses 
were done to calculate the measures of diagnostic accuracy limited to subgroups 
with both CRP and ESR done together (Table 14) and with CRP and PV together 
(Table 15); minimal differences to overall results were found. Very few patients 
had both ESR and PV done together so it was not possible to directly compare 
these tests.  
 





























































































































Plasma viscosity n = 13,989 
Any relevant 
disease 


















































*p<0.001 **DOR=Diagnostic odds ratio: the ratio of the odds of test being positive in disease relative to the odds of positivity in the non-disease 
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*DOR=diagnostic odds ratio, adjusted for age and gender 
 

















































*DOR=diagnostic odds ratio, adjusted for age and gender
 
 Diagnostic accuracy of test results in 
combination: sensitivity, specificity, PPV and 
NPV 
For two simultaneous inflammatory marker tests, by definition, sensitivity and 
specificity vary depending on how the results are interpreted. Where tests were 
performed simultaneously, measures of diagnostic accuracy 
(sensitivity/specificity/PPV/NPV) were calculated for two alternative 
definitions of an overall positive result: 
 
Both inflammatory markers raised 
(denoted, for example, as CRP + ESR or CRP + PV)  
Defined as a combined test where both inflammatory markers tested were 
positive. 
Either inflammatory marker raised  
(denoted, for example, as CRP|ESR or CRP|PV)  
Defined as a combined test where either of the inflammatory markers tested 
were positive. 
 
Results are shown in Table 16. If an overall positive result was defined as both 
inflammatory markers raised (e.g. CRP + ESR), then PPVs were higher, 
specificity was increased, but at the price of lower sensitivity, compared to using 
any single test.   
If the combined test was defined as either inflammatory marker raised (e.g. 
CRP|ESR), then sensitivity increased but specificity fell compared to any single 
test. This led to fewer false negatives or reduced risk of missed diagnoses but a 
markedly increased frequency of false positives; for example, CRP alone 
generated false positives in 19.3% of those tested, compared to 32.5% false 
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positives for CRP|PV.  The maximum sensitivity was 60.6% for the test 
combination CRP|PV. The maximum specificity was 89.3% for the test 
combination CRP + ESR.  
 
 
Table 16: Measures of diagnostic accuracy of two inflammatory marker tests in combination for relevant disease (infection, 











































































































*CRP + ESR; positive test defined as both CRP and ESR positive. **CRP | ESR; positive test defined as either CRP or ESR positive ***DOR=diagnostic odds 
ratio, adjusted for age and gender 
 
 Comparative accuracy of inflammatory marker 
tests: area under curve (AUC) 
Pairwise comparisons of AUC for CRP versus ESR (Table 17; Figure 12) and CRP 
versus PV (Table 18; Figure 13) were done in those with multiple simultaneous 
tests, in a model containing age and gender as additional explanatory variables. 
Receiver operating curves comparing CRP and ESR are shown in Figure 12, 
curves comparing CRP and PV are shown in Figure 13. Very few patients had 
ESR and PV simultaneously, so it was not possible to directly compare these two 
tests.  
Comparing CRP with ESR, CRP had a slightly higher AUC for infection (Table 
17: AUC 0.617 versus 0.589, p=<0.0001). There was no significant difference in 
the AUC of CRP and ESR for diagnosis of cancer or autoimmune disease 
(including the main subtypes of autoimmune disease: rheumatoid arthritis, 
seronegative arthritis, polymyalgia rheumatica or inflammatory bowel disease).  
Comparing CRP and PV, a higher AUC of CRP for infection was found (Table 
18: AUC 0.638 versus 0.597, p=0.004), with no difference for cancer (p=0.49) or 
autoimmune disease (p=0.97). The accuracy of CRP versus PV was not compared 





Figure 12: ROC curves comparing CRP (blue lines) and ESR (red lines) in 
patients with both CRP and ESR performed simultaneously (n=43,820) for any 





Figure 13: ROC curves comparing CRP (blue lines) and PV (red lines) in patients 
with both tests performed simultaneously (n=9,575) for any relevant disease, 




 Comparative accuracy of test results in 
combination: area under curve (AUC) 
The accuracy of CRP and ESR in combination, was compared to the better of the 
two individual tests (Table 17). There was no improvement in AUC for CRP and 
ESR in combination for infection. The combined test CRP plus ESR gave an 
increase of 0.014 in the AUC for autoimmune disease (p<0.001) and 0.003 
increase in AUC for cancers (p=0.006). Whilst these p-values reach conventional 
thresholds for statistical significance, the differences are unlikely to be of a 
magnitude to be clinically significant. The combined test did not increase the 
AUC for polymyalgia rheumatica, seronegative arthritis or inflammatory bowel 
disease, and led to a small increase of 0.009 in the AUC for rheumatoid arthritis 
(p=0.007). 
Similarly, the combination of CRP and PV together gave no improvement in 
AUC, compared to the better of the two individual tests, for infection or cancer 
(Table 18). The combined test CRP and PV gave an increase of 0.022 in the AUC 
for autoimmune disease, although the p-value was 0.09 the magnitude of the 
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*AUC = area under the receiver operating curve, where AUC=0.5 is equivalent to no diagnostic 
utility and AUC=1 is perfect diagnostic accuracy. AUC was calculated using logistic regression 
modelling with test result(s) on a log scale and age and gender as additional explanatory 
variables **Where disease sub-types were examined, diseases other than the specified condition 





Table 18: Comparison of overall test performance amongst those with both CRP 









for CRP v 
PV 
CRP and PV 
AUC (95% 
CI) 































Cancer (n=183) 0.753 






*AUC = area under the receiver operating curve, where AUC=0.5 is equivalent to no diagnostic 
utility and AUC=1 is perfect diagnostic accuracy. AUC was calculated using logistic regression 
modelling with test result(s) on a log scale and age and gender as additional explanatory 
variables 
**Where disease sub-types were examined, diseases other than the specified condition reported 
were classified as non-disease 
 
 
 Sensitivity analyses 
In order to test the robustness of the data, several additional sensitivity analyses 
were performed. Firstly, analysis was restricted to those with ≥1 year of follow 
up, to ensure that loss to follow up was not introducing significant bias. 
Secondly, analysis was repeated using the laboratory specified upper limit of 
normal to define a raised inflammatory marker (rather than the mean upper limit 
of normal see 2.4.4 methods chapter).  
These sensitivity analyses gave minor differences in results which were not 





Table 19: Overall incidence of relevant disease in those with raised inflammatory 
markers, normal inflammatory markers and untested controls, in selected 
subgroups 









Full cohort  
(n=174,500) 
15.0% (14.7-15.4) 5.97% (5.83-6.12) 3.44% (3.26-3.63) 
Restricting to 
patients with ≥1 year 
follow up in CPRD 
(n=141,319) 
15.8% (15.4-16.2) 6.22% (6.05-6.39) 3.56% (3.36-3.77) 
Using laboratory 
specified upper limit 
of normal 
(n=174,500) 






 Objective 3: Symptoms and cascade testing 
Objective 3 was to determine the symptomatology of patients with inflammatory 
marker testing in primary care and measure the consequences of testing in terms 
of numbers of consultations, blood tests and referrals. 
 
 Symptoms associated with inflammatory 
marker testing 
Table 20 shows the most common symptoms in the 28 days before testing, 
ordered according to whether they were relatively more common in patients 
with normal inflammatory markers (top) or more common in those with raised 
inflammatory markers (bottom). Broadly the symptoms could be categorised into 
non-specific symptoms, abdominal symptoms, joint symptoms and infective 
symptoms. Non-specific symptoms such as tiredness, dizziness and low mood 
were relatively more common in the test negative compared to test positive 
groups, indicating that these non-specific symptoms are less likely to generate 
raised inflammatory markers. In comparison, infective symptoms such as cough, 
UTI and chest infection were more likely to be associated with a raised 




Table 20: Most frequently recorded symptoms in the 28 days before inflammatory 
marker testing 




Symptom n % n % n % 
Tiredness 82 0.21 6390 5.73 2148 4.43 
Dizziness  126 0.32 2156 1.93 755 1.56 
Headache 98 0.25 2498 2.24 965 1.99 
Low mood 111 0.28 964 0.86 390 0.8 
Low back pain 138 0.35 2079 1.87 857 1.77 
Back pain 156 0.4 2202 1.98 964 1.99 
Abdominal 
pain 
166 0.42 7132 6.40 3232 6.67 
Chest pain 100 0.26 1922 1.72 872 1.8 
Rash 145 0.37 1663 1.49 797 1.64 
Joint pain 52 0.13 2515 2.26 1215 2.51 
Pain 
generalised 
87 0.22 1841 1.65 1011 2.09 
Diarrhoea 64 0.16 2297 2.06 1266 2.61 
Shoulder pain 123 0.31 1103 0.99 631 1.3 
Throat 
symptoms 
102 0.26 1018 0.91 598 1.23 
Knee pain 182 0.47 1599 1.43 916 1.89 
Nausea & 
vomiting 
56 0.14 1171 1.05 720 1.49 
Cough 496 1.27 3361 3.02 2336 4.82 
Malaise 27 0.07 1005 0.9 720 1.49 
UTI 189 0.48 1291 1.16 1057 2.18 
Chest 
infection 
130 0.33 720 0.65 804 1.66 
Symptoms are ordered according to whether they were relatively more common in patients with 





 Diagnostic activity after initial inflammatory 
marker test 
Table 21 shows the blood tests, appointments, and referrals in the 6 months after 
testing for ‘true positive’, ‘false positive’, ‘true negative’ or ‘false negative’ 
groups, plus untested controls. Test positives were defined as individuals with 
any one or more raised inflammatory markers at the index date; disease positive 
was defined as any relevant disease (infection, autoimmune conditions or 
cancers). Follow on blood tests, appointments and referrals were higher in the 
false positives compared to the true negatives. Both groups consist of tested 
patients without subsequent pathology, the main difference being the 
inflammatory marker result. Based on this, for 1000 inflammatory marker tests 
performed, one would expect 236 false positives, associated with an additional 
710 GP appointments, 229 phlebotomy appointments and 24 referrals in the 6 
months following testing. 
 
Table 21: Diagnostic activity in the 6-month period after testing 
True positives = people with a positive test who develop relevant disease; false negatives = people with a negative 
test who develop relevant disease; false positives = people with a positive test with no relevant disease; true 











in 6 months 
Mean number 
of total tests 
requested 
Mean number 




















































*p<0.001 – comparing true positives to false negatives and comparing false positives to true 
negatives **Includes face to face consultations, home visits and telephone consultations 
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 Objective 4: Inflammatory markers and 
cancer 
Objective 4 was to determine the diagnostic accuracy of inflammatory markers 
for cancer diagnosis in primary care, including stratification by age, gender, 
inflammatory marker level and cancer type. This objective was further broken 
down as follows: 
4a) What is the diagnostic accuracy of inflammatory markers, singly and in 
combination for cancer? This is covered in section 3.5.2 to 3.5.6 
4b) How does this vary by age and gender? This is covered in section 3.5.7 
4c) What is the association between inflammatory marker level and cancer? This 
is covered in section 3.5.8 
4d) Which types of cancer are diagnosed following inflammatory marker testing? 
This is covered in section 3.5.9 
The results described below have been published in the following Open Access 
article distributed in accordance with the terms of the Creative Commons 
Attribution (CC BY 4.0) license: 
• Watson J, Salisbury C, Banks J, Whiting P, & Hamilton W. (2019). 
Predictive value of inflammatory markers for cancer diagnosis in primary 
care: a prospective cohort study using electronic health records. British 
Journal of Cancer, 120(11), 1045-1051. https://doi.org/10.1038/s41416-
019-0458-x   
 
 Study sample 
Out of the 160,000 patients with inflammatory markers tested in 2014 and 39,928 
untested matched controls (described in 2.2.2), only those with a pre-existing 
cancer diagnosis (n=4,489), and patients who had missing or spurious 
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inflammatory marker test results (n=662) were excluded from this analysis 
(Figure 14). This was to ensure the results were generalisable to a primary care 
population without a current cancer diagnosis, but not limited to those without 
other co-morbidities.  
After exclusions, the inflammatory marker cohort contained 155,646 patients; of 
these 111,440 (71.6%) had a CRP test, 90,478 (58.1%) had an ESR test, and 15,670 
(10.1%) had a PV test. Altogether, 61,545 (39.5%) had more than one test 
performed on the index date, mostly CRP and ESR (50,522), followed by CRP and 
PV (10,494). Of the tested cohort, 46,092 (29.6%) had at least one raised 
inflammatory marker.
 
Figure 14: Flowchart showing exclusions for cancer analyses 
 
Linked data from the English Cancer Registry was obtained by the CPRD for 110, 
245 patients. Patients in whom it was not possible to obtain linked data were 
resident outside England, lacked a valid NHS identifier, were registered at a GP 
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practice which had not consented to linkage or were individuals who had 
personally dissented from linkage.  
 
 Overall cancer incidence according to test 
results 
Table 22 shows the overall cancer incidence according to test results. In patients 
with a raised inflammatory marker, cancer incidence was 3.53% (95% CI 3.37 to 
3.70), compared to 1.50% (1.43 to 1.58) with normal inflammatory markers 
(p<0.001). The untested cohort had a cancer incidence of 0.97% (0.87 to 1.07). 
Most cancer diagnoses were made within one year of testing (see Figure 15), with 
no evidence of significantly increased cancer risk in the second year after a raised 
inflammatory marker compared to untested controls.  
 








Number of patients 
(n) 
 
46 092 109 554 39 131 
Cancers diagnosed 
in 1 year (n) 
1 629 1 648 379 
1-year cancer 
incidence % (95% 
CI)*** 
3.53 (3.37-3.70) 1.50 (1.43-1.58) 0.97 (0.87-1.07) 
Second year cancer 
incidence % (95% CI) 
1.07 (0.97-1.16) 0.77 (0.72-0.82) 0.96 (0.86-1.05) 
*One or more inflammatory marker raised **All inflammatory markers tested normal 





Figure 15: Histogram showing time interval in days between index date and the 
date of cancer diagnosis for those with a raised inflammatory marker 
 
 Cancer incidence and multiple inflammatory 
marker testing 
For the 61,545 who had more than one inflammatory marker test done together, 
if both were normal (n=39 368; 64.0%), the cancer incidence was 1.28% (1.17 to 
1.39); with one raised and the other normal (n=13 472; 21.9%) the cancer 
incidence was 2.27% (2.02 to 2.52); if both were raised (n=8 705; 14.1%) then 
cancer incidence was 4.71% (4.26 to 5.16).  
 
 Cancer incidence and repeat testing 
When patients with a raised inflammatory marker (n=46 092) had a second 
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was greatest if the second test result was further increased, at 6.86% (5.73 to 7.99) 
for CRP, 5.04% (4.01 to 6.08) for ESR and 4.13% (2.00 to 6.26) for PV. If the second 
test was lower than the first, but still above the normal range, the cancer 
incidence was 4.35% (3.66 to 5.04) for CRP, 3.55% (2.86 to 4.24) for ESR and 3.28% 
(1.79 to 4.78) for PV. If the repeat test was normal the cancer incidence fell to 
1.98% (1.49 to 2.47) for CRP, 2.49% (1.73 to 3.26) for ESR, and 1.32% (0.34 to 2.29) 
for PV. Figure 16 shows this as a flowchart of cancer incidence according to 









 Measures of diagnostic accuracy: sensitivity, 
specificity, PPV and NPV 
For each of the three tests, sensitivities, specificities, PPV, NPV and DOR for a 
positive result are shown in Table 23. All three inflammatory markers had a low 

































































*p<0.0001 **Diagnostic odds ratio 
 
 Measures of diagnostic accuracy: area under 
curve (AUC) 
A logistic regression model containing age and gender had an AUC of 0.736, 
compared to 0.747 for a full model containing age, gender and CRP test result as 
a continuous variable (p<0.001); 0.759 with age, gender and ESR (p<0.001); and 
0.760 with age gender and PV (p<0.001).  
 
 Effects of age and gender 
Breakdown by age and gender (Figure 17) shows that cancer incidence increases 
with age and is higher in men. Women over 60 with a raised inflammatory 
marker and men over 50 with a raised inflammatory marker, have a cancer 
incidence of 4.22% (3.90 to 4.45) and 6.44% (6.00 to 6.88) respectively, which 
exceeds the NICE 3% threshold for urgent cancer referral. For women under the 
age of 60 with a raised inflammatory marker, cancer incidence was 1.20% (1.03 to 
1.37); for men under 50 with a raised inflammatory marker it was 1.03% (0.72 to 
1.33). Patients with normal inflammatory markers have a cancer incidence which 
exceeds that of untested controls but is lower than the raised inflammatory 
marker group. In particular, men over 60 with normal inflammatory markers 




Figure 17: One-year cancer incidence, stratified by age, gender and inflammatory 
marker test result. The red line represents the 3% threshold used by NICE for 
urgent cancer investigation or referral. 
 
 Cancer incidence and inflammatory marker 
levels 
The incidence of cancer increased with rising inflammatory markers with a dose-
response relationship; see Figure 18. Out of 506 people with ESR≥100, 69 (13.6%) 
developed cancer in 1 year; with CRP ≥100 (n=1,983), 135 (6.81%) developed 
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Figure 18: Polynomial logistic regression of cancer incidence against CRP test 
result as a continuous variable 
 
 Cancer sites 
The types of cancer are shown in Table 24; the cancer sites broadly reflect overall 
cancer incidence in 2014 from National Cancer Registry figures, apart from breast 
cancer and prostate cancer, which are notably less frequent in the raised 
inflammatory marker group. Myeloma contributed only 45 out of 2,145 cancers 
in the raised inflammatory marker group; sensitivity analysis demonstrated 
minimal difference in overall results when these were excluded (cancer incidence 
in the raised inflammatory marker group 3.45% excluding myeloma, versus 
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Table 24: Types of cancer diagnosed by gender in those with raised inflammatory 
markers compared to types of cancer diagnosed nationally in England in 
2014.(205) 











Cancer site % (n) % % (n) % 
Bladder 3.91 (41) 4.14 1.59 (17) 1.56 
Breast 0.19 (2) 0.22 15.78 (169) 31.56 
Cervix - - 1.12 (12) 1.77 
Head and 
neck 
1.34 (14) 1.56 0.19 (2) 1.66 
Kidney 3.82 (40) 3.79 2.80 (30) 2.34 
Leukaemia 2.10 (22) 3.25 2.43 (26) 2.21 
Lymphoma 2.29 (24) 4.94 3.08 (33) 4.07 
Myeloma 2.58 (27) 1.72 1.68 (18) 1.41 
Oesophagus 3.24 (34) 3.27 1.31 (14) 1.63 
Pancreas 4.01 (42) 2.70 4.48 (48) 2.75 
Stomach 1.81 (19) 2.32 2.15 (23) 1.26 
Testis 0.19 (2) 1.34 - - 
Uterus - - 3.64 (39) 5.27 
Brain 1.43 (15) 1.59 1.12 (12) 1.23 
Colorectal 12.69 (133) 12.46 12.98 (139) 10.43 
Lung 17.56 (184) 13.34 14.75 (158) 11.86 
Ovary 
  
4.20 (45) 4.32 
Oral 1.34 (14) 3.07 0.75 (8) 1.64 
Melanoma 1.53 (16) 4.30 2.24 (24) 4.45 
Prostate 14.98 (157) 26.35   
Other 25.0 (262) 9.64 23.72 (254) 8.58 
Total 100 (1074) 100 100 (1071) 100 
 
 Symptoms 
Table 25 shows the most frequently occurring symptoms in the 28 days before 
the index date, and cancer incidence in patients with normal and raised 
inflammatory markers with these symptoms. None of the symptoms identified 
are high-risk symptoms warranting urgent cancer referrals under current NICE 
guidelines. The commonest symptoms were abdominal symptoms, joint 
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symptoms, infective symptoms, and non-specific symptoms. Cancer incidence 
was significantly higher for those with a raised versus normal inflammatory 
markers in all symptom subgroups except patients with throat symptoms. 
Positive predictive values were >5% for those with raised inflammatory markers 
associated with cough, back pain, nausea and vomiting, and chest pain.   
 
Table 25: Top 20 most frequently occurring symptoms in the 28 days before the 
index date, and cancer incidence in patients with normal and raised inflammatory 
markers with these symptoms* 
 Normal inflammatory 
marker cancer 
incidence % (95% CI) 
Raised inflammatory 
markers cancer 














Cough (n=5,801) 2.03 
(1.54-2.51) 
5.29 
(4.33 – 6.25) 
<0.001 
Joint pain (n=3,678) 1.31 
(0.87 – 1.75) 
2.34 
(1.45 – 3.24) 
0.023 
Diarrhoea (n=3,463) 1.01 
(0.60 – 1.42) 
3.11  
(2.09 – 4.12) 
<0.001 
Headache (n=3,451) 0.96 
(0.58 – 1.35) 
2.07 
(1.12 – 3.02) 
0.012 
Back pain (n=3,141) 1.81 
(1.24 – 2.37) 
6.21 
(4.57 – 7.84) 
<0.001 
Lower back pain 
(n=2,937) 
1.81 
(1.23 – 2.38) 
5.32 
(3.71 – 6.93) 
<0.001 
Dizziness (n=2,854) 1.58  
(1.04 – 2.11) 
3.85 





(0.70 – 1.69) 
3.42  
(2.23 – 4.60) 
<0.001 
Chest pain (n=2,700) 1.83 
(1.22 – 2.44) 
6.13 
(4.41 – 7.84) 
<0.001 
Knee pain (n=2,597) 0.56 
(0.20-0.93) 
2.42  
(1.37 – 3.47) 
<0.001 















































*Frequency of symptoms in untested patients was too low to allow calculations of cancer 
incidence in symptomatic untested subgroups 
 
 
 Sensitivity analyses  
In order to check the robustness of the data and explore potential sources of bias 
a number of sensitivity analyses were done (Table 26). Firstly, analysis was 
restricted to those with ≥1 year of follow up, to ensure that loss to follow up was 
not introducing significant bias. Secondly, analysis was repeated using the 
laboratory specified upper limit of normal to define a raised inflammatory 
marker (rather than the mean upper limit of normal see 2.4.4 methods chapter). 
Thirdly analysis was restricted to only the 110,245 patients eligible for Cancer 
Registry linkage. Fourthly, analysis was restricted to patients without pre-
existing infections or autoimmune conditions (in other words keeping the same 
cohort as defined in section 3.3.1). Finally, patients with myeloma were excluded; 
on the basis that the association between raised inflammatory markers and 
myeloma was well established, and to demonstrate that our association persisted 
when these patients were discounted.  
These sensitivity analyses gave minor differences in results which were not 
clinically significant. Restricting analysis to the 110 245 patients eligible for 
Cancer Registry linkage increased cancer incidence marginally to 3.82% (3.58 to 
4.05) in the raised inflammatory marker group, 1.63% (1.53 to 1.73) in the normal 




Table 26: Sensitivity analyses - cancer incidence in those with raised 
inflammatory markers, normal inflammatory markers and untested controls, in 
selected subgroups 









Full cohort  
(n=194,777) 
3.53 (3.37-3.70) 1.50 (1.43-1.58) 0.97 (0.87-1.07) 
 
Restricting to patients 
with ≥1 year follow up 
in CPRD (n=158,025) 
3.87 (3.67-4.06) 1.60 (1.52-1.68) 1.02 (0.91-1.13) 
Using laboratory 
specified upper limit 
of normal 
(n=194,777) 
3.38 (3.22-3.54) 1.50 (1.43-1.58) 0.97 (0.87-1.07) 
Restricting to patients 
eligible for cancer 
registry linkage 
(n=110,245) 
3.82 (3.58-4.05) 1.63 (1.53-1.73) 1.04 (0.90-1.17) 














 Objective 5: Inflammatory markers and 
mortality 
Objective 5 was to explore the association between inflammatory markers and 
one-year mortality in primary care. This objective was further broken down as 
follows: 
5a) What is the predictive value of inflammatory markers, singly and in 
combination for one-year mortality? This is addressed in section 3.6.2 to 3.6.6 
5b) How does this vary by age and gender? This is addressed in section 3.6.2 
5c) What is the association between inflammatory marker level and mortality? 
This is addressed in section 3.6.7 
5d) What is the cause of death in patients with a raised inflammatory marker? 
This is addressed in section 3.6.8 
The results described below have been published in the following Open Access 
article distributed in accordance with the terms of the Creative Commons 
Attribution (CC BY 4.0) license: 
• Watson J, Whiting P, Salisbury C, Banks J, & Hamilton W. (2020). Raised 
inflammatory markers as a predictor of one-year mortality: A cohort study 
using primary care electronic health record data. BMJ Open. 
https://doi.org/10.1136/bmjopen-2019-036027    
 
 Study sample 
For this analysis patients were excluded from the analysis only if the 
inflammatory marker test result was missing (n=673) or if results were so 
abnormal as to be considered spurious (n=2), to avoid excluding any patients on 
the basis of multimorbidity. This left a total of 159,325 patients with 
inflammatory marker tests and 39,928 age, sex and practice matched controls 
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without inflammatory marker testing. Linkage to ONS death registry data was 
available for 109,966. Cause of death was available from death certification data 
in 3,141 out of 5,512 deaths where ONS linkage was available. 
 
 Overall mortality by test results 
In total 5,512 patients died within one-year of the index date: 648 deaths in the 
untested group, 1,572 deaths in the normal inflammatory marker group and 
3,292 deaths in the group with one or more raised inflammatory marker.  
Table 27 shows one-year mortality subdivided by age, gender and inflammatory 
marker test result. Patients with a raised inflammatory marker (n=47,797) had an 
overall one-year mortality of 6.89%, compared to 1.41% in those with normal 
inflammatory markers (p<0.001). In the untested comparison cohort, one-year 
mortality was 1.62%.  The association between raised inflammatory markers and 
one-year mortality was seen in all age groups apart from the under 30-year-olds. 
In older age groups the absolute increase in risk was considerable; a raised 
inflammatory marker in the over 80s was associated with a one-year mortality of 
21.8%, compared to 8.6% in the over 80s with normal inflammatory markers. 
Men with a raised inflammatory marker had a significantly higher one-year 
mortality rate than women with a raised inflammatory marker (9.78% versus 
5.29%). Patients with a raised CRP had a one-year mortality of 8.76% compared 
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Figure 19 shows graphically one-year mortality stratified by age, gender and 
inflammatory marker test result. This shows that those with normal 
inflammatory marker test results are not at an increased mortality risk compared 
to untested controls. This is in contrast with cancer outcomes, where patients 
with normal inflammatory markers have an increased cancer risk compared to 




Figure 19: One-year mortality stratified by age, gender and inflammatory marker 
test result 
 
 Multiple inflammatory marker tests and 
mortality 
In the 62,789 patients with more than one inflammatory marker performed 
simultaneously on the index date, one-year mortality was higher in the 9,029 
patients with concordant raised values at 6.94% (95% CI 6.42 to 7.47), compared 
to the 13,783 with discordant results (one raised, one normal) who had a one-year 
mortality of 2.77% (2.50-3.04). In the 39,977 patients with two simultaneous 
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 Mortality and repeat inflammatory marker 
testing 
Figure 20 shows the one-year mortality in patients according to the subsequent 
repeat inflammatory marker results, using the most common test performed, 
CRP. The fact that a CRP test was requested by a GP was in itself, predictive of 
increased mortality, with one-year mortality of 3.30% in the tested versus 1.62% 
in the untested cohort. This increased to 8.76% one-year mortality if a single CRP 
test was raised, 9.13% if a second test was persistently raised and 14.5% the 
second test was raised further still. Those with a raised inflammatory marker 
which was not subsequently rechecked had a one-year mortality rate of 10.2%, 
compared to 3.25% if a subsequent CRP normalised.  
 
 
Figure 20: Flowchart of one-year mortality (95% confidence intervals) according to CRP test results. 




 Measures of diagnostic accuracy - sensitivity 
and specificity 
Table 28 shows the performance characteristics of inflammatory markers, 
including sensitivity, specificity and AUC. CRP had the highest sensitivity of the 
three tests at 67.8% and the greatest AUC at 0.78. Odds ratios (OR) reduced after 
adjustment for age and gender but were still significant with an adjusted OR for 
a raised CRP of 4.5 (p<0.001), 2.9 for raised ESR and 2.1 for raised PV. 
 
 






Adjusted for age and 
gender 














































*AUC calculated using log transformed test results as a continuous variable
 
 Measures of diagnostic accuracy – area under 
curve (AUC)  
The logistic regression model containing age (as a continuous variable) and 
gender, had an AUC of 0.85, compared to 0.89 for a full model containing age, 
gender and CRP test result as a continuous variable (p < 0.001); 0.88 with age, 
gender and ESR (p < 0.001); and 0.87 with age gender and PV (p < 0.001). 
 
 Mortality and inflammatory marker levels 
A dose response relationship was found between CRP result as a continuous 
variable and one-year mortality (Figure 21). In 2,184 people with a CRP 
>=100mg/L overall one-year mortality was 20.2%. Similar associations, with 
wider confidence intervals, were found for ESR and PV (not shown). 
 




 Cause of death 
Cause of death from ONS death certification was available for 3,141 out of 5,512 
total deaths in the cohort. Table 29 summarises the cause of death amongst 
patients with raised inflammatory markers, compared to those with normal 
inflammatory markers, and untested controls. The commonest cause of death in 
the 26,507 patients with raised inflammatory markers was cancer (696 deaths) 
followed by cardiovascular disease (449 deaths). Odds of mortality in the raised 
versus normal inflammatory marker groups was highest for cancer (adjusted OR 
6.34), followed by infections (adjusted OR 4.11). However significant increased 
odds of mortality were seen for all disease categories with the exception of 
deaths due to falls, musculoskeletal causes and senility.  
Table 30 shows cause of death stratified by age group for patients with raised 
inflammatory markers; cancer was the commonest cause of death in 40 to 79 
year-olds, cardiovascular disease increased with age and was the commonest 





Table 29: Cause of death amongst patients with ONS death registry linkage 
(n=109,966) 
*p<0.001 


























































































































Table 30: Cause of death amongst patients with one or more raised inflammatory 
markers at the index date subdivided by age category (n=1,872 deaths) 
Age group Cause of death n (%) 
 Cancer  Cardiovascular Respiratory Other 
<30 0 (0) 0 (0) 0 (0) 1 (100) 
30-39 4 (40.0) 1 (10.0) 0 (0) 5 (50.0) 
40-49 21 (45.7) 4 (8.7) 1 (2.2) 20 (43.5) 
50-59 56 (56.6) 16 (16.2) 9 (9.1) 18 (18.2) 
60-69 152 (61.0) 31 (12.5) 25 (10.0) 41 (16.5) 
70-79 199 (46.6) 88 (20.6) 59 (13.8) 81 (19.0) 
≥80 264 (25.4) 309 (29.7) 170 (16.4) 297 (28.6) 
Total 696 (37.2) 449 (24.0) 264 (14.1) 463 (24.7) 
 
 Chapter summary 
This chapter describes the diagnostic utility of inflammatory markers (CRP, ESR 
and PV) in primary care for relevant disease, namely infection, autoimmune 
disease and cancer. I will summarise the findings in relation to each of the 
objectives listed in 1.9.2. 
 
 Objective 1: Epidemiology of inflammatory 
marker testing 
Testing multiple simultaneous inflammatory markers was common, and 
abnormal results were frequent, particularly in older age-groups. Testing was 
more common in women, in white ethnic groups and in more affluent 
socioeconomic groups. Conversely, abnormal results were more common in 
patients from the most socially deprived socioeconomic groups. This is in 
keeping with the inverse care law; with potential over-testing in the affluent, and 
relative undertesting in more deprived groups. Higher testing rates may also in 
part reflect higher consultation rates in certain socio-demographic groups. 
Repeat inflammatory marker testing is common, particularly in those with an 
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initial raised inflammatory marker; most repeat tests were done within 3 months 
of the index date.  
 
 Objective 2: Inflammatory markers and overall 
disease outcomes 
In patients with a raised inflammatory marker, the most common diagnoses were 
infection (6.3%), followed by autoimmune conditions (5.6%) and cancers (3.7%). 
Disease incidence was higher in those with more than one simultaneous raised 
inflammatory marker (22.6%) and in those with a second repeat test which was 
persistently raised (23.8%).  
Inflammatory markers have low sensitivity (<50%) and are therefore not useful 
as a ‘rule-out’ test. Instead, they are classic Bayesian tests, with a positive test 
somewhat increasing the chance of disease whilst not being definitive, and a 
negative test reducing the chance of disease, again not to zero.  
Disease incidence increases with rising inflammatory marker levels in a dose-
response relationship.  
For any relevant disease, small differences were seen between the three tests: 
areas under receiver operating curve (AUC) ranging from 0.659–0.682. CRP has 
the highest overall AUC, largely because of marginally superior performance in 
diagnosis of infection (AUC CRP 0.617 versus ESR 0.589, p<0.001). The three tests 
are equivalent for diagnosis of autoimmune diseases and cancers.  
Adding a second test gave limited improvement in the AUC for relevant disease 
(CRP 0.682 versus CRP+ESR 0.688, p<0.001); this is unlikely to be of clinical 
value, even if statistically significant. The negative predictive value for any single 
normal inflammatory marker was 94.0%, compared to 94.1% with multiple 
normal tests. No combination of inflammatory marker tests can be used to rule-in 
or rule-out disease confidently. The maximum sensitivity of 60.6% (for the 
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combined test CRP|PV) is low, yet comes at a price of increased false positives 
compared to using single tests.  
 
 Objective 3: Symptoms and cascade testing 
Although the CPRD data does not give information on the reasons for 
inflammatory marker testing, the frequency of non-specific symptoms such as 
tiredness suggests that these tests are commonly used as a non-specific test for 
underlying systemic disease.  
Raised inflammatory markers are associated with higher rates of GP 
consultations, blood tests, and referrals compared to normal inflammatory 
markers. This is likely to relate to the wide range of potential differential 
diagnoses in patients with raised inflammatory markers. Although the unit cost 
of inflammatory marker tests is relatively low, the total costs, including these 
follow-on consultations, investigations and referrals are likely to be substantial. 
   
 Objective 4: Inflammatory markers and cancer 
Primary care patients with a raised inflammatory marker have an overall one-
year cancer incidence of 3.53%, more than twice the risk in those with a normal 
test. Cancer incidence rises with rising levels of inflammatory markers and is 
higher still if a second test shows persistent raised inflammatory markers. 
However, inflammatory markers are not a useful rule-out test for cancer, as with 
a sensitivity of 46.1% for CRP, 43.6% for ESR and 49.7% for PV, roughly half of 
the tested patients with subsequent cancer diagnosis had a normal inflammatory 
marker test. Patients with normal inflammatory markers have a cancer incidence 
of 1.50%, higher than the untested group with 0.97% cancer incidence. 
Importantly, women under 60 and men under 50 with raised inflammatory 
markers have a risk of cancer below 3% so investigations for cancers would not 
usually be warranted.  
 152 
 
 Objective 5: Inflammatory markers and 
mortality 
Inflammatory markers are a strong predictor of all-cause mortality in primary 
care. The association between raised inflammatory markers and all-cause 
mortality is seen in all age groups except patients aged less than thirty years. 
Men with raised inflammatory markers have a higher one-year mortality than 
women (9.78% versus 5.29%). Of the three tests examined, CRP has the highest 
predictive accuracy for mortality.  
Further discussion, including the clinical implications and strengths and 
limitations of these findings can be found in Chapter 6; the overall discussion 




CHAPTER 4.  QUALITATIVE 
METHODS 
 Chapter overview 
This chapter describes the methods of the qualitative study. The overall aim is to 
explore the meaning of inflammatory marker tests for doctors and patients in 
primary care. Whilst the quantitative study provided information to improve 
clinicians’ understanding of the diagnostic utility of inflammatory markers in 
primary care, this is not sufficient to improve clinical practice; doctors need to 
share this information about inflammatory marker testing appropriately with 
patients.  
The specific objectives of this study were: 
1) To explore to what extent doctors and patients have a shared 
understanding of the use of inflammatory marker blood tests. 
2) To provide in-depth exploration of patients’ experiences of testing – from 
GP consultation to results. 
3) To identify barriers and facilitators to improved communication, in order 
to inform improved communication in future.  
Qualitative methods were chosen as the most suitable way of providing in-depth 
exploration of doctors’ and patients’ experiences. To achieve these objectives, I 
used qualitative interviews with patients who recently had inflammatory marker 
blood tests in primary care, and the GPs who requested these tests. To achieve 
objective 1, it was important for me to obtain paired data to allow me to compare 
doctors’ and patients’ differing perspectives on the same healthcare encounter. 
To achieve objective 2, it was important for me to interview patients both at the 
time of testing, and also after they had received their blood test results. 
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In this chapter I first describe the methods of sampling and recruitment, data 
collection and analysis. Next, I explore reflexivity and the ethical issues raised by 
the study. Finally, I discuss the patient and public involvement which 
underpinned the research. 
 
 Sampling and Recruitment 
Practices were recruited via the West of England Primary Care Clinical Research 
Network eBulletin. Practices were purposively selected to include a range of 
urban and rural practices, and to reflect a range of practice populations in terms 
of deprivation, age, and ethnicity. Participating practices were visited prior to 
commencing recruitment and the study was explained to GPs at a practice 
meeting. Participant Information Sheets (PIL) were then emailed to all GPs via 
the practice manager. All GPs in participating practices were eligible to 
participate, including locums, salaried GPs, and partners. GPs who were 
interested in participating were asked to complete a contact sheet which enabled 
them to be contacted once a patient whom they had consulted had been 
recruited.  
Patients were eligible to participate if they were: 
• aged >18 years. 
• having blood tests which included CRP, ESR or plasma viscosity 
(henceforth referred to as ‘blood tests’). 
• having tests requested by participating GPs (who had completed a 
contact sheet). 
• able to speak English sufficiently for interview. 
The sampling strategy for patients was purposive, in order to include a range of 
patient gender, age and socioeconomic status. Eligible patients were provided 
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with information about the study by their healthcare team but were under no 
pressure to participate.  
Methods of patient recruitment were flexible, to accommodate different practice 
procedures for taking blood for testing. In five out of six practices, I was able to 
sit in a spare room during phlebotomy clinics. At the start of these clinics, I met 
with the phlebotomists to explain the study and eligibility criteria. Phlebotomists 
then offered eligible patients a Participant Information Leaflet (PIL). If 
participants were interested, they were invited to discuss the study with me. I 
could then either complete the interview immediately or arrange a suitable 
interview time at a location of the patient’s choice. Two practices supplemented 
this by GPs explaining the study at the time of requesting blood tests and 
obtaining permission for the research team to contact patients. One practice did 
not have available space for a researcher to sit in surgery; in this practice all 
participants were recruited by phlebotomists, patient contact details were sent 
securely to me using an nhs.net secure email, and patient interviews were 
arranged at the patient’s convenience.  
At the end of the first patient interview, a second follow-on interview with the 
patient was arranged 1-2 weeks later, in order to explore the communication of 
the test results.   
Once a patient had been recruited, the GP who had requested the blood tests was 
contacted to arrange a telephone interview. Each GP could complete a maximum 
of two interviews each (about different patients), to ensure that a range of GPs 
were sampled. All GPs had received the test results at the time of interviewing; 
this is likely to reflect the fact that electronic test reporting means most results are 
returned to GPs within 24 hours. 
For each test requested I therefore aimed to complete three interviews 
(henceforth referred to as ‘cases’); firstly, with the patient around the time of 
testing, secondly with the patient after the test results were obtained, and finally 




Twenty-one of the initial patient interviews took place in participants’ GP 
practices, six took place at the University of Bristol and one was done via 
telephone.  All second interviews and all GP interviews were done by telephone. 
Interviews were semi-structured, using topic guides based on the research 
questions but flexible enough to allow exploration of issues raised by the 
participant. The topic guide (see Appendix C) was adapted iteratively during the 
study, using information emerging in early interviews to inform further 
questions for exploration in subsequent interviews. The first patient interview 
focussed on patients’ experience of testing, their understanding of the rationale 
for testing, their expectations of testing and the communication they had 
received about their tests. The second patient interview allowed me to explore 
whether patients’ views and understanding of testing changed between initial 
consultation and results, with questions focussing on patients’ experience of 
receiving and interpreting their test results. The GP interviews allowed me to 
compare patient and GP perspectives of reasons for testing, expectations of tests 
and communication around testing. GPs undertook the interviews with access to 
the patient’s electronic medical records at the time of interviewing as an aide 
memoire.    
The interviews were recorded, with consent, using a digital encrypted audio 
recorder. Written informed consent was obtained at the start of each interview; 
for telephone interviews verbal consent was recorded and documented 
replicating the consenting text used on the written consent forms.  
Patients received £20 high street voucher payment to recompense their time 
participating. GP practices were paid £60 for each GP interview completed, in 
keeping with Primary Care Research Network agreed rates. Interviews were 
continued until data saturation was achieved, meaning that a diverse sample had 





Fieldnotes were recorded during and immediately after each encounter. These 
included observations, reflections and evolving analytical thoughts. These were 
used as a prompt and reminder prior to follow up interviews with patients. They 
were also used to aid the iterative development of the topic guide, including 
changes and additions to the flow and structure of the questions and prompts. 
Finally, they were used when re-reading and listening to the audio-recorded 
interviews to help with recollection of the non-verbal communication and 
interactions, which were recorded in NVivo as memos, and contributed to the 
evolving analytical ideas. Examples of the use of these field notes included a 
patient who was reticent and appeared anxious during the initial interview. This 
anxiety was not verbally expressed, and the patient was reluctant to open up, so 
this was not easy to recognise in the first interview transcript. Memos were 
added to NVivo to reflect my observations of the non-verbal communication, 
and my field notes were re-read ahead of the second interview. I used careful 
probes in the second interview to help improve the flow of the conversation and 
develop rapport and managed to get a better exploration of the patient’s 
experiences and anxieties in the second interview.  
 
 Analysis 
Audio recordings were transferred to secure servers at the University of Bristol 
and transcribed verbatim by an experienced University of Bristol approved 
transcriber. I listened to all audio-recordings and cross-checked these with the 
transcripts making minor corrections. All written data were anonymised. 
Analysis began when the first transcripts were available, so that data collection 
and analysis were conducted concurrently, with early interviews informing the 
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iterative development of the topic guide for subsequent interviews. This process 
of iterative development did not continue throughout, the topic guide stabilised 
as saturation was achieved. Data were read and re-read to aid familiarity.  
All transcripts were uploaded into NVivo and files were classified into three 
categories: initial patient interviews, follow up patient interviews and GP 
interviews. Files were also organised into cases which included data from the 
same patient before and after testing and the paired GP interviews.  
I analysed the transcripts using thematic analysis, involving a mixture of 
inductive and deductive coding and constant comparison.(207) This involved an 
iterative process of close reading of the data, coding, constant comparison and 
elaboration of emerging themes. Inductive coding aims to discover the meaning 
of the data without making assumptions based on previous understanding; by 
comparison deductive coding is informed by existing theories and by the 
research questions. It would not be realistic to claim that I could (or should) 
completely free myself from my own preconceptions given my clinical and 
research experience in this topic area; I was also influenced in my coding by my 
research questions. I therefore chose to combine a mixture of inductive and 
deductive approaches. Thematic analysis was chosen as this is a flexible 
approach, allowing me to make comparison within cases (i.e. before-after test 
results and between doctor-patients) and also between cases (i.e. comparing 
patients and GPs as a group).  
My qualitative supervisor (JB) and I independently reviewed four of the 
transcripts (including first and second patient interviews and GP interview) to 
develop an initial coding framework that reflected the research objectives. This 
was amended and adapted iteratively following feedback and discussion with 
my supervisor (JB), and also following discussion with my PPI panel. The 
modified framework was then tested independently by myself and my 
supervisor (JB) using a further three transcripts. Once the final coding framework 
was agreed (see Appendix D), I then took responsibility for ongoing coding and 
categorisation of the data, using the NVivo qualitative data management 
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software. To assure the reliability of the coding and analysis process, codes and 
categories were reviewed in regular meetings with JB to ensure the accuracy of 
interpretation and internal consistency of codes.  
As I developed the coding framework, I read the data case by case, and wrote a 
narrative case summary for each participant, to retain my understanding of each 
case as a whole. I identified key differences between cases, which were important 
in order to retain an overview of the extent of information sharing and shared 
decision-making in the consultations. I chose to further analyse the data using 
qualitative content analysis to categorise and capture this information.(208) I 
used a coding framework which had been developed and tested for the purpose 
of analysing and quantifying the extent of shared decision-making in video-
recorded primary care consultations by a Foundation Year 2 doctor Jess Martin 
whom I supervised during the course of my PhD.(181) I made minor adaptions 
to this framework in response to the data in my interviews. This allowed me to 
categorise each case based on whether the patient knew which tests were being 
done, why tests were being done, whether decision-making was shared or not, 
how results were communicated and whether they understood the meaning of 
their test results. This provided an overview of my data, which triangulated and 
strengthened the findings of my thematic analysis. These categorical codes were 
recorded using NVivo case classifications; definitions of each code are detailed in 
Chapter 5 (Table 35, Table 36 and Table 37). 
When all the data were coded, I began to make comparisons between doctors’ 
and patients’ interviews, scrutinising the data for areas of congruence and 
dissonance. As well as exploring emerging themes and patterns I sought out 
apparently contradictory quotes and examples; these were coded and noted as 
memos in NVivo. I met regularly with JB to discuss my understanding of the 
data and developing themes. Categories of data and thematic relationships were 
identified and written up as descriptive and interpretive accounts, supported by 




Reflexivity was important for me to consider, as I have a dual role as both a 
researcher and a GP. My own experiences as a GP therefore influence my 
perspectives and my interactions with the research participants.  
It is recognised that research participants are influenced by how they identify 
with a researcher.(185) I chose to be open with participants (both patients and 
GPs) and to identify myself as being a GP, as it felt dishonest to withhold this 
information. I was influenced in this decision by the discussions and advice from 
my Patient and Public Involvement group (see section 4.8) 
In the GP interviews I emphasised that the interviews were non-judgemental, 
and were focussed on exploring communication around testing, not on 
scrutinising the clinical decision-making. During my interviews I noticed that the 
fact I was a doctor did impact on the way some GPs interacted with me. Some 
slipped into the use of medical jargon or made assumptions that I had a shared 
understanding of testing and medical knowledge. I therefore had to prompt to 
ensure they explicitly explained their rationale for testing in lay terms where 
necessary. In a small number of interviews, the GPs I spoke to were clearly aware 
of my published research into inflammatory marker testing. This may have 
impacted on the way they presented their diagnostic argument for testing, to try 
to fit with what they thought they ‘should’ do. However, my experience overall 
was that GPs were very open with me, their reflection on uncertainties around 
inflammatory marker testing indicated they were articulating their actions and 
thought processes at the time of the consultation. Overall, being a GP did not 
prove to be a barrier and may have facilitated my communication with GPs as 
they felt comfortable discussing cases with a fellow clinician with shared 
understanding. 
I anticipated that by identifying myself as a GP, patients might ask me questions 
about their health. In practice this was not a significant issue. On the small 
number of occasions where patients asked me for my views or opinions, I felt 
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comfortable explaining that I had no access to their medical records or 
information about their tests and was not in a position as a researcher to be able 
to make any comments. In one case I felt slightly conflicted as the patient had not 
yet obtained their test result, but I knew from my interview with the GP that it 
had shown a significant abnormality. As I was not able to disclose this 
information, I recommended that they should contact the practice for their test 
results, which they assured me they would.  
It was possible that because I identified as a GP, patients could have been 
reluctant to share negative information about their GP with a fellow doctor. 
However, my experience did not seem to match with this, as patients appeared 
to be very open and were often forthright in sharing their experiences, including 
negative experiences. The fact that I identified with participants as a GP did 
appear to enhance my credibility with patients and helped enable my access to 
the practices as a researcher. It also seemed to help some patients to feel 
comfortable discussing medical information with someone whom they identified 
as trustworthy by virtue of being a doctor.  
I kept reflective notes throughout the study, identifying points where I felt the 
doctor or patient had been influenced by my status as a GP. During the analysis, 
I added an additional post hoc code entitled ‘study impact’ in which I coded any 
examples where a participant seemed to have been influenced by their 
participation in the study, so that I could take this into account during my 
analysis.  
I was aware that my role as a clinician could affect my analysis, as I have my 
own experiences and preconceptions of blood testing. This was addressed by 
ensuring that my non-clinical qualitative supervisor (JB) read and coded the 
initial interviews and helped develop the coding framework and also by 
involving my PPI group in the early development of the coding framework. 
Throughout the course of my analysis, I had regular meetings with JB to check 
and discuss my evolving analytical thoughts with a non-clinician.  
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  Research governance and approvals 
The Integrated Research Application System (IRAS) system was used to obtain 
ethical approval, Health Research Authority (HRA) approval and confirmation 
local capacity and capability. The study was adopted and included in the NIHR 
Clinical Research Network (CRN) portfolio. Ethical approval was obtained from 
the proportionate review sub-committee of the London – Hampstead Research 
Ethics committee REC reference 19/LO/0405, who concluded that ‘this was a 
well-presented study with no material ethical issues’.  
 
 Ethical issues 
The main ethical considerations which were listed in the IRAS (Integrated 
Research Application System) application were as follows: 
 
Recruitment 
Recruitment could cause inconvenience for GP practices, GPs, and patients, 
which was particularly important to consider given the workload pressures 
primary care is facing. I minimised this by making recruitment as simple as 
possible and by ensuring that methods of recruitment were flexible so that 
different practice procedures for blood testing could be accommodated. Practice 
staff were not required to consent patients, only to issue Participant Information 
Leaflets to eligible patients. I did not approach patients directly.  
 
Consent 
Eligible patients were provided with information about the study by their 
healthcare team but were under no pressure to participate. As a researcher I 
undertake regular Good Clinical Practice training including training in obtaining 
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informed consent; I also have relevant experience in obtaining consent from of 
my clinical role as a GP.  
 
Interviews 
There was a small risk that patient interviews could cause anxiety - thinking and 
talking about blood tests could potentially raise questions or worries patients 
might not otherwise have considered. To minimise this, I piloted the topic guide 
with my Patient and Public Involvement (PPI) panel and adjusted it based on 
their feedback. My experience as a GP ensured that I was used to discussing 
sensitive information with patients. Although interviews did not directly discuss 
patients’ medical history, there was a risk that patients could make medical 
disclosures. I emphasised that I could not provide medical advice in these 
circumstances and advised them to see their GP with any medical queries. I also 
explained that although interviews were confidential this is not absolute and 
disclosure would be necessary in line with my duty of care, if a safeguarding 
concern was identified. Although I considered these possibilities, in reality I did 
not have to break confidentiality at any time for these reasons.  
 
Data handling 
Storage and handling of all data complied with the Data Protection Act 2018, the 
General Data Protection Regulation (GDPR) 2018 and University of Bristol’s data 
protection policies. All written data was anonymised, and participants were 
assigned a unique identifier. I was the only person with access to identifiable 
participant information in a master document linking this with the participant’s 
unique identifier.  
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 Patient and public involvement 
A Patient and Public Involvement (PPI) group comprising five participants was 
established in October 2018. Participants were recruited from the Health 
Research Panel of the NIHR Collaboration for Leadership in Applied Health 
Research and Care West (CLAHRC West – now ‘ARC West’), with support of the 
CLARHC West PPI lead. The PPI group met three times face to face for two 
hours on 4th October 2018, 13th December 2018, and 22nd October 2019. Meetings 
were chaired by myself, with my qualitative supervisor JB attending to provide 
support and take notes. Refreshments were provided and participants were paid 
at NIHR rates. A final 1.5-hour meeting was held on 16th July 2020 via online 
teleconferencing due to the coronavirus pandemic. Further feedback was 
provided via email in between meetings.  
In the first meeting on the 4th of October 2018, the discussions focussed on the 
aims and objectives of the research and the wording of the Participant 
Information Leaflets. Initially I had planned to focus on how GPs communicate 
inflammatory marker test results to patients (see Table 31). The PPI group 
discussion highlighted the importance of broadening this and exploring the 
patient experience of test communication from initial GP consultation through to 
test results. They emphasised that this should encompass not only doctor-patient 
communication but also communication with phlebotomists, receptionists, 
nurses, and allied health professionals. They suggested this could also include 
patient understanding of the systems and processes of testing and obtaining test 
results. The PPI panel also emphasised the importance of exploring not just 
communication but also patient understanding of why the tests were being done, 
and what the results would be able to tell them and their GP.  This led to changes 
in the overall aims and objectives of the study (see Table 31) which had a 
significant impact on the final outcomes of the study. 
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Table 31: Aims and objectives before and after PPI input 
Original aims and objectives Final aims and objectives 
Aims: 
• To help GPs discuss inflammatory marker 
blood tests with patients in a way they 
can understand. 
Aims:  
• To explore how an understanding of 
inflammatory markers is shared between 
doctors and patients in primary care. 
Specific objectives: 
• Do patients understand why blood tests 
are being done? 
• Do patients understand what their test 
results mean? 
• How could doctors better explain tests to 
patients? 
Specific objectives: 
• To explore to what extent doctors and 
patients have a shared understanding of 
the use of inflammatory marker blood 
tests. 
• To provide in-depth exploration of 
patients’ experiences of testing – from 
GP consultation to results. 
• To identify barriers and facilitators to 
improved communication.  
 
Another key message from the first PPI meeting was their suggestion that the 
term ‘inflammatory markers’ should be avoided in patient interviews, unless the 
patient themselves mentioned it first. The PPI group explained that from a lay 
perspective ‘inflammatory markers’ sounded worrying and serious, and this 
could cause anxiety or confusion for participants. As doctors would usually be 
testing inflammatory markers alongside several other blood tests, the PPI group 
felt it would not be meaningful to try to discuss inflammatory markers in 
isolation. Instead, they recommended exploring what patients understood about 
the different tests they were having done and why. The Participant Information 
Leaflet (PIL) and topic guide were therefore amended and the term ‘blood test’ 
was used throughout. These insights helped me to consider the wider context of 
blood test communication and ensure the findings had broad applicability. The 
PPI group provided further support via email after the initial face-to-face 
meeting, including reviewing participant information leaflets and topic guide 
questions to ensure that these were written in accessible language.  
In the second meeting on the 13th of December 2018, the PPI group provided in-
depth feedback on the interview topic guide, making suggestions to ensure that 
the wording was clear and easy to understand and would not provoke anxiety. 
They also suggested additional questions to explore patients’ understanding of 
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the process for obtaining their test results, and patients’ understanding of the 
meaning of their test results. In particular, the PPI group felt it was important to 
explore whether patients understood the implications of test results for their 
health, and what patients should do with the test results.  
The PPI group were also involved in planning methods of recruitment. We 
discussed the tension between giving participants enough time to reflect on the 
study and capturing the interviews as soon as possible after the initial 
consultation. The PPI panel emphasised the importance of ensuring that the 
interviews were convenient for participants. The PPI panel felt that offering the 
option of an interview in the GP surgery at the time of testing might make the 
study easier and less burdensome for many patients, but that flexibility was 
needed to accommodate patient preference. As a result of this feedback, I 
decided to make the methods of recruitment flexible, incorporating the option of 
sitting in a side room during phlebotomy clinics, so that patient and GP practice 
preferences could be easily accommodated. The method of sitting in the surgery 
during phlebotomy clinics turned out to be the most successful method of 
recruitment, accounting for the majority of interviews completed.  
Finally, I also discussed with the PPI panel my own reflexivity as a researcher 
and a clinician, as I was uncertain how I should identify and introduce myself to 
research participants. After reflection, the PPI group agreed it would seem 
dishonest not to inform research participants that I was a GP myself. This 
information was included in the PIL for both patients and GPs. The PPI group 
emphasised the important of explaining that I was conducting the interviews in 
my role as an independent researcher and emphasising that the results would 
not be fed back to their GP and would have no bearing on their care.  
During the third meeting, on 22nd October 2019, early interview transcripts of the 
study were shared with the PPI panel members. The findings resonated with the 
PPI panel members, who provided feedback which was used to help with 
development of the coding framework. The PPI panel noted differences in the 
interview transcripts between patients who were active and engaged in 
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communication and shared decision-making compared to those who were more 
passive and disengaged and additional codes were added to the coding 
framework to capture this.  
At the final PPI meeting on 16th July 2020 the early findings of both the 
qualitative and quantitative aspects of the thesis were shared with the PPI group. 
Feedback was used to explore how the qualitative and quantitative components 
of the thesis could be synthesised. We discussed how the uncertainty in 
interpreting inflammatory marker tests uncovered in the quantitative component 
of the thesis could be shared with patients. We also explored future ideas for 
improving the communication of inflammatory marker testing in future. This is 
discussed in more detail in the discussion chapter section 6.6.  
 
 Summary 
This chapter sets out the methods for the qualitative study, which explored 
doctors’ and patients’ expectations and experiences of testing in primary care. 
For each case, three interviews were undertaken; firstly, with the patient prior to 
testing, secondly with the patient after the test results had been obtained, and 
thirdly with the requesting GP. This provided rich data allowing me to compare 
and contrast the accounts and experiences of patients and doctors, to explore 
areas of congruence and dissonance and develop an understanding of the 
interactions which underpin a shared understanding of testing. The results of the 
qualitative study are presented in the next chapter.  
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CHAPTER 5.  QUALITATIVE 
RESULTS 
 
 Chapter overview 
This chapter describes the results of the qualitative study. The overall aim was to 
explore the meaning of inflammatory marker tests for doctors and patients in 
primary care. The specific objectives were: 
1) To explore to what extent doctors and patients have a shared 
understanding of the use of inflammatory marker blood tests. 
2) To provide in-depth exploration of patients’ experiences of testing – from 
GP consultation to results. 
3) To identify barriers and facilitators to improved communication, in order 
to inform improved communication in future.  
The data presented in this chapter cuts across these three objectives, so results 
will not be structured according to the objectives. Instead, I will first describe the 
participant sample, then the results of the thematic analysis and qualitative 
content analysis. The results of the qualitative content analysis are presented in 
Table 35, Table 36 and Table 37. All other data are derived from the thematic 
analysis. The thematic analysis firstly focuses on doctors’ and patients’ 
expectations of blood tests, next the process of decision-making, communication, 
and shared understanding of tests, and then the consequences of testing. Finally, 
I discuss the barriers to a shared understanding of tests which were identified by 
doctors and patients, relating to knowledge, attitudes, and systems of testing. To 
summarise, I then reflect on the results in relation to the three main objectives.  
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The results described in this chapter are currently in preparation for submission 
to a peer-reviewed journal, with a planned submission date of June 2021.   
Discussion of the strengths and limitations, comparison to existing literature and 
implications for clinical practice are covered in the discussion Chapter 6.  
 
 Description of the sample 
In total 28 patients and 19 GPs from six GP practices were recruited. Eighty 
interviews were carried out between 31st May 2019 and 17th March 2020; 26 GP 
interviews and 54 patient interviews (most patients and some GPs were 
interviewed twice).  
 
 Practice demographics 
All practices in the West of England Primary Care Research Network were 
invited to participate by email, and expressions of interest were received from 
twenty-three practices. Of these, six were chosen to participate, to reflect a range 
of socio-demographic characteristics (see Table 32). In participating practices, 
information sheets were sent to all GPs, and completed contact sheets were 
received from 40 GPs in total; this enabled me to contact the relevant GP once a 




Table 32: Demographics of participating practices 
Practice 
name 
List size* Deprivation 
score* 
Rural/urban Ethnicity* 
A 20,026 Third least 
deprived 
decile 
Urban 3.4% mixed, 9.3% Asian, 
3.0% black, 1.2% other 
non-white 
B 32,158 Least deprived 
decile 
Rural 1.1% Asian 1% other non-
white 
C 19,903 Third more 
deprived 
decile 
Suburban 3.1% mixed, 4.9% Asian, 
3.2% black 
D 8,960 Most deprived Urban 5.6% mixed, 6.7% Asian, 
22% black 2% other non-
black 
E  15,625 Second least 
deprived 
Suburban 3% mixed, 5.1% Asian, 
1.5% black 
F 11,280 Third more 
deprived 
decile 
Urban 2% mixed, 2% Asian, 2.1% 
black 
*Public Health England National General Practice Profiles [accessed April 2019]  
 
 Patient characteristics and reasons for testing 
Table 33 summarises the characteristics of the 28 patients who participated. The 
proportion of women recruited (64%) is in keeping with the quantitative research 
from CPRD which showed that 62% of inflammatory marker tested patients were 
female. The most common reasons for testing (based on GP interviews) were 
joint symptoms (n=5), suspected polymyalgia (n=3), tiredness (n=3), bowel 
symptoms (n=3), monitoring of pre-existing inflammatory conditions (n=3), 
headache (n=2) and hospital follow up (n=2). Other reasons for testing included 
breathlessness, weight loss, lymphadenopathy, eating disorder, pleural effusion, 
gynaecological symptoms, and patient requested screening (all n=1). Out of the 
28 patients recruited, 21 interviews were carried out in the GP practice at the 
time of their phlebotomy appointment, 7 interviews were carried out soon after 
testing either in the GP practice or at the University of Bristol. Out of the 28 
patients recruited, 23 patients had two interviews; one at around the time of 
testing, and a second follow up interview. At the time of the second interview, 
five of these patients had still not received their test results. Three of these agreed 
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to be interviewed a third time to discuss their experience of receiving their 
results, two were not planning to obtain their results, so were not interviewed 
again (both had bloods done for routine monitoring purposes). Five patients had 
only one interview; four of these had already received their results at the time of 
the first interview and one patient was uncontactable for follow up.  
 
 
Table 33: Demographics of participating patients (n=28) 
Characteristic n (%) 
Gender   
Female 18 (64%) 
Male 10 (36%) 
Ethnicity   
White British 23 (82%) 
BAME 3 (11%) 
Other non-British 2 (7%) 
Age group  
18-24 8 (29%) 
25-34 3 (11%) 
35-44 3 (11%) 
45-54 3 (11%) 
55-64 3 (11%) 
65-74 1 (4%) 
75+ 7 (25%) 
Socioeconomic status  
(based on postcode IMD) 
 
1 (most deprived) 2 (7%) 
2 5 (18%) 
3 2 (7%) 
4 4 (14%) 
5 0 (0%) 
6 2 (7%) 
7 2 (7%) 
8 3 (11%) 
9 2 (7%) 
10 (most affluent) 1 (4%) 
Postcode unavailable 5 (18%) 
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 GP demographics 
A total of 26 interviews with 19 GPs who requested the blood tests were 
completed. I was unable to obtain an interview from the requesting GP for two of 
the patient interviews. The characteristics of participating GPs are summarised in 
Table 34. Out of 19 GPs recruited, 14 were female (74%). More male GPs 
contributed >1 interview so overall 8 interviews (31%) were with male GPs and 
18 interviews (69%) were with female GPs.  
 
Table 34: Characteristics of participating GPs (n=19) 
Characteristic n (%) 
Gender  
Female 14 (74%) 
Male 5 (26%) 
Type of GP  
Partner 13 (68%) 
Salaried 5 (26%) 
Locum 1 (5%) 
Years’ experience  
0-5 years 5 (26%) 
5-10 years 2 (11%) 
10-20 years 8 (42%) 
20+ years 4 (21%) 
 
 Expectations of testing 
Doctors and patients had differing expectations of testing. Firstly, I explore 
patients’ expectations, then compare this with doctors’ expectations. Finally, I 
explore the paired data to identify the impact of different expectations occurring 
within a doctor-patient encounter.  
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 Patients’ expectations 
Few patients directly requested tests, but most saw them as ‘a good thing’. 
Patients saw blood tests as a way of moving forward with their problem, for 
example, by determining the cause of unexplained symptoms, and saw testing as 
a sign that the doctor was taking their symptoms and concerns seriously.  
I’ve been happy they’ve done them because you feel oh that’s good because 
he’s looking out for me in some way (Patient 18, female, 76 years) 
Patients had high expectations of their tests; they hope that tests will provide 
answers, and therefore lead to solutions for their symptoms.  
I was happy she was doing blood tests and extra tests because I need 
answers (Patient 20, male, 76 years) 
Even if solutions are not found, having greater certainty or a diagnosis for their 
symptoms was felt to be important. 
I’m quite happy with that. I feel at least I’m getting somewhere. I can get the 
results back and I might say, you know, I’ve got arthritis. (laughs) I could cope 
with anything. (Patient 2, female, 82 years) 
Some patients said that they were hoping for a result which would provide 
validation that they had an underlying reason for their symptoms.  
I think it will make me feel a bit better knowing that it’s not just me like 
taking care of myself badly and there’s actually a reason why I might feel the 
way I do sometimes (Patient 17, female, 18 years) 
You almost hope for a result that’s going to come back with something that 
can be treated in some way (Patient 21, female, 29 years) 
Patients have limited understanding of specific details of their blood tests but 
perceive them as providing a powerful way of getting an accurate validation of 
what is happening inside their body, and their overall health status.  
Kind of shows what’s happening on the inside.  Like on the outside I could be 
fine and kind of- but then the inside, my blood may be having some different 
story or knowing before I get really ill (Patient 3, female, 20 years)  
In some atypical cases, blood tests were viewed as transactional. This was 
particularly noted for the three patients who were having blood tests for 
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monitoring rather than due to symptoms. These patients had been told to get 
tests done by the practice and regarded these tests as being mainly for the GP 
and not for themselves. As a result, the patients appeared relatively passive and 
uninterested in results.  
I just know I need to get this blood test so that my medication keeps going 
and that’s it… If there’s a problem somebody will ring me.  If there’s no 
problem then nobody will ring me, but actual fact I’m fine with that, I’m 
absolutely fine with that (Patient 10, female, 56 years) 
 
 Doctors’ expectations 
Doctors tended to have lower expectations of testing, particularly if tests were 
being done in patients with non-specific symptoms. In these cases, a ‘panel’ or 
‘battery’ of routine tests were seen as a useful ‘screen’ to help to rule-out serious 
causes of symptoms, rather than to rule-in specific diagnoses.  
I think it was kind of the panel really would guide me in which direction we 
needed to move forwards (Doctor 9, male, GP partner, 0-5 years’ experience) 
I just arranged some baseline bloods as a bit of a general screen (Doctor 25, 
female, locum, 0-5 years’ experience) 
Probably most of ours have got irritable bowel but we sort of need to make 
sure we’ve excluded those other things first…yes, excluding more 
undiagnosed disease first before we move to anxiety or irritable bowels as a 
diagnosis (Doctor 15, female, GP partner, 10-20 years’ experience) 
Doctors’ decision-making encompassed both medical and non-medical aspects of 
testing. As well as diagnostic purposes, tests were also felt to be useful to manage 
patient anxiety and as a tool for managing patient interactions. In these cases, 
doctors often had an expectation that the test result was most likely to be normal. 
To be honest I think I was probably expecting them to come back normal and 
just as an added tool or, yeah, an added tool to reassure the patient (doctor 
12, female, salaried GP, 0-5 years’ experience) 
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 Mismatch between doctors’ and patients’ 
expectation 
A mismatch in expectations could be seen when analysing the paired data on 
patients and doctors. For example, patient 18 expected the blood tests to give 
answers to the cause of her symptoms, whereas her doctor expected the results to 
be normal. 
I think I was pretty much expecting them to 
be normal ‘cos I didn’t treat her or anything 
at the time. (Doctor 18, male, GP partner, 0-5 
years’ experience) 
Well just that he would discover what it was 
and confirm what it was and give me some 
help (Patient 18, female, 76 years) 
Some doctors were aware of this mismatch in expectations, and therefore tried to 
discuss and share their expectations with patients to pre-empt and prepare 
patients for the possibility of a normal test result.  
What I normally do say if I think they’re going to be normal, I normally try 
and pre-empt that by saying to patients I expect they’ll be normal but that 




Most decisions to order a blood test were led by doctors. Although doctors 
perceived that some patients expected, or wanted blood tests, this was rarely 
reflected in the patient interviews. For example, doctor 11 perceived that the 
patient was looking for a decision on further tests, whereas patient 11 was 
reassured by the normal examination findings and was not expecting tests. 
I think that she was coming for reassurance 
and for a decision as to whether she needs 
further tests at this stage. (Doctor 11, female, 
GP partner, 20+ years’ experience) 
It didn’t enter our head about a blood test… I 
was glad really that she done the…examined 
me ‘cos I didn’t know if there was anything 
wrong.  All I knew was I had the breathing 
problem.  So, I was glad she examined me 
and she said there was nothing there didn’t 
she?  (patient 11, female, 88 years) 
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There were no clear examples of the doctor involving the patient in a shared 
decision to test in any of the interviews (Table 35). Although some of the patients 
said that they thought that they had shared the decision, their description of 
events suggested that the doctor had made the decision and the patient agreed or 
acquiesced without evidence of the patient being involved in decision-making. 
None of the patients recalled being offered any options or alternatives to testing, 
such as an alternative test or the option of no testing, which is generally accepted 
to be one of the prerequisites for shared decision-making.  
I think it was shared.  When she suggested it, I said yeah, it’s obviously worth 
checking (patient 6, female, 54 years)   
Patients generally did not perceive blood tests to be a decision where options or 
choices were possible and there was a lack of demand from patients for shared 
decision-making.  
I think you can always say, ‘no, I don’t want it done’, but then if you’ve got 
that condition, I mean what choice do you have really? (patient 4, female, 79 
years) 
Well, you’ve got to have it done because you’ve got to find out what the 
problem is. (Patient 24, male, 79 years) 
In three atypical cases, patients reported that they had asked their doctor directly 
for blood tests; all these cases had previous abnormal blood test results which 
they wanted to recheck or monitor, which perhaps empowered or enabled them 
to make this request. One of the patients reflected that he felt frustrated that he 
was not able to directly book a test and that he had to wait to get the doctor’s 
‘permission’ first, reflecting an imbalance in power and control over decisions 
around blood tests. 
I mean I don’t see any reason why I can’t phone the receptionist and say I 
want a blood test and she’ll say well I can’t book you in because you haven’t 
had permission from the doctor, whereas if someone in my case and 
someone who regularly is going to have blood tests, it should be notified on 
the computer and the receptionist can book you in and speed it all up 




Table 35: Decision-making 
Code Definition  n=28 Example quotes 
Doctor led 
decision 
Doctor/patient agree that 
the decision to test was led 
by the doctor 
24 I went to the doctor and then she 
decided to ask me to go for a 
blood test (patient 25, male, 59 
years) 
 
I get told to go to them, so I go to 
them (patient 3, female, 20 years) 
 
I would say that with the blood 
test was initiated on my decision 
really, rather than hers (doctor 




Where testing was 
instigated by patient 
request 
3 I request to them this blood test 
because when I had my second 
child, I had inflammation, so I just 
want to check- (patient 22, 
female, 44 years) 
 
Then I asked if I could have a 




Shared decision – where 
doctor and patient felt that 
a joint decision was made.  
If the doctor makes a 
decision and the patient 
agrees this is not shared. 
Need some evidence that 
doctor involved the patient 
in decision-making 
0  
Unclear No information about 
decision-making, or doctor 
and patient interview 
conflicting. 
1 So, my GP said, Dr M, she 
recommended it. (patient 13, 
female, 22 years) 
 
So, her background seemed to be 
that she was concerned that she 
might have an underactive 
thyroid… Yeah, I think [it was a] 
shared decision. (doctor 13, 
female, GP partner, unclear/ 




 Information sharing  
Whilst decision-making was a single step, shared understanding required a 
process of information sharing before, during and after testing.  
 
 Sharing information on reasons for testing  
Overall, there was a lack of understanding amongst patients about which tests 
they were having done and why, with 17 out of 28 patients saying they either did 
not know or were unsure why tests were being done (Table 36).  
You walk out and you see somebody, oh what have, you know, you’ll see a 
friend and they’ll say what have you been in there for? Had to have blood 
tests. What for? Don’t really know (laughs). And you don’t (Patient 9, female, 
72 years) 
Although the lack of shared decision-making was generally perceived as 
acceptable, the lack of information sharing was perceived as less acceptable by 
patients.  
I like to be told ‘ok, we’ll run some blood tests, we’ll have a look for this, that 
and everything else’, but again unless I suppose I’d said to him what are you 
testing for, I suppose the responsibility, the onus is on me.  I sometimes think, 
like I said, it’s like the Secret Service… because the doctors tend to, I don’t 
know.  How can I put it?  It’s almost like they kind of shut you out, you- Oh 
we’ll just check your levels. (Patient 9, female, 72 years) 
All I know is I’m just given my four vials of blood and I’m just like where’s its 
going and what’s it for, I don’t know what you’re looking for (Patient 21, 
female, 29 years) 
Patients saw phlebotomists as another source of information about blood tests. 
Although phlebotomists could generally explain which tests were being done, 
my data does not indicate they were able to explain why. 
I just asked (the phlebotomist) what the blood tests were looking for and how 
they would show…but they weren’t a hundred percent sure what they were. 
They said what the blood tests would test for, but they didn’t really say what 
they were looking for, if that makes sense. (Patient 27, male, 19 years) 
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Table 36: Information sharing 
Category Definition n=28 Example quotes 
1. Does patient know why tested? 
Yes Based on patients own 
perception of whether they 
know the reason for testing. 
Patient has some 
understanding of what the 
tests are looking for e.g., 
aiding diagnosis, guiding 
treatment, excluding disease, 
‘baseline’. 
11 This is for the giant cell 
arteritis because apparently 
you get inflammation, and it 
can cause blindness. (Patient 
4, female, 79 years) 
No If the patient says they don’t 
know what the tests are 
looking for or why they were 
done. 
10 I had a phone call to say would 
I have a repeat [test] a month 
later but I wasn’t told why, but 
I didn’t ask why so that’s 
probably my fault. (Patient 1, 
female, 83 years) 
Unsure If the patient says they are 
uncertain, if they offer a 
guess or use tacit knowledge 
to say why they think the 
tests were done (rather than 
reporting what the GP told 
them) 
7 So, I don’t really know [why] 
and I suppose Dr M, I said 
what do you think and he said 
well we’ll do a blood test to 
confirm and to confirm I 
presume he meant whether I 
had this poly fibromyalgia. 
(Patient 2, female, 82 years) 
2. Does patient know which tests were done? * 
No Patient only uses vague terms 
to describe tests e.g., 
‘bloods’, ‘blood tests’, but 
cannot give any more detail. 
10 Interviewer - And do you know 
which blood tests are 
checked? 
P I’m assuming practically 
everything (Patient 1, female, 
83 years) 
Category Patient knows the category of 
tests e.g., ‘liver function', 
'kidney function', 'markers of 
inflammation'. Include where 
they just describe testing 
organs e.g., ‘your kidneys’, 
‘thyroid’.  
12 It was just for renal to check in 
your… sort of renal, 
waterworks, you know 




Use of specific named tests 
e.g., ‘CRP', 'PSA'. 
7 For bloods they’re checking to 
see if I’ve got an above 
average white blood cell 
count, just to see if there’s an 
infection or something. 




Patient names diagnosis to 
describe test e.g., ‘check for 
anaemia’, ‘coeliac test’, 
‘blood test for diabetes’. 
1 A rheumatoid arthritis test, I 
think. (Patient 19, female, 52 
years) 
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Unsure Unsure if the patient says 
they are uncertain, if they 
offer a guess or use tacit 
knowledge to say which tests 
were done (rather than 
reporting what the GP told 
them) 
1 And did you know which blood 
tests you were having done? 
P No.  I didn’t. 
I Did you know anything 
about what was being 
detected in the blood test? 
P No.  Well, I assume that 
it would be white blood count 
and possibly something similar 
(Patient 28, male, 49 years) 
3. Does patient know anything about limitations of testing? 
No No awareness or 
understanding of the 
limitations of tests 
27 Interviewer - And have any of 
the doctors talked about any 
benefits or limitations of blood 
tests to you? 
Patient - Only to- No, I only 
think just to find out what is 
wrong, that’s all. (Patient 4, 
female, 79 years) 
Yes Some understanding of the 
limitations of tests e.g., false 
positives, false negatives. 
Mentioning that the diagnosis 
may still remain unclear after 
test does not count as 
explanation, unless there is a 
specific mention of this in 
context of the test e.g., “this 
test may not rule X out”. 
1 It could show up levels of 
inflammation, which is not a 
positive thing for that 
diagnosis, but it could mean 
that there was something like 
that. (Patient 6, female, 54 
years) 
*Total adds up to >28 because three patients were aware of some categories of tests and also 
some specific named tests being done. 
 
GPs reported sharing more information with patients than was reflected in the 
patient narratives. For example, doctor 11 expected her explanation of the tests to 
give the patient a much better level of understanding than the patient reported.  
I think she would have understood when I 
said some people are breathless because of 
anaemia and I said I’m checking your full 
blood count and your iron.  I think she would 
have known that that was looking for signs of 
potential anaemia. (doctor 11, female, GP 
partner, 20+ years’ experience) 
Interviewer  Do you know what they’re 
looking for in those tests or what they might 
pick up? 
Patient All I understood was the 
inflammation in the blood. 
Interviewer And what do you know about- do 
you know what that means or-? 
Patient No I don’t know, no.  
(patient 11, female, 88 years) 
 181 
Although patients commonly mentioned that they were having tests for 
‘inflammation’, few had a clear understanding of what was meant by this. 
Patients had very little awareness of potential limitations of testing, indeed even 
the concept of tests having pitfalls or limitations was one that they were mostly 
unaware of.  
Interviewer  Have any of the doctors talked about any benefits or 
limitations of blood tests to you? 
Patient  Only to- No, I only think just to find out what is wrong, that’s 
all. (Patient 4, female, 79 years)   
In contrast when discussing decision-making around blood testing GPs 
commonly discussed weighing up and considering limitations of testing.  
As I say, you know, it is that can of worms isn’t it?  When you do a test and 
you think why the hell did I put a tick in that box and then it just start- and 
then almost an avalanche of things, so a raised PV then could end up with 
BJPs, calcium, serum protein electrophoresis, so more and more tests that I’m 
less and less experienced with. (Doctor 2, male, GP partner, 20+ years’ 
experience) 
 
 Sharing test results 
Most patients were told whether their tests were normal or abnormal, but few 
knew the actual results (Table 37). This reflects a paternalistic position, as 
highlighted by one of the patients. 
I mean you say you’ve got your results back; I haven’t got my results back, 
I’ve got a doctor’s interpretation of my results.  (Patient 23, female, 24 years) 
Some patients felt that it would be helpful to have copies of the written or 
printed test results as actual numbers, but this needed suitable explanation. 
It would be nice if you had the results of the blood test written down but in a 
way that you could understand what it meant.  Like if they said like blood 
sugar should be under 42 or something like that, but yours is this so do 
something about it. (Patient 4, female, 79 years) 
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Patients generally wanted more information about the meaning of their test 
results, in terms of what was causing their problems and what they could do 
about this.  
What I want is direct input.  I want the doctor to tell me ok this is what it 
means and so this is what I suggest you do (Patient 25, male, 59 years) 
All patients who had abnormal test results (n=7) had some explanation and 
understanding of the meaning of their results. By comparison, only 3 out of 11 
patients with normal results had any understanding of the meaning of the 
results.  
GPs generally assumed that normal test results needed less communication and 
explanation, so patients were either texted with the results or GPs would leave it 
to the patient to make contact.   
I’ve kind of left the ball in her court now whereas before I think if they were 
raised and shown signs of inflammation then I would probably make an 
active plan for follow-up. (Doctor 18, male, GP partner, 0-5 years’ experience) 
Four out of seven patients whom the GP reported had ‘borderline’ test results 
were not aware of these borderline abnormalities and were under the impression 
that their tests were normal. 
Her plasma viscosity was 1.87 so a little bit 
raised, there or thereabouts. (Doctor 2, male, 
GP partner, 20+ years’ experience) 
Well, he just said the blood tests came back 
and it was perfectly normal.  No problem, he 
said no worries at all. (Patient 2, female, 82 
years) 
Two patients did not receive their test result at all; both were having routine 
monitoring bloods for chronic conditions and said that they would not usually 
contact the practice for results, so were not followed up further. One patient was 





Table 37: Sharing test results 
Code Definition n Example quotes 
Patient awareness of test result (n=27*) 
Results only Numerical value only 0  
Assessment only Assessment of result 
e.g., normal / 
abnormal  
24 So, I didn’t actually get any specific 
numbers and she- so with the Vitamin D 
result she said oh no actually your levels 
are really, really low, I am going to have 
to prescribe you some- But with the CRP 
she just says yeah, you’ve got a raised 
CRP. (Patient 13, female, 22 years) 
Result and 
assessment 
Numerical value and 
assessment of 
whether this is 
normal/abnormal  
1 Apparently my blood levels… not my 
blood levels, oh whatever it is, it’s going 
up, it’s improving all the time.  It’s gone 
from 9.5 to 9.8. (Patient 24, male, 79 
years) 
No result Patient unaware of 
test result 
2 So as things are, I haven’t heard 
anything back on the back of having 
them taken at all.  So, I presume nothing 
alarming there but likewise I also don’t 
know whether there is anything positive 
there either. (laughs) (Patient 8, male, 
37 years) 
Patient understanding of meaning of result (n=25**) 
No understanding Patient is aware of 
result +/- assessment 
e.g., ‘low’, ‘high’, but 
no understanding of 
what that means e.g. 
pathophysiology, 
aetiology, diagnosis 
12 Well obviously it’s good to know that 
nothing hideous has been brought up in 
any of the blood tests but I have 
absolutely no idea what the blood test 
was for in the first place so it’s kind of a 
bit like ok, so they’re just now saying it’s 
just nothing’s come back or nothing’s 
come up sort of thing, saying that its 
normal but I’m like what’s normal?  I 
didn’t know what the blood was for, I 
don’t know what the results really tell us 
(Patient 21, female, 29 years) 
Some understanding Patient has some 
understanding of 
what the test results 
mean for the patient, 
beyond assessment 
13 They just explained that everything like 
came up to no concerns and that, but 
that they explained about the protein 
levels being a bit high because of the 
cold I’ve just had. (Patient 16, male, 19 
years) 
So they explained that from the results 
they could see signs of an infection so 
then from there they recommended that 
I go on a course of antibiotics (Patient 
15, male, 18 years) 
*n=27, one patient was uncontactable for follow up, so not included 
**n=25, one patient uncontactable, two patients did not receive their test results, so not 
included 
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 Consequences of testing 
Tests had medical consequences such as further investigations, treatments, or 
referral, but also important non-medical consequences which could include 
anxiety, reassurance, uncertainty, or frustration. Testing allowed doctors and 
patients to construct meaning and explanation of patients’ symptoms, but this 
required a shared understanding of testing. Without meaning and explanation 
and without a shared understanding, tests could lead to increased uncertainty 
and anxiety. The consequences of testing therefore depended on doctor-patient 
expectations and communication. This is illustrated by paired quotes from case 4 
and 26; in both cases the GP felt that the normal result provided reassurance or 
‘progress’ for the patient and doctor, whereas the patient felt anxious that the 
cause of the symptoms had not been found.  
So yeah, I think they [test results] were 
reassuring for the patient and they were 
reassuring for me and the rheumatologist 
that we weren’t missing anything potentially 
serious.  (Doctor 4, male, GP partner, 10-20 
years’ experience) 
Well I’m, you know, I get worried really as to 
why I’m getting these things and nobody 
knows why. Obviously the blood tests can’t be 
showing anything.  I mean I’ve had MRI scan 
a while back, but nothing came of that really.  
I’m just a bit worried as to why I’m getting 
these things. (Patient 4, female, 79 years) 
So his CRP had come back normal, a coeliac 
screen and his faecal calprotectin as well was 
also normal, so then we’re sort of able to 
progress in thinking this is most likely IBS 
that’s causing this type of pain and talk about 
ways to manage that. (Doctor 26, female, 
locum, 0-5 years’ experience) 
It’s reassuring obviously that it’s told me the 
result that it’s not something but it’s not 
reassuring in a way because I don’t know 
what it is and neither does my GP.  (Patient 
26, male, 25 years) 
Where differing beliefs and expectations were not resolved through 
communication, this could lead to a distorted understanding between doctor and 
patient. For example, one patient, having blood tests for joint symptoms and 
possible arthritis, assumed that negative blood test tests had ruled out cancer.  
They said it all seems to be clear, but I was worried about cancers, but 
obviously there’s no cancers going on otherwise they would have told me if 
there was. You would have thought, so wouldn’t you? (Patient 25, male, 59 
years) 
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A lack of shared understanding was particularly problematic for symptomatic 
patients with normal test results who were left without explanation for their 
symptoms. 
I definitely don’t feel that a normal result is a win for me by any means and I 
can’t continue to feel the way that I do so I’m just going to have to keep on 
looking into it and getting that sorted and just kind of being as honest about 
my symptoms and things with the doctors as I can so that they know where 
to go with it, I guess. (Patient 21, female, 29 years) 
The fact that the doctor had recommended testing could increase patients’ 
expectations that there must be an underlying problem causing their symptoms, 
normal test results could therefore, paradoxically, lead to increased expectation 
that further tests are needed. 
I mean obviously the blood test was saying that my levels are better so… I 
suppose there should be other tests then ‘cos they haven’t found out what’s 
causing the pain and the discomfort and everything. (patient 7, female, 60 
years) 
Some patients also felt a sense of frustration, not only that test results did not 
provide answers or explanation for their symptoms, but also that normal test 
results in the context of ongoing symptoms seemed to invalidate their 
experiences, making them feel as if they were being dismissed or written off.  
Its semi-frustrating because you think well that’s another thing that doesn’t 
give me the answer then, that’s another reason for them to go there’s 
nothing wrong with you (patient 21, female, 29 years) 
Whilst doctors generally perceived that normal test results need less explanation 
than abnormal results, these findings suggest that the need to construct meaning 
and shared understanding is just as important with normal blood test results.  
Doctors generally assumed that normal results were reassuring, whereas patients 
were often actually reassured by abnormal results, even when the abnormalities 
which were picked up were unlikely to be related to the presenting problem. 
It was like oh I have a surprise deficiency. (laughs) Obviously I’m really 
pleased that that was found (Patient 23, female, 24 years) 
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 Barriers to shared understanding of blood 
testing 
There was a perception from both doctors and patients that sharing information 
about testing was the right thing to do ‘in an ideal world’, but multiple barriers to 
information sharing were identified by both doctors and patients. These could be 
categorised into barriers around knowledge, attitudes, and systems of testing.  
 
 Barriers to shared understanding: knowledge  
Challenges sharing technical and complex information 
Both doctors and patients perceived that tests are sometimes too complex or too 
technical for patients to understand. There was a lack of shared language which 
meant that even when doctors tried to share information, patients did not always 
understand what was being said.  
I can’t remember now whether it was full count or this or that, whatever, I 
don’t know what she was taking about to be honest. (Patient 20, male, 76 
years) 
One example was the word ‘inflammation’, which was often used by doctors and 
patients, despite the fact that many patients did not understand what this meant. 
Another example was the fact that if written test results were provided, they 
were generally printed in a format designed for healthcare professionals not for 
patients. 
You could have a copy of your results but it don’t mean a thing to ordinary 
people. (Patient 4, female, 79 years) 
If they’re bad they will explain to me and show me the results in strange 
numbers and letters…Yeah, I get a print of it with all the- I don’t normally 
know too much of what it means, just letters and numbers but if something’s 
odd then they’ll show me what is odd. (Patient 3, female, 20 years) 
Doctors and patients both perceived that too much information could be 
confusing and unhelpful for patients.  
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I don’t think she probably fully understood the ins and outs of each blood 
test, I don’t think I went through every test detailing exactly what it might 
show or what it’s for ‘cos I think sometimes that’s probably a bit too much 
information. (Doctor 9, male, 0-5 years’ experience) 
I think sometimes you can confuse yourself if you’ve got too much 
information you can sort of read too much into it. (Patient 6, female, 54 
years) 
Testing was often only one small part of the overall consultation and GPs needed 
to balance out the most important information for the patient to take away. 
Sometimes you don’t want to bamboozle people with too much and if you 
want them just to remember one specific thing about the consultation. 
(Doctor 21, female, salaried GP, 10-20 years’ experience) 
Some patients reported that they had been given information about their tests, 
but that they struggled to retain this information. This is in keeping with the 
observation that the GPs account of information sharing did not always match 
with patient recollection. The use of unfamiliar technical terms made it harder for 
patients to retain information. 
She’s requested a Vitamin D test as well as just the test to… I don’t know, she 
said some initials, but I just forgot what they were. (Patient 17, female, 18 
years) 
Some patients perceived that it was their responsibility to ask questions if they 
wanted to know about their blood tests, rather than the doctor’s responsibility to 
give this information. 
I like to be told ok we’ll run some blood tests, we’ll have a look for this, that 
and everything else but again, unless I suppose I’d said to him what are you 
testing for, I suppose the responsibility, the onus is on me. (Patient 9, female, 
72 years)  
I wasn’t told why, but I didn’t ask why so that’s probably my fault (Patient 1, 
female, 83 years) 
Patients did not always feel able to ask these questions or might not think of the 
questions until after the consultation.  
I definitely would have preferred if they had told me what they were testing 
for. Perhaps if I had actually asked maybe then they would have but I didn’t 




Lack of resources for information sharing 
Although doctors and patients discussed using resources such as leaflets and 
websites to share information about diseases, resources to share information 
about tests were not used in any of the cases.  
I use a lot of patient.co.uk handouts if I know they’ve got a condition or I 
think they’ve got a condition to give some sort of simple patient information 
leaflets but I don’t usually give them one about blood tests. (Doctor 17, 
female, GP partner, 5-10 years’ experience) 
Patients and doctors both said that they thought that written information would 
be useful, but doctors were concerned that leaflets about tests could potentially 
cause anxiety.  
I think actually, you know, now you say it, I think if we were to have patient 
information leaflets on the meaning of a plasma viscosity and a CRP that 
might be really helpful.  Having said that, if you have any information leaflet 
that lists all the things it could be, that leads to anxiety itself in patients. 
(Doctor 5, female, GP partner, 10-20 years’ experience) 
Where doctors discussed information resources for blood tests these were mostly 
felt to be designed for patients who had received test results, but were often not 
suitable for shared decision-making around whether to test. 
I mean labtests online is quite good isn’t it but it’s not very- It doesn’t really 
go into the pros and cons of having the tests done, it’s further down the line 
isn’t it, it’s you’ve had the test done, this is what it potentially means. (Doctor 
4, male, GP partner, 10-20 years’ experience) 
Some patients said they usually looked up health information on the internet. 
However, without information about which blood tests had been requested, they 
were not empowered to look up information on their tests. 
I know NHS has a website and they have some information on there as well.  
But I guess I don’t know what I’m searching for because I don’t know what 
blood test was being run so I wouldn’t know where to start I guess. (Patient 
12, female, 27 years) 
Others actively chose not to look up health information online because of the 
difficulty accessing trustworthy information, and risks of causing anxiety.  
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I try not to Google because as you know with the internet everything tells you 
you’re dying (laughs), and I didn’t want to hear that. (Patient 21, female, 29 
years) 
 
 Barriers to shared understanding: attitudes 
Blood tests perceived as low priority 
Doctors perceived that tests were relatively trivial interventions and were 
therefore low priority for information sharing. Doctors described having 
multiple other issues to discuss in a consultation and had a perception that 
patients generally did not want to know much about blood tests.  
I don’t find patients ask terribly much about what the blood tests are that 
we’re testing for…  I don’t have a massive feeling that they want to know 
terribly much more but maybe I’m wrong about that, I don’t know. (Doctor 
15, female, GP partner, 10-20 years’ experience) 
 
Paternalism 
Some doctors and patients felt that testing is an area which justified a more 
paternalistic approach. The imbalance of knowledge and power between doctors 
and patients meant that patients did not think it was possible for them to engage 
with decisions around testing. Patients reported ‘trusting’ their doctors to make 
the right decisions on their behalf, and this was seen as a reason not to ask 
further questions.  
I kind of trust them enough to know I know they know what they’re doing 
therefore I don’t really like need to have too much involvement in what 
they’re- not necessarily what they’re looking for but what they’re doing, I 
trust them. (Patient 3, female, 20 years) 
I think that’s still one of those areas of being a GP that patients just trust 
you’re going to ask for the right tests. (Doctor 15, female, GP partner, 10-20 
years’ experience) 
The perception that testing is ‘still one of those areas’ seems to reflect an awareness 
amongst GPs of the changes over time in medical decision-making, and the 
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gradual move away from paternalism. Some doctors reflected on this during the 
interviews and felt that this was an area where they could try to improve their 
practice.  
I’m probably not as good as I might be at sharing that decision, so it’s 
probably more mine actually but I think I will reflect on that.  Yes, I’m 
probably, you know, I think our GP trainees and our trainers are very good at 
doing shared decision-making.  I’m probably perhaps a bit more old-
fashioned in my approach. (Doctor 6, female, GP partner, 5-10 years’ 
experience) 
 
Justification for paternalistic approach: protecting patients 
from anxiety? 
Doctors perceived protecting patients from undue anxiety was sometimes a 
justification for withholding information about blood tests. Doctors perceived 
that minor abnormalities which were not clinically relevant, could cause anxiety 
if shared with patients.  
The difficulty with that is that there are lots of minor variations… you see all 
the red exclamation marks that come up when you get your blood results 
back and whilst we know that the vast majority of those are nothing to be 
concerned about and we would file that as a normal result or satisfactory, it 
could cause a lot of concern for patients potentially. (Doctor 8, male, GP 
partner, 0-5 years’ experience) 
Doctors also perceived that sharing possible diagnoses, before test results were 
available, might cause unnecessary anxiety. Rather than giving details of which 
tests were being done, or what was being tested for, they might therefore use 
more general terms.  
[I said]…there is one condition that can give you both pain with that, so I 
want to do some extra tests to just rule that out.  And that’s thinking about 
myeloma.  I don’t think I said to her the word myeloma or what it was 
necessarily. (Doctor 7, female, GP partner, 5-10 years’ experience) 
In this case the possible diagnosis being checked for, myeloma, is a type of 
cancer, but the doctor avoided mentioning this explicitly. Rather than 
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mentioning the word ‘cancer’, doctors and patients tended to allude to 
possibilities of something ‘serious’ or ‘worrying’.   
I probably sort of don’t say exactly what I’m looking for, maybe saying make 
sure there’s nothing else worrying going on is probably what I’d be saying 
more.  I think a lot of people tend to understand what that means.  I mean a 
lot of people are worried about cancers and things like that. (Doctor 24, 
female, salaried GP, 0-5 years’ experience) 
However, even when these possible serious diagnoses were unspoken, or only 
alluded to in the consultation, patients used guesswork or tacit knowledge to 
infer the possibilities. 
Interviewer What do you think they might be looking for in those tests? 
Patient Something in the blood, like this time I thought maybe 
because I’ve got lumps in my neck, I thought maybe 
leukaemia ‘cos I know that’s something, but again that’s just 
a guess.   
Interviewer Was there anything like that mentioned? 
Patient  No.  It was just to look out for symptoms like night sweats, 
weight loss and just feeling unwell.     
(Patient 12, female, 27 years) 
Some patients also perceived that doctors ‘couldn’t’ share information with them 
until they had definite answers. 
I imagine my GP is on the ball, I’ve always thought she was anyway, but as I 
say obviously there’s more to this than meets the eye, more to this than I’ve 
been told.  They can’t tell me anything till they know for certain, can they? 
(Patient 1, female, 83 years) 
Some patients felt that this was justifiable, and would rather doctors did not 
share possibilities or uncertainties as they wanted to avoid unnecessary anxiety.  
I’d rather not know possibilities; I only really want to know definites… 
because there’s no point worrying yourself sick about something that you 
might not have but you can’t stop yourself. (Patient 23, female, 24 years) 
Other patients wanted more information about the possible diseases or diagnoses 
before testing, so that they could be aware not just what diagnoses had been 
made, but also about what possibilities had been ruled out.  
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I think it’s just good to know what you’re looking at… It would just be good to 
know because then once it comes back negative you can chuck that away, it’s 
gone, its eliminated but if there is a tick list of things that it could be, it’s good 
to be able to cross those things off …So the more information they can give 
people about what they’re looking into the better I think personally. (Patient 
21, female, 29 years) 
Another justification for holding back information about testing, and taking a 
more paternalistic approach, was the perception that tests were sometimes done 
for doctors’ purposes, ‘sort of behind closed doors’, that they were not meant for 
patients, and that doctors needed to have thinking space to work out what was 
going on before they could share this with patients.  
No, I mean it’s difficult to say but plasma viscosity is one of those ones that I 
often use to reassure myself to look for things but honestly, sometimes it’s 
one of the ones that I try not to discuss in too much detail with patients 
because I think generally it can lead to more alarm.  It sounds awful but the 
interpretation of it is so difficult, I perhaps downplay it until I know it’s a 
significant thing. (Doctor 5, female, GP partner, 10-20 years’ experience) 
In my head the results have always been for the doctors, they’re not for me, 
do you know what I mean?  ‘Cos, they tell you whether you have anything to 
worry about or anything to follow up with but you’re never going to 
understand what those things are so really it seems to be for the doctor’s 
eyes only. (Patient 21, female, 29 years) 
However, although information about testing was sometimes withheld by 
doctors to prevent patient anxiety, some patients perceived that a lack of 
information sharing was more likely to provoke anxiety. 
I worry more by not knowing.  I do personally.  I prefer to know.  I think right, 
I’m sort of like- then I’m prepared, aren’t I?  I can sort of get all my ducks in a 
row (laughs). (Patient 9, female, 72 years) 
 
 Barriers to shared understanding: systems of 
testing 
Another potential barrier to shared understanding was the systems of testing, 
particularly around how test results were communicated.   
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Uncertainty and variation in test result communication 
Patients could receive their results face to face, by telephone, text message or by 
letter, and communication could come from a doctor, allied health professional 
or from receptionists. This communication of test result could be instigated by 
the GP practice, or it could be up to the patient to initiate communication. Most 
doctors made individualised decisions about how to share results depending on 
their knowledge of the patient, the clinical context, and the test results. Methods 
of communicating results varied between doctors and were based on habits, 
unwritten heuristics, and personal preferences rather than protocols.  
There aren’t protocols that we use.  There's a lot of debate in the practice as 
to how we manage blood test results in that the onus is always put on the 
patients to call about the results of the blood tests. So, it depends what the 
results show.  If there’s any significant abnormality that needs action, we 
normally speak to the patient straightaway. (Doctor 8, male, GP partner, 0-5 
years’ experience) 
It’s always difficult when people in a practice do different things or if I’m 
away, so somebody else is filing my results they may do it in a different way. 
Yeah, I think it’s up to the individual. (Doctor 17, female, GP partner, 10-20 
years’ experience) 
As a result of this variation patients often struggled to navigate the system and 
often used guesswork to decide whether or when to contact the practice for 
results.  
Certain tests can be given to you via text message.  If there is, well sometimes 
its sent to you via paper, letter form, and if there’s any cause for concern 
sometimes the reception will call you and say can we book you in with, it 
really does, it differs so much as a change in different methods really for 
every different type of test, so I just kind of go oh ok, I haven’t heard for a 
certain amount of time, I’ll call up the reception. (Patient 21, female, 29 
years) 
Although doctors often assumed that patients would contact the surgery for their 
test results, this was not always the case. For example, in case 8 the doctor had 
recorded in the notes that the patient should make an appointment to see a 
doctor, relying on the patient to contact the practice to receive this message. The 
patient, who has regular blood tests for monitoring, admits he has never phoned 
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for his test results. Instead, the patient assumed that the practice would contact 
him if there was any problem.  
His CRP is 114, she’s put on there see doctor if 
still has the symptoms.  I think I probably 
would have contacted him with that CRP 
result …But I’m sure, I know he would call if 
he was deteriorating anyway (Doctor 8, male, 
GP partner, 0-5 years’ experience) 
I’ve never, ever asked for my test results.  I’ve 
always just turned up, had my blood taken, 
gone away and always with the assumption 
that if there was anything wrong someone 
would let me know. (laughs) (Patient 8, male, 
37 years) 
Similarly, in case 20 the doctor put a comment to repeat the test, assuming the 
patient would contact the practice to receive this message. When the patient did 
contact the practice, he felt aggrieved that he had not been contacted. 
I didn’t speak to him, I just put a comment 
that they were all improving and to 
repeat in two weeks’ time. (Doctor 20, male, 
GP partner, 0-5 years’ experience) 
So anyway, I waited a week, went there last 
Friday and asked the lady and she said yeah it 
was all clear, oh but they wanted you to have 
a blood test again on one particular thing and 
I’m thinking well I would have never known 
that if I hadn’t had come and asked…. How 
many people ring up and ask for their results, 
how many people make the effort to go down 
and ask, it’s a bit…Yeah, I thought well it’s a 
bit lax. (Patient 20, male, 76 years) 
Doctors generally expected patients to know how to access their test results, but 
patients were often unsure about the best way of doing this.  
I always say you must get a result one way or 
another hearing that it’s either normal or 
abnormal, you need to make sure you contact 
us for a result if it hasn’t come through to 
you. (Doctor 13, female, GP partner, 10-20 
years’ experience) 
I don’t know how I do that actually.  Maybe I 
ring up and- probably ring up and just ask the 
receptionist how I’d go about doing that, ‘cos 
I don’t know if I need like a whole 
appointment for that, I don’t know if they 
could send those [blood test results] to me.  I 
don’t know how it works. (Patient 13, female, 
22 years) 
 
Communication of results by non-clinical staff 
Another barrier to shared understanding was the system of communicating test 
results via receptionists or non-clinical staff, who were unable to give 
explanation of the meaning of test results.  
 195 
The receptionist said, I told her why I was phoning, I said I haven’t had the 
results of my blood test and she said yes, oh yes, I’ve looked it up, 
everything’s fine, no further action.  So, I didn’t need to go back to see the 
doctor and then you think well in a way you’ve got a closure of a sort but not 
of what you’d originally perhaps come about… So, I don’t know. (Patient 18, 
female, 76 years) 
Some patients felt unhappy about receiving test results from non-clinical staff 
members who might not have the training to understand test results. 
Chasing results is difficult to get from the secretary.  No disrespect to them 
either but that’s a very difficult situation ‘cos she’s having to discuss what she 
sees on the screen.  And are they right to do that and are they right- do they 
understand that?  I don’t know. (Patient 5, male, 43 years) 
I don’t even bother- I could ring here and find out the results but I don’t know 
about the receptionists and I’m sure they’re well trained, but do they actually 
know how to read the blood results? (Patient 10, female, 56 years) 
 
Text messages 
Whilst systems of texting patients about their test results was generally perceived 
positively by doctors, there were mixed views from patients. Some welcomed 
this as a quick and easy way to get reassurance with normal test results. 
 That’s suits me ‘cos I know… the doctor explained that if they were normal 
results, they’d come through text so then I knew when I got the text and I 
quickly read through I was like oh its fine.  But obviously if it was abnormal, I 
wouldn’t want to receive that by text. (Patient 12, female, 27 years) 
Others felt that text messages did not really convey sufficient information or 
explanation to allow an understanding of the meaning of these results. 
I think having a text saying everything was normal sort of reassured me that 
nothing greater was going on, but also again having it saying it was normal 
was a little bit like well I’d kind of like a little bit more explanation. (Patient 
27, male, 19 years) 
Text messaging systems were generally designed to prevent two-way 
communication, making them efficient for doctors. However, when doctors 
included safety-netting advice asking the patient to get back in touch if they had 
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concerns or questions, patients perceived that they had no clear route to 
communicate back to the doctor. 
I find it quite new now to be texted by my doctor and its very much I feel a 
one-way method of communication because I can’t reply, and I can’t just text 
my doctor back.  So, my doctor has said several times in texts if this hasn’t 
worked let me know if you have any more questions, please get in contact 
with me, but the only way I know of doing that is by booking an appointment 
or a phone call.  I can’t just post a message on a message board or send a 
text to that doctor.  So that’s a confusing communication method for me. 
(Patient 23, female, 24 years) 
Some patients even felt that a text was perhaps an inappropriate, or ‘flippant’ 
way of communicating test results, particularly for those with more complex, 
ongoing problems. 
I’d say in people’s situations like mine where it’s an ongoing thing, I don’t feel 
that a text message is sufficient… I feel if there’s more investigations to be 
done from that point on, just sending a blunt text isn’t really sufficient 
because it means nothing to me… So, I don’t know, it just feels a bit, 
sometimes when you get a text about something like that it seems a tad 
flippant. (Patient 21, female 29 years) 
This contrasted with doctors’ perceptions of patients, most of whom assumed 
that patients were very happy to receive text message communication. 
I love it.  I think it doesn’t work for all patients and it’s good that there’s an 
opt in/opt out option but I think particularly our patients they’re very 
proactive, they like to receive communication from us and they quite often 
are happy to be texted. (Doctor 12, female, salaried GP, 0-5 years’ 
experience) 
The patients love them, generally the feedback’s been very good. (Doctor 27, 
female, locum, 0-5 years’ experience) 
Multiple issues relating to primary care systems which are not specific to testing 
were also mentioned as a barrier to test result communication, including time 
pressures, access to GP appointments, lack of continuity of care, and GP 
workload. These issues have been widely discussed in the academic literature so 
have not been analysed further.  
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 What do patients want to know about their 
blood tests? 
Although the complexity and technical nature of tests was perceived to be a 
barrier to information sharing, patients did not necessarily want technical 
information, but they did want to know what was being tested and why.  
I mean I know obviously it’s probably very technical and it’s not my expertise 
at all, but they could just say this is what we’re checking, this is what we’re 
hoping for and x, y and z really.  They took I think three vials of blood and I 
don’t know which ones (laughs). (Patient 26, male, 25 years) 
By building a shared understanding of the reasons for testing and a shared 
expectation of tests, doctors and patients could create meaning from the result. 
Case six illustrates a successful example of this; the GP shared her expectations of 
testing with the patient, explaining that the tests might be normal and what that 
would mean. She then also contacted the patient to discuss the meaning of the 
normal test results.   
So I said to her if they’re completely normal I’ll be very happy that it’s not this 
condition.  If they are very raised, I will phone you and we’ll treat you with 
steroids but I expect they may well be normal.  So I kind of gave her the 
expectation that they probably would be normal and I phoned her and what 
I’ve written is ‘phoned to reassure inflammatory markers normal, she’s happy 
to wait and see how things go’ because she was feeling slightly better after 
resting on her holiday. (Doctor 6, female, GP partner, 5-10 years’ experience) 
The patient in this case reflected on the importance of creating meaning through 
a shared understanding of testing. 
I think as long as people know what the tests are for, it’s not just oh we’ll do 
a blood test.  It’s just making people aware of what they’re testing for and 
then people can understand… because blood tests don’t really mean anything 




The first objective of the qualitative research described in this chapter was to 
explore to what extent doctors and patients have a shared understanding of the 
use of inflammatory marker blood tests. My findings demonstrate a mismatch 
between patients’ and doctors’ expectation and understanding of testing. Patients 
were frequently unaware which tests have been done and why. Patients had high 
expectations of tests; expecting them to provide clear-cut answers, whereas 
doctors’ expectations were more modest.  
The second objective was to provide in-depth exploration of patients’ 
experiences of testing, from GP consultation to results. I found that none of the 
patients interviewed engaged in shared decision-making around testing, nor did 
they perceive blood tests to be a decision where options or choices were possible. 
Whilst decision-making was a single step, shared understanding required a 
process of information sharing before, during and after testing. ‘Normal’ test 
results required explanation and understanding to generate meaning and 
reassurance for patients; results without understanding could lead to further 
uncertainty and anxiety and for some people led to a feeling of being dismissed 
or written off.  
The final objective was to identify barriers and facilitators to improved 
communication, in order to inform improved communication in future. Barriers 
to shared understanding were identified in areas of knowledge, attitudes, and 
systems of testing. Barriers in knowledge included the perception that tests were 
complex, technical, and difficult to explain, and a lack of resources for 
information sharing. Barriers in attitude included perceptions that tests were 
relatively trivial interventions and therefore low priority for information sharing, 
and that tests were an area where a more paternalistic approach could be 
justified, particularly when sharing information could potentially cause anxiety. 
Finally, barriers in systems of testing included uncertainty and variation in 
methods for communicating test results, and the fact that test results were 
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frequently communicated by non-clinical staff, or by text message, which could 
leave patients with unanswered questions and no clear route for addressing this.  
In the next chapter I will discuss the strengths and weaknesses of this research, 
comparisons to existing literature and the clinical implications of these findings, 
alongside the quantitative research.  
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CHAPTER 6.  DISCUSSION 
 
 Chapter overview 
In this chapter I discuss the findings of my quantitative and qualitative research. 
First, I discuss the overall findings, linking these back to my thesis aims and 
objectives. Next, I compare these findings to the existing literature, then I discuss 
the strengths and limitations of my research. After that, I discuss the implications 
for research and clinical practice, before considering how the qualitative and 
quantitative research components of the thesis can be synthesised and making 
some final personal reflections.  
 
 Overall summary of findings 
The overall aim of this thesis was to explore the diagnostic utility and clinical 
practice of inflammatory marker testing in primary care, including how results 
are shared with patients, using a mixed methods approach. I will summarise the 
key findings of my research by referring to the thesis objectives as outlined in the 
background chapter 1.9.  
 
 Summary of quantitative results 
For the quantitative component of the thesis there were five main objectives. 
Results are summarised under each of these objectives.  
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Objective 1: Epidemiology of inflammatory marker testing 
Objective 1 of my thesis was to describe the baseline characteristics in terms of 
age, gender, socioeconomic status, and ethnicity of patients having inflammatory 
marker tests in primary care.  
Inflammatory marker testing was more common in females, in white ethnic 
groups, and in the more affluent. Conversely, abnormal results were more 
common in patients from more deprived socioeconomic groups. This is in 
keeping with the inverse care law,(209) with relative over-testing in the affluent, 
and relative under-testing in more deprived groups. Higher testing rates may 
also in part reflect higher consultation rates in certain socio-demographic groups; 
for example, women represent 60.2% of GP attendances, and comprise 61.8% of 
the inflammatory marker tested cohort. 
 
Objective 2: Inflammatory markers and overall disease 
outcomes 
Objective 2 was to determine the diagnostic accuracy of CRP, ESR and PV, singly 
and in combination, for relevant disease (infection, autoimmune conditions, and 
cancers) in primary care, and compare disease incidence in tested versus 
untested populations.  
Overall incidence of relevant disease was 15.0% in the raised inflammatory 
marker group, in comparison to 6.0% in the normal inflammatory marker group 
and 3.4% in the untested comparison cohort. In patients with a raised 
inflammatory marker, the most common diagnoses were infection (6.3%), 
followed by autoimmune conditions (5.6%) and cancers (3.7%). Disease incidence 
was higher in those with more than one simultaneous raised inflammatory 
marker (22.6%) and in those with a second repeat test which was persistently 
raised (23.8%). Disease incidence increased with rising inflammatory marker 
levels in a dose-response relationship. The overall sensitivity of inflammatory 
markers for relevant disease was low (<50%), meaning over half of patients with 
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relevant disease were missed by the tests. Inflammatory markers are therefore 
not suitable as a ‘rule-out’ test, which would require high sensitivity to avoid 
missed pathology.  
To explore comparative accuracy of the three inflammatory marker tests, area 
under receiver operating curves (AUC) were compared for any relevant disease 
for those with two tests performed simultaneously. Small differences were seen 
with AUC ranging from 0.659–0.682. CRP had the highest overall AUC, largely 
because of marginally superior performance in infection (AUC CRP 0.617 versus 
ESR 0.589, p<0.001).  
Overall, 39.4% of the tested cohort had more than one inflammatory marker 
tested simultaneously; mostly CRP and ESR (51,949), followed by CRP and PV 
(11,107). Testing multiple inflammatory markers simultaneously was associated 
with more abnormal and discordant results; when a single inflammatory marker 
was tested, 25.9% were found to be raised, when multiple inflammatory markers 
were tested, 36.3% had one or more raised inflammatory marker (14.4% 
concordant raised values and 22.0% discordant). Adding a second test led to a 
tiny increase in discriminatory ability for relevant disease measured by the AUC 
(CRP 0.682 versus CRP+ESR 0.688); whilst the p-value reached thresholds 
generally considered to be statistically significant (p<0.001), this was very 
unlikely to be clinically significant. The negative predictive value (NPV) of a 
single inflammatory marker (94.0%) was effectively the same as the NPV of 
combined inflammatory markers (94.1%), suggesting that testing multiple 
simultaneous inflammatory markers does not help to rule-out serious pathology. 
No combination of inflammatory marker tests can be used to rule-in or rule-out 
disease confidently, with a maximum sensitivity of 60.6% for the combined test 
defined as positive if either CRP or PV were raised.  
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Objective 3: Symptoms and cascade testing 
Objective 3 was to determine the symptomatology of patients with inflammatory 
marker testing in primary care and measure the consequences of testing in terms 
of numbers of consultations, blood tests and referrals.  
The most common symptoms associated with inflammatory marker testing were 
abdominal pain, tiredness symptoms, joint symptoms and infective symptoms. 
Non-specific symptoms such as tiredness, dizziness and low mood were 
relatively more common in the normal inflammatory marker compared to raised 
inflammatory marker groups, indicating that these non-specific symptoms are 
less likely to generate raised inflammatory markers. Raised inflammatory 
markers were associated with higher rates of GP consultations, blood tests, and 
referrals compared to normal inflammatory markers. This is likely to relate to the 
wide range of potential differential diagnoses in patients with raised 
inflammatory markers. Although the unit cost of inflammatory marker tests is 
relatively low, the total costs, including these follow-on consultations, 
investigations and referrals are likely to be substantial.   
 
Objective 4: Inflammatory markers and cancer 
Objective 4 was to determine the diagnostic accuracy of inflammatory markers 
for cancer diagnosis in primary care, including stratification by age, gender, 
inflammatory marker level and cancer type.  
Inflammatory marker tests were not a useful rule-out test for cancer, with a 
sensitivity of 46.1% for CRP, 43.6% for ESR and 49.7% for PV; however, a raised 
inflammatory marker could still be a useful clue to cancer diagnosis. Men aged 
over 50 and women over 60 with a raised inflammatory marker had a one-year 
cancer incidence of 6.44% and 4.22% respectively - above the 3% threshold 




Objective 5: Inflammatory markers and mortality 
Objective 5 was to explore the association between inflammatory markers and 
one-year mortality in primary care. 
Inflammatory markers are a strong predictor of all-cause mortality in primary 
care. The association between raised inflammatory markers and all-cause 
mortality is seen in all age groups except patients aged less than thirty years. 
Men with raised inflammatory markers have a higher one-year mortality than 
women (9.78% vs 5.29%). Of the three tests examined, CRP has the highest 
predictive accuracy for mortality. A logistic regression model containing age, 
gender and CRP test result had an AUC of 0.89. Whilst these findings are 
interesting from a research perspective, the clinical implications of these findings 
are less clear-cut, as discussed further in section 6.5.1. 
 
 Summary of qualitative results 
For the qualitative component of the thesis there were three main objectives, 
results are summarised below under each of these objectives.   
 
Objective 1: To explore to what extent doctors and patients 
have a shared understanding of the use of inflammatory 
marker blood tests 
The results of the qualitative study demonstrated a mismatch between patients’ 
and doctors’ expectations and understanding of inflammatory marker testing. 
Patients were frequently unaware of which tests had been done and why. This 
has important implications for the legal and ethical principles of informed 
consent. Patients expected that tests would provide diagnostic certainty and had 
little or no awareness of any limitations of tests. Doctors were aware of the 
limitations of testing, but rarely shared this with patients. Most patients were 
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told whether their tests were normal or abnormal, but few knew the actual 
results. Whilst doctors tended to be reassured by normal results, patients with 
ongoing symptoms often perceived that normal results were unhelpful. 
 
Objective 2: To provide in-depth exploration of patients’ 
experience of testing – from GP consultation to results 
None of the patients interviewed engaged in shared decision-making around 
testing, nor did they perceive blood tests to be a decision where options or 
choices were possible. Whilst decision-making was a single step, shared 
understanding required a process of information sharing before, during and after 
testing. ‘Normal’ test results required explanation and understanding to generate 
meaning and reassurance for patients; results without understanding could lead 
to further uncertainty and anxiety and for some people led to a feeling of being 
dismissed or written off.  
 
Objective 3: To identify barriers and facilitators to 
communication and shared understanding  
Multiple barriers to communication and shared understanding of testing were 
identified. Knowledge barriers included a perception that tests were too complex 
or technical for patients to understand, a lack of shared language, and a lack of 
resources for information sharing. Attitudinal barriers included the perception 
that tests were low priority for information sharing and a perception that a more 
paternalistic approach could be justified when testing, in order to protect patients 
from unnecessary anxiety. Finally, multiple barriers relating to systems of testing 
were identified, with systems often unclear and confusing for patients, and based 
on habits and routines rather than clear protocols. Doctors and patients each 
often assumed that the other party would make contact regarding test results, 
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with implications for patient safety. These barriers to shared understanding have 
important implications for clinical practice, and future research.  
Overall, the CPRD research unmasked and quantified limitations and 
uncertainties inherent in inflammatory marker testing, which are not unique to 
these tests, but can be a particular challenge due to the non-specific nature of 
inflammatory markers. The qualitative study showed that whilst doctors were 
aware of these limitations and uncertainty in testing, this was rarely, if ever, 
discussed with patients. This led to a lack of shared understanding and shared 
decision-making. Although doctors perceived that normal test results were 
useful for reassurance, this was not reflected in patients’ accounts of testing.  
 
 Findings in the context of existing 
literature 
 Quantitative study 
Epidemiology of inflammatory marker testing 
The inverse care law has been described for many decades,(209) yet there is 
limited evidence exploring the influence of socioeconomic status on rates of 
blood testing. Evidence of lower rates of testing, and higher rates of abnormality 
in deprived populations have been demonstrated for HbA1c testing in patients 
with diabetes,(210) prostate specific antigen testing and breast cancer 
screening.(211, 212) Previous studies exploring variation in inflammatory marker 
testing rates between GP practices used statistical analyses to control for 
differences in socioeconomic status.(13) This is because socioeconomic status is a 
strong predictor of multimorbidity and ill health, and therefore some observed 
differences may be clinically warranted, however this approach risks masking 
evidence of the inverse care law. The findings in this thesis that testing was less 
frequent and abnormal results were more common in those with higher 
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deprivation measured by postcode IMD, suggests that higher testing rates do not 
necessarily match the populations with higher rates of disease. It is unclear from 
these results to what extent this reflects under-testing in more deprived 
populations, or possible over-testing in more affluent populations, as previously 
suggested by Spence.(213) Future research into diagnostic testing and the inverse 
care law could help to elucidate this further.  
 
Inflammatory markers and overall disease outcomes 
Most studies of inflammatory markers, which I have reviewed previously,(1) 
consider single diseases, and most have been based in secondary care. The 
evidence in this thesis confirms the association between inflammatory markers 
and inflammatory conditions; however, the PPVs are lower in a primary care 
population with its lower prevalence of these conditions.  
This research has shown that inflammatory markers have an overall sensitivity of 
<50%, which means they are not a useful test of exclusion. This is discordant 
with the practices of GPs revealed by my pre-doctoral qualitative research, in 
which GPs described how inflammatory markers could be used as a ‘fishing’ test, 
and to help rule-out disease:(2)  
So if we had a test that, a single blood test, that doctors could do which 
would reassure the patient there was nothing bloody wrong at all, then that 
would be a very popular test. We’ll have the “nothing wrong at all” test for 
you, sir … You know, all the other tests are, well, you might have this 
specifically wrong with you or you might have this … But the CRP is probably 
the closest thing that we’ve got to a “nothing wrong at all” test. 
The finding that 50% of patients with infection, autoimmune disease or cancer 
had a negative inflammatory marker is therefore at odds with GPs’ perceptions 
of these tests as a ‘nothing wrong at all’ test. This is also discordant with current 
guidelines for chronic fatigue, irritable bowel disease, and suspected dementia, 
which recommend inflammatory marker testing in order to ‘exclude other 
diagnoses.’(114-116)  
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Not only is the sensitivity of inflammatory markers poor, but this research has 
also shown that patients with a normal inflammatory marker are in fact at an 
increased risk of relevant disease compared to untested controls, demonstrating 
the risk of false reassurance from a negative test. This is because the mere fact 
that an inflammatory marker test has been conducted, irrespective of the actual 
result, predicts disease.(22) This additional risk is only partly eliminated by a 
negative test result, leaving the negative test group still at a higher risk than 
those untested (6% relevant disease in test negatives versus 3.4% in the untested). 
This is in keeping with previous research in primary care patients with a normal 
platelet count (<400x109/1) who have a 4.1% one-year cancer risk.(189) Similarly, 
a normal primary care haemoglobin result has been showed to be associated with 
colorectal cancer (odds ratio 1.5; p=0.001) and a normal chest x-ray is associated 
with lung cancer (odds ratio 6.9; p=0.001).(214) Likewise, in secondary care 
settings, the timing and repetition of testing has been shown to be frequently 
more predictive of disease outcomes than the actual test result.(215)  
Interestingly, the one outcome measure which did not follow this pattern was 
mortality - patients with a normal inflammatory marker had an overall one-year 
mortality of 1.41% compared to a one-year mortality of 1.62% in the untested 
comparison cohort. This suggests that the negative likelihood ratio of a negative 
inflammatory marker test result is greater than the positive likelihood ratio of the 
clinicians’ decision to test, in other words the additional mortality risk associated 
with the clinicians’ decision to test is eliminated by a negative result.  
 
Comparative test accuracy 
In a previous systematic review, limited evidence directly comparing CRP and 
ESR was found for a small number of specialist disease outcomes in secondary 
care settings, preventing the authors from making recommendations about the 
preferred choice of test.(144) The authors concluded that a combined CRP|ESR 
test (defined as positive if either CRP or ESR were positive) had consistently 
higher sensitivity and lower specificity than individual CRP and ESR tests, in 
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keeping with the results in this thesis. These findings are entirely predictable, 
given that a less stringent criteria for a positive test (either CRP or ESR positive) 
is equivalent to a lowered threshold, which by definition leads to an increase in 
sensitivity and a drop in specificity. The large number of people with multiple 
simultaneous inflammatory marker tests in the research presented in this thesis 
allowed direct comparisons of the area under ROC curves for inflammatory 
marker tests singly and in combination. These findings confirm that CRP has 
slightly higher diagnostic accuracy for infections; however, no significant 
differences were found for autoimmune conditions and cancers. Furthermore, 
testing multiple simultaneous inflammatory markers did not lead to clinically 
significant improvements in diagnostic accuracy as measured by the AUC.  
 
Symptoms and cascade testing 
The frequency of non-specific symptoms in this study is in keeping with my pre-
doctoral qualitative research findings in which GPs described using 
inflammatory markers in patients with undifferentiated symptoms to help 
manage diagnostic uncertainty.(2)  
The research presented in this thesis identifies a significant difference in the rate 
of GP consultations, blood tests, and referrals in those with abnormal tests but no 
relevant disease (‘false positives’), compared to those with normal tests and no 
relevant disease (‘true negatives’). This has previously been described by Deyo et 
al as the ‘cascade effect of medical technology’.(25, 216) Sah et al described this as 
‘investigation momentum’ - whereby an inconclusive or ambiguous test result 
leads to increased uncertainty and generates additional diagnostic testing which 
would not have been deemed necessary if the index test had not been 
performed.(217) Whilst this cascade effect has been measured following prostate 
specific antigen testing,(217) and in one small primary care cohort of patients 
with low pre-test probability of disease in primary care,(27) this is the first time it 
has been demonstrated following inflammatory marker testing. The findings are 
in keeping with my previous qualitative research in which GPs described 
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cascades of further tests following a raised inflammatory marker as a particular 
problem due to the non-specific nature of these tests:  
Then you think suddenly, well should I be looking further and further and 
further, but that could mean more and more random investigations until you 
get the point where you goes, oh, I’ll just do a whole body CT scan to see if 
anything pops up I suppose.’ (2) 
 
Inflammatory markers and cancer 
Previous cohort studies in the general population have explored the association 
between inflammatory markers and risk of future cancer,(64, 111, 218) including 
colorectal,(129, 219) lung,(128) ovarian(220) and breast cancer.(130, 221) There are 
also a small number of primary care case-control studies of specific cancers 
including bladder and kidney cancers, Hodgkin and non-Hodgkin lymphomas, 
and myeloma, although for single cancers these showed very low positive 
predictive values (PPVs) for a raised inflammatory marker.(61-63, 222)  
Several older studies have examined cancer risk in patients with significantly 
raised inflammatory markers in secondary care settings. For example in a cohort 
of 1004 hospital outpatients with an ESR > 100 mm/h, 17% had malignancy,(149) 
while in another hospital cohort 16% of those with ESR > 100 mm/h had 
malignancy.(150) In the CPRD cohort presented in this thesis, a comparable 
13.6% of those with ESR > 100 mm/h developed cancer in one year, the slightly 
lower figure possibly representing the primary care setting.  
There have been no previous studies to my knowledge measuring the overall 
clinical utility of inflammatory markers for cancer diagnosis in primary care. 
CRP and ESR have been evaluated as a tool for predicting cancer in a highly 
selected cohort of patients with non-specific symptoms referred to Diagnostic 
Outpatient Clinics for rapid access to cancer diagnostics in Denmark.(223) In this 
setting the cancer prevalence was much higher at 19.8%; those with raised CRP 
had an odds ratio of 1.41 for cancer, after adjustment for age and sex, comparable 
to our adjusted DOR for raised CRP of 1.79.  
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The findings in this thesis demonstrate that this association exists, not only in the 
highly selected group of patients referred with suspected cancer, but also in 
unselected primary care patients, where the initial triaging and referral decisions 
must be made. Although positive predictive values were clinically useful, the 
low sensitivity means that inflammatory markers should not be used as a rule-
out test. No evidence was found that CRP, ESR or PV were superior to one 
another in relation to overall cancer detection, however this may not be true for 
all types of cancer; for example recent studies have shown that ESR and PV are 
superior to CRP for myeloma diagnosis.(59)  
 
Inflammatory markers and mortality 
The association between CRP and mortality is in keeping with population-based 
studies examining all-cause mortality(134, 224) and cardiovascular 
mortality,(125) as well as hospital-based studies of patients with specific diseases 
including COPD,(225) diabetes,(226) chronic kidney disease,(227) 
pneumonia,(228) cancer,(112, 229) and more recently covid-19.(230) The research 
reported in this thesis is the first (to my knowledge) to demonstrate that an 
association between inflammatory markers and mortality is also seen in a 
primary care setting and over the shorter term. The finding that men with raised 
inflammatory markers are at higher mortality risk than women may reflect 
gender differences in healthcare-seeking behaviour in primary care; men have 
lower rates of consultation, so might be ‘sicker’ on average when selected for 
blood tests. 
Multiple risk tools have been developed to identify patients with frailty and 
some of these have been validated by measuring how well they predict 
mortality.(231) The aims of these tools include helping predict those at risk of 
unplanned hospital admissions and to allow targeted interventions to people at 
an increased mortality risk. The National Institute for Health and Care Excellence 
multimorbidity guidelines systematically reviewed 41 of these risk tools for 
predicting mortality; the majority were of low or very low quality and a need for 
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further research in this area was identified.(231) Current risk tools include 
variables such as disease status, socio-demographic factors and laboratory test 
results (e.g., anaemia, raised platelets). However, none in current use include an 
inflammatory marker test. The most commonly used of these risk tools are the 
electronic Frailty Index(137) and Qmortality.(136) The former has an AUC for 
mortality of 0.76; the latter an AUC of 0.85 for women and 0.84 for men. More 
recent research by Deelen et al has used combinations of biomarkers to predict 
mortality across all age groups; 226 potential biomarkers were selected, but CRP, 
ESR and PV were not considered.(232) Deelen et al generated a model using 14 
biomarkers with an AUC of 0.837: however, of the biomarkers considered, only 
albumin is available in primary care, limiting the clinical usefulness of their 
findings. CRP by comparison is a low cost and widely available test. The 
evidence in this thesis shows that CRP alone has an AUC of 0.78, increasing to 
0.89 for a model including CRP, age and gender. This suggests that inflammatory 
markers could be a simple indicator with a comparable or better accuracy than 
currently used mortality prediction tools. Although these findings are interesting 
from a research perspective, the clinical utility of these findings is less 
straightforward, and is discussed further in 6.5.1. 
 
 Qualitative study 
A recent BMJ review article explored communication of laboratory tests to 
patients; however, patients’ perspectives were not addressed and 
recommendations were based on clinicians’ experiences rather than empirical 
evidence.(233) The qualitative research presented in this thesis helps build this 
empirical evidence and identifies significant gaps between doctors’ and patients’ 
understanding of tests.  
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Expectations of tests 
Patients in this study had high expectations of tests. This is in keeping with 
previous qualitative interviews with patients in general practice waiting rooms 
in the Netherlands, where patients expected tests to provide diagnostic certainty 
or proof of good health.(166) Interviews with patients who reported omissions of 
care also corroborate the high value patients apply to tests.(234) In a systematic 
review of survey and interview studies that have measured patients’ 
expectations of the benefits and harms of tests and screening, the majority of 
participants were found to overestimate the benefits and underestimate 
harms.(167)  
Doctors’ expectations of tests were more limited, and doctors’ decision-making 
encompassed both medical and non-medical reasons for testing, in keeping with 
my pre-doctoral qualitative interviews with doctors,(164) and other qualitative 
research exploring doctors’ perspectives of tests.(162, 235-237) This is in 
accordance with a group of social cognitive theories, known as situativity 
theories, which conceptualise diagnostic decision making as a social and situated 
processes, shaped not only by medical knowledge, but by complex, dynamic 
interactions between doctor, patient and environmental factors.(238) Although 
previous studies have explored doctors’ and patients’ expectations of blood tests 
separately, this study offered the benefits of comparing and contrasting these 
expectations within individual healthcare encounters, illustrating how 
mismatched expectations influence the outcomes of testing.  
 
Decision-making 
Shared decision-making is a process in which patients and clinicians work 
together to make decisions based on evidence and patients’ preferences, and is 
widely recognised as ‘best practice’.(160, 239) Awareness of the importance of 
shared decision-making is widespread, yet most research focuses on treatment 
decisions. This research demonstrated a lack of shared decision-making around 
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diagnostic testing. Although these findings are based on patient and clinician 
recall, they are in keeping with research which I co-authored, using video 
recorded UK general practice consultations, where the majority of blood testing 
decisions were instigated by doctors, with a lack of information sharing and 
shared decision-making.(181) Similarly Ford et al analysed 212 video-recorded 
primary care consultations and rated the extent to which patients were involved 
in decisions as well as measuring patient preferences for decision-making; 91% of 
decisions about investigations were doctor led, 9% patient led and none of the 
consultations observed demonstrated shared decision-making around 
investigations.(182)    
Previous ethnographic and focus group research with patients and the general 
public in a UK hospital setting demonstrated that patients have limited 
understanding of blood testing, which is seen as a routine, everyday practice 
which patients routinely accept without questioning.(240) This is in keeping with 
the perception by patients in this study that blood test decisions were not an area 
where options or choices were available to them.  
 
Information sharing 
This research showed a lack of information sharing, with patients frequently 
unaware of which tests had been requested and why. This is in keeping with a 
previous survey by Kljakovic et al using patient questionnaires, in which only 
19% of patients could name the tests which they had had done.(241) In contrast, 
Kljakovic et al found that 90% of patients reported that they understood the 
reasons for blood tests.(241) The higher self-reported levels of understanding in 
this survey could reflect the different study design, and the different setting, of 
Australian primary care.  
The findings from my research, that most patients were given an assessment of 
whether their test result was normal or abnormal, but few knew the actual result, 
is in keeping with conversation analysis research from Pomeranz et al, who used 
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a sample of 33 video-recorded consultations in US ambulatory care, to examine 
how test results were conveyed to patients; they suggest that offering an 
assessment only was an example of paternalism, whereas providing test results 
empowers patients as an independent expert.(242)  
 
Consequences of testing 
Tests allow doctors and patients to construct meaning and explanation for 
patients’ symptoms and have value beyond their medical purposes. Kravitz et al 
found that patients perceived tests to have symbolic value, offering a way of 
validating the patients concerns, demonstrating an interest in the patient and 
building an empathic connection.(234) This is in line with social constructionist 
theories, the concept that illness is not only determined by biology and 
physiology but is socially constructed.(243) Test results have biological meaning, 
but this meaning is interpreted by patient and doctor in the context of their ideas, 
concerns and expectations. The concept that tests do more than just passively 
reveal facts, but that they form part of the social interaction and can generate 
meaning has been described in the social science literature by Mol, who explored 
the non-medical consequences of blood sugar measurement on patients.(244) Mol 
says: ‘It fits all too beautifully (and sadly) into a pattern that has often been described in 
critiques of diagnostic devices: by being put in the position of correcting subjective 
sensations with objective findings they end up eroding the subjective sensations, or at 
least, by making them of little relevance in the daily management of (chronic) disease.’ 
This is in keeping with the finding in this thesis that patients with normal test 
results may feel that their own subjective experiences were being invalidated. 
This also resonates with qualitative interviews exploring patients’ experiences of 
diagnostic tests for chronic back pain; patients had high hopes invested in testing 
and described how negative or normal tests results led to patients feeling 
delegitimized.(245)      
Patients in this study with normal test results who had ongoing symptoms did 
not report feeling reassured, which contrasted with doctors’ accounts. This fits 
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with the findings of several systematic reviews of quantitative studies measuring 
patient outcomes following testing, which demonstrate a lack of reassurance 
from normal tests.(169, 170, 246) Patients wanted more information and 
explanation of the meaning of normal test results. Improving the communication 
of normal test results has been shown to lead to greater patient reassurance and 
reduced reporting of symptoms in a randomised trial in chest pain clinics.(247)  
 
Barriers to shared decision-making 
This research identified multiple barriers to shared understanding and shared 
decision-making, which were categorised into barriers around knowledge, 
attitudes and systems of testing. Blood tests were perceived by doctors as 
relatively trivial interventions which were therefore low priority for information 
sharing. This is in keeping with a recent realist review exploring test ordering in 
primary care from clinicians’ perspectives, which identified a commonly held 
perception that laboratory tests are relatively inconsequential interventions.(165) 
In this study it was proposed that doctors, facing high workloads, prioritise 
efficiency over thoroughness in test-ordering decisions. This ‘efficiency-
thoroughness trade off’ principle described by Hollnagel may underlie the 
limited information sharing around blood testing.(248) Clinicians interviewed for 
this thesis described prioritising other aspects of information sharing which were 
perceived as more important, in the context of time limited consultations. 
Although workload can be a barrier to shared decision-making, there is evidence 
that interventions to increase shared decision-making may reduce healthcare 
utilisation and overall costs;(249) similarly, patient-centred communication has 
been shown to be associated with lower rates of diagnostic testing.(250)  
Another barrier to information sharing identified in this research was the 
imbalance in knowledge and power between doctors and patients; this has been 
widely discussed in the shared decision-making literature in relation to 
treatment decisions, but in a recent systematic review of barriers and facilitators 
to shared decision-making, none of the 45 articles included explored decisions 
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pertaining to diagnostic testing.(251, 252) In a qualitative interview study 
O’Flynn et al found that GPs perceived test ordering to be a biomedical decision, 
that formed part of their professional identify, and was not appropriate or 
available for shared decision-making.(253) This is in keeping with the 
perceptions of some GPs in my study that testing was ‘still one of those areas’ 
where a more paternalistic approach was justified. O’Flynn et al proposed that a 
shift in perception of medical identity, to enable sharing of power and 
responsibility, was required to enable more shared decision-making.  
Another reason for withholding information about tests which was mentioned 
by GPs in this study was the wish to protect patients from unnecessary anxiety 
and uncertainty. Although GPs were concerned that sharing too much 
information could cause anxiety, patients in this study perceived that improved 
communication about blood tests could reduce anxiety.  
The challenges of communicating uncertainty have been discussed in the wider 
medical literature.(254) Some have argued that open communication of 
uncertainty is necessary for true shared decision-making,(255) with some 
evidence that sharing uncertainty does not reduce trust.(256) Conversely, others 
have shown that presenting uncertainty may decrease patient understanding in 
relation to treatment decisions,(257) and explicit expression of uncertainty can be 
associated with lower perceived technical competence.(258) There is a lack of 
evidence around communication of uncertainty in relation to tests. One recent 
trial measured information sharing and public understanding of Covid-19 test 
results: when participants were given information about tests which 
incorporated uncertainty, fewer participants interpreted results as definitive, 
however this information was felt to be more difficult to understand and slightly 
less ‘trustworthy’.(259)  
Systems of test result communication were found to be another barrier to shared 
understanding of blood tests, with uncertainty, variation and a lack protocols for 
test result communication. This is in keeping with previous surveys of UK 
general practices which demonstrated that most rely on patients contacting the 
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practice for their test results, with a lack of fail-safe mechanisms.(158) Qualitative 
interviews with UK clinical and office staff in primary care demonstrated the 
complexity, lack of standard protocols and problems with test result 
communication in primary care,(156) in keeping with this research. Similarly, 
interviews with US physicians in primary and secondary care demonstrated that 
many clinicians lacked methods to ensure test results were received and 
communicated to patients.(260) Studies quantifying failures in test result follow 
up have been systematically reviewed, with between 6.8% and 62% of laboratory 
tests reportedly not followed-up in US settings, and no relevant UK research 
identified.(155) These failures in test result communication can lead to serious 
lapses in care.(261)   
Patients’ perspectives have received relatively little attention; focus group 
discussions with patients about their preferred methods of test communication 
highlighted patient dissatisfaction with non-clinical staff relaying results,(157, 
262) in keeping with my findings. By comparing doctors’ and patients’ 
perspectives on a single healthcare encounter, the research presented in this 
thesis was able to highlight problems which occur when both doctors and 
patients assume that the other party is responsible for obtaining test results.  
 
Shared decision-making or shared understanding? 
Despite the barriers to shared decision-making around testing identified in this 
study, there are examples in the literature of shared decision-making for tests, 
mostly in relation to specific tests such as prostate specific antigen (PSA), genetic 
testing(178, 263) and screening tests.(179, 264) Whilst genetic testing and 
screening are arguably less relevant to primary care, PSA is commonly tested in 
primary care. Multiple qualitative studies of PSA testing have explored patients’ 
perspectives.(265) Information resources(266) and decision aids(180) for PSA 
testing have been developed and systematically reviewed,(177) demonstrating 
that it is possible to share information on testing in primary care. Although PSA 
is regarded as something of a ‘special case’, as testing can lead to patient harms 
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including invasive further tests and over-diagnosis, arguably similar harms of 
cascade testing, anxiety and over-diagnosis could occur following inflammatory 
marker blood tests.  
Shared decision-making is recommended by NICE for ‘people who use services and 
their families and carers to choose tests, treatments, management or support packages’, 
with NICE recommended decision aids for PSA testing, BRCA genetic testing, 
Down’s testing, prenatal screening, HPV testing and colorectal cancer 
screening.(176) However, there is a lack of discussion in the literature of how this 
relates to routine blood tests in primary care. Patients in this study did not 
express a desire to share decisions about every test, but they did express the need 
to understand the meaning of their test results in the context of their symptoms. 
Shared decision-making conceptualises the practice of medicine as a series of 
discrete choices; this does not seem to fit with the experiences and perspectives 
of patients and clinicians interviewed, who describe tests as only one part of a 
complex medical and social interaction. A broader model of shared 
understanding seems to be more relevant to the complexity of primary care 
diagnosis which rarely involves simple binary choices, but instead involves 
intuition, ambiguity and uncertainty.(267) Shared understanding of medicine, in 
contrast to shared decision-making, is a continuous process, described by 
Richard Lehman as follows: (239) 
Clinical care does not consist of a series of easily defined take-it-or-leave it 
choices but is a process of understanding developed and deepened over time. 
Sharing understanding with patients is a form of dialogue and interaction 
which cumulatively develops and which effects changes in both parties: it lies 
at the heart of primary care, and it is essential for kind and effective clinical 
practice in all specialties.  
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 Strengths and limitations of research 
 Quantitative study 
The main strengths of my CPRD research are the size of the study and the setting 
in primary care, where initial suspicion of disease usually arises. Most previous 
research focuses on single disease outcomes, and most is based in secondary 
care; whereas this research examined multiple disease outcomes. This allows 
exploration of the utility of tests to distinguish between ‘healthy’ versus 
‘unhealthy’. This is important as it matches the way the GPs describe using 
inflammatory markers in practice.(2) The use of a test-consequences graphic 
based on a nominal population of 1000 tested patients allowed results to be 
presented in natural frequencies, (184) which are easier for patients and clinicians 
to interpret,(268) and to aid implementation into practice. Traditional diagnostic 
accuracy studies only consider the performance of an index test in comparison to 
a reference standard; however, the use of routine data allowed process outcomes 
to be measured including rates of consultation, referral and follow-on blood 
tests, to explore the diagnostic activity following inflammatory marker testing. 
This is important because the unit cost of these blood tests is low, yet the 
downstream consequences may be costly.  
The large sample size and large numbers of participants with multiple 
simultaneous blood tests allowed direct comparisons between the accuracy of 
different inflammatory marker tests. This reduces the potential for selection bias, 
where tests might perform better for certain disease outcomes due to GPs pre-
selecting those at higher risk to have a specific test, for example, preferentially 
using CRP when an infection is suspected. 
 
Limitations: Reasons for testing 
The main limitation is lack of information about the reason for testing; it is not 
possible from CRPD to determine which tests were done for specific diagnostic 
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purposes, and which were done as a general rule-out for any relevant underlying 
disease. To try to gain an indication of the main reasons for testing, the 
symptoms in the 28 days prior to testing were measured; the frequency of non-
specific symptoms in the cohort (tiredness, malaise, dizziness, low mood) 
suggests that non-specific testing is likely to be common. A limitation of this 
approach is that symptoms are less likely to be well coded by GPs in CPRD 
compared to coding of diagnoses. The benefit of this approach is that it reflects 
real-life clinical practice: although GPs may not have a specific diagnosis in mind 
when they request inflammatory markers, they need to consider a wide range of 
possible diagnoses if the test is positive. 
 
Limitations: Reference standard 
The reference standard for diagnostic accuracy research is usually defined as the 
best available method for classifying whether people have the target condition or 
not. In this study one-year incidence of cancer and autoimmune disease and one-
month incidence of infection were used as a proxy measure for presence of 
disease at the time of testing; thus, the reference standard is dependent on the 
quality of GP diagnosis and coding of disease. Blood tests are electronically 
transmitted to the GP records, reducing the risk of missing or erroneous data in 
the index tests. Rigorous methods were used to develop disease code-lists,(192) 
but it is possible that there were some omissions, and relevant diseases linked to 
a raised inflammatory marker apart from infections, autoimmune conditions or 
cancers could have been missed. Some diseases may have been diagnosed but 
not coded: though this is likely to be rare for serious conditions such as cancers 
and autoimmune diseases, it could be more common for minor infections. It is 
also possible that some diseases remained undiagnosed, or were not diagnosed 
within one year of the test. This could mean that the numbers of ‘false positives’ 
reported in this study could be an over-estimate, as some people with a positive 
test result could have had relevant disease which was undiagnosed, or uncoded.  
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The decision to use the time period of one-year for incidence of cancer and 
autoimmune disease as reference standard was based on evidence of time from 
symptom onset to cancer diagnosis.(214) To check for a late effect, two-year 
incidences of cancer and autoimmune disease were also explored. A shorter one-
month time period for incident infections compared to cancer and autoimmune 
conditions was chosen on the basis that patients could have multiple infections 
within a one-year time period; infections beyond one-month were deemed 
unlikely to be related to the initial raised inflammatory marker.  
There is some risk that the diagnoses made by the clinician were on the basis of 
the inflammatory marker test result. This is known as incorporation bias, where 
the index test is part of the reference standard, and generally leads to an 
overestimation of the sensitivity of a test.(269) For significant diagnoses such as 
cancer and autoimmune disease this is unlikely to occur, as confirmatory 
diagnostic testing would usually be expected, but for infections this is more 
likely to be an issue.  
Cardiovascular disease was not included within the reference standard within 
the definition of ‘relevant disease’. Whilst CRP has prognostic value for 
prediction of future cardiovascular disease,(125) it does not form part of any 
cardiovascular diagnostic algorithm. Inflammatory marker testing would not 
therefore be used as a diagnostic test for cardiovascular disease in primary care, 
and therefore does not fit within the remit of this thesis to explore the diagnostic 
utility of inflammatory markers.    
Linked data including Cancer Registry linkage and ONS death registration data 
were used to improve outcome ascertainment for the outcomes of cancer and 
mortality; however, the cohort was not limited to only those eligible for data 
linkage, lest this introduce bias, as some regions are not linked to the cancer 
registry. Instead, sensitivity analyses were done to explore the effect of this; 
minimal differences were seen when analyses were restricted to those eligible for 
linkage. On reflection, a reasonable alternative approach might have been to limit 
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the study to patients in England only, to reduce the numbers within the cohort 
who were ineligible for linkage.  
 
Limitations: Participant selection 
Another limitation of the observational cohort design is that patients having 
blood tests in primary care are a selected group and will be generally ‘sicker’ 
than those attending primary care who are not tested, or the general population. 
This is clearly demonstrated by the fact that the overall disease incidence was 
lower in the untested comparison group than the tested group. The disease 
incidence in the test positive group therefore reflects two things: the risk 
associated with the test result, and risk associated with the clinicians’ decision to 
test. The benefit of having a comparison group was that it allowed the predictive 
value of the clinicians’ decision to test to be quantified. However, this means that 
caution is needed when interpreting the findings. It is tempting to suggest that 
these tests could be useful for cancer diagnosis in primary care; however, the 
results do not necessarily support the use of inflammatory markers to detect 
cancer in patients who would not otherwise have been tested. This also 
potentially limits the generalisability of the results, as the findings may not be 
applicable to different healthcare systems with a higher or lower threshold for 
inflammatory marker testing. To address this, predictive modelling research is 
needed, to explore how inflammatory marker test results could be combined 
with symptoms, signs and other test results to predict future disease outcomes, 
particularly cancer.  
 
Limitations: diagnostic activity after inflammatory marker 
testing 
The increased rates of consultations in those with ‘false positive’ inflammatory 
marker test results compared to ‘true negatives’ is interesting, but this observed 
association does not prove causality. One possibility is that some of the ‘false 
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positives’ did have relevant disease, which was not diagnosed or coded, or was 
omitted from my code-list. This could generate an appropriate increase in 
healthcare usage. Another possibility is that those who are selected for 
inflammatory marker testing represent high users of healthcare, which is then 
perpetuated by the abnormal results. On reflection, stronger evidence of 
causality could therefore have been obtained if I had adjusted for baseline 
consultation rates.   
 
Limitations: Clinical significance of findings 
Initial sample size calculations suggested 80,000 tested and 20,000 untested 
patients would be sufficient; the CPRD suggested a larger sample size (at no 
extra cost) could be used to allow extra power for rarer disease outcomes. A 
consequence of this large sample size is the potential for the study to be 
overpowered; tiny differences in AUC were detected, which had small p-values, 
but which are very unlikely to be clinically significant. For example, the overall 
AUC for relevant disease for CRP and ESR in combination was 0.688, compared 
to 0.682 for CRP alone. Although the p-value was <0.001, a difference of 0.006 in 
AUC is very unlikely to be of clinical benefit. This demonstrates the importance 
of considering results in a clinical context, rather than focussing on measures of 
statistical significance.  
 
 Strengths and Limitations: Qualitative study 
The main benefit of this research was the ability to compare doctors’ and 
patients’ perspectives on the same healthcare encounter. This allowed direct 
comparisons which highlighted how mismatches in communication and 
understanding could play out within a single healthcare encounter and how this 
could influence patients’ experiences.  
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Strengths and limitations: representativeness 
Recruitment was purposive and sampling included a range of patients in relation 
to age, gender, socioeconomic status and ethnicity; this was important in order to 
capture a range of views and perspectives. The patient sample had a higher 
proportion of women (64%); however this is in keeping with the CPRD data 
which showed that 62% of tested patients were female. All interviews were 
conducted in Bristol, North Somerset and South Gloucestershire region for 
practical reasons, although efforts were made to ensure a mix of urban, suburban 
and rural practices. However, blood testing may have regional variation, and 
many of those interviewed will have used the same laboratory. This means the 
findings may not reflect the processes around testing used in other health care 
systems. However, they do highlight the potential for misunderstanding when 
information around testing and the communication of results is not shared.  
 
Strengths and limitations: recall bias 
The majority of the initial interviews with patients were done at the time of their 
blood test appointment; this had the benefit of allowing me to capture patients’ 
immediate thoughts and feelings at a time when their tests were foremost in their 
minds. The second interview allowed me to compare how these perspectives 
changed after they had received their test results.  
The main limitation is that the interviews were based on patients’ and GPs’ 
recollection of the healthcare encounter, rather than direct observation of the 
doctor-patient interaction and communication. This could lead to recall bias; for 
example, it is possible that GPs may reinterpret their reasons for testing in order 
to rationalise their decision-making, or to overestimate the information that they 
shared with patients. However, my experience was that GPs did share openly the 
limitations in how they communicated blood tests with patients during 
interviews. The benefit of interviewing patients rather than directly observing 
consultations, is that it allowed me to find out what patients understand and 
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retain after a consultation. During the course of my PhD, I was able to supervise 
an Academic Foundation year 2 doctor, Jess Martin, who analysed the content of 
video recorded GP consultations from the One-in-a-Million database, to explore 
communication around blood testing. The findings from these video recorded 
encounters are in keeping with the findings from this thesis, with limited 
information and a lack of shared decision-making observed.(181) 
Whilst patient interviews were conducted at the time of testing, the time interval 
between the consultation and GP interviews was longer, due to the practical 
challenges of trying to arrange interviews with GPs with busy clinical workloads. 
GPs were asked to ensure they had access to the medical records as an aide 
memoire during GP interviews; nonetheless it is possible that they had incomplete 
recollection of the specific consultation. Their recollection might therefore 
partially be based on how they feel they would usually communicate in that 
clinical scenario.  
 
Strengths and limitations: reflexivity 
Overall, my experiences of being both a GP and a researcher was that this helped 
facilitate my access to GP practices, and may also have facilitated my 
communication with GPs who seemed comfortable discussing cases with a 
fellow clinician with shared understanding. The GPs whom I interviewed were 
aware that I was a fellow clinician, and some were aware of my published 
research into inflammatory marker testing. In the GP interviews I emphasised 
that the interviews were non-judgemental, and were focussed on exploring 
communication around testing, not on scrutinising clinical decision-making. 
Nonetheless, clinicians who were less confident about inflammatory marker 
testing may have declined to take part. Other issues arising from my dual role as 
a clinician and a researcher are discussed further in section 4.6. 
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 Strengths and limitations of a mixed methods 
approach to inflammatory marker testing 
The mixed methods approach used in this thesis allowed me to gain very 
different but complementary perspectives of inflammatory marker testing in 
primary care. The findings of my pre-doctoral qualitative research(2) informed 
the questions for my CPRD study; in particular the decision to focus on multiple 
disease outcomes and to explore the accuracy of inflammatory markers as a ‘rule-
out’ test.  Similarly, the findings of my CPRD research informed the questions for 
my qualitative study; in particular the fact that these tests lead to false positives 
and false negatives with potential negative consequences meant it was important 
to explore how information on benefits and limitations of testing was shared 
with patients (or not) and how patients engage in decision-making.  
A limitation to the approach used is that I could not use formal methods to 
synthesise the results of the qualitative and quantitative research. After 
undertaking the qualitative interviews, I decided to conduct focus groups with 
patients and GPs, aiming to bring together the qualitative and quantitative 
findings of my thesis and explore ways of improving communication and shared 
understanding of inflammatory markers. I was particularly interested to use 
these focus groups to explore how patients would respond to information about 
the uncertainty of tests, and whether they would feel that this information 
should be shared with them. Unfortunately, due to the exceptional circumstances 
of the Covid-19 pandemic, it was very challenging to recruit to these focus 
groups; despite hard work I was only able to recruit three patients from the 
original qualitative study back for further focus group discussions. Although this 
could have provided helpful further insights, it was not part of my original 
doctoral thesis plans. On reflection, a larger piece of work would be needed to 
generate meaningful insights to improve the shared understanding of tests; this 
is one of the areas I hope to explore as a post-doctoral researcher.  
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 Implications for research and clinical 
practice 
 Quantitative study 
My pre-doctoral qualitative work found that doctors perceive inflammatory 
markers to be a useful rule-out test for patients with non-specific symptoms.(2) 
The finding from this thesis that these tests have a low sensitivity contradicts 
this, demonstrating clearly that they are not suitable as a rule-out test. Instead 
they are classic Bayesian tests, with a positive test somewhat increasing the 
chance of disease, though not definitively, and a negative test reducing the 
chance of disease, but not to zero.  
In patients with a raised inflammatory marker, the range of differential 
diagnoses is wide, which is one explanation for the additional consultations, 
tests, and referrals. With very high inflammatory marker test results, the risk of 
disease is higher. Interpretation should take into account the reason for testing 
and the pre-test likelihood of disease; a negative test in the context of low-risk 
symptoms reduces disease likelihood further, but with the potential for harm 
from false-positive tests. False-negative tests may also lead to false reassurance, 
as patients with normal inflammatory markers are at higher disease risk than 
untested controls. GPs should not be excessively reassured by a repeat negative 
inflammatory marker; those with normal repeat tests had higher overall 
incidence of disease (18.6%) compared to those who did not have repeat tests 
performed (12.5%). Presumably, this reflects the fact that the GP’s decision to 
repeat the test meant they were more suspicious that the patient had underlying 
disease. 
Testing multiple inflammatory markers does not improve the ability to rule-out 
disease, but does increase the risk that at least one of the tests will give a false-
positive, compared with a strategy of using a single test.  
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The overall diagnostic utility of all three inflammatory markers is similar, 
however CRP marginally outperforms ESR and PV for infections. CRP is also 
cheaper than either ESR or PV (£1.19 for CRP, £3.18 for ESR, £3.18 for PV, source 
Bristol North Somerset and South Gloucester CCG laboratory costings). It seems 
sensible therefore to use CRP as the first-line test in most circumstances. 
Exceptions might include the use of ESR or PV rather than CRP for suspected 
myeloma, though if there is strong clinical suspicion then direct testing using 
electrophoresis and Bence Jones protein would be reasonable. 
There is no combination of inflammatory markers that can be used as a reliable 
rule-in or rule-out test strategy. Results and decisions to test must be made in the 
context of other clinical findings. A negative test in the clinical context of a low-
likelihood situation may be sufficient to provide reassurance. 
Although inflammatory markers have a moderate predictive value for 
inflammatory bowel disease (IBD), the AUC for CRP of 0.698 (in a model that 
includes age and sex) is much lower than for calprotectin, with a published AUC 
of 0.95,(270) meaning that calprotectin is to be preferred if IBD is under 
consideration. Similarly, though inflammatory markers have a modest AUC for 
rheumatoid arthritis, low sensitivities found in the present study are in keeping 
with previous studies, which have found that 35% to 45% of patients with 
rheumatoid arthritis have normal inflammatory marker levels at diagnosis.(56) 
National Institute for Health and Care Excellence guidelines therefore 
recommend referral of patients with clinical evidence of rheumatoid arthritis, 
even with normal inflammatory marker test results.(55) It is therefore hard to see 
any benefits from inflammatory marker testing where rheumatoid arthritis is 
suspected diagnostically, though it may have a useful role in disease monitoring. 
Cancer is worthy of special consideration, as current UK NICE guidelines 
recommend urgent cancer referral for any patient with a risk of cancer of 3% or 
higher,(65) with studies of patient preferences suggesting an even lower 
threshold of 1%.(271) Inflammatory markers are not recognised within current 
guidelines for cancer diagnosis,(65) with the exception of myeloma, where first 
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line tests include ESR or PV. With overall PPVs of 3.53%, inflammatory markers 
may therefore have some role in early diagnosis of cancer.  
Interpretation of inflammatory marker test results must take into account the 
reasons for testing: if there is a clinically obvious explanation for raised 
inflammatory markers from history and examination, then further investigations 
for cancer would not usually be appropriate. Women under 60 and men under 50 
with raised inflammatory markers have a risk of cancer below the 3% threshold, 
and in the absence of other risk factors, further investigations for cancers would 
not usually be warranted. For older patients with unexplained raised 
inflammatory markers, these findings support a strategy of repeat testing, with 
lower cancer incidence in those for whom the test returns to normal, and higher 
cancer incidence in those with rising inflammatory markers. Further 
investigations for cancer should be considered in patients with persistent 
unexplained raised inflammatory markers, particularly in older men, who are at 
highest risk. With significantly raised inflammatory markers, especially if 
accompanied by ‘low-risk but not no-risk’ cancer symptoms or signs, urgent 
investigation or referral may be appropriate, without repeat testing. The range of 
possible cancers is wide, so the choice of further investigations will vary 
depending on the clinical history and examination findings; recently introduced 
multidisciplinary diagnostic centres for patients with non-specific but concerning 
symptoms may be appropriate if a clear source cannot be found. Excluding 
myeloma is not sufficient, as this only contributes a small proportion of the 
cancers diagnosed in the raised inflammatory marker cohort. 
Although the PPVs from a raised inflammatory marker are clinically significant, 
inflammatory markers have poor sensitivity, so cannot be used to rule-out 
cancer. The clinical usefulness of these finding are therefore in guiding the 
clinical management of a patient with a raised inflammatory marker. 
Inflammatory markers should be used judiciously for possible cancer, taking into 
account the risks of false positives, which may generate anxiety, and false 
negatives, which may generate inappropriate reassurance. Further research is 
 231 
needed to explore how inflammatory marker blood test results, combined with 
other common blood tests, such as platelet, haemoglobin and calcium levels, 
alongside symptoms and signs, could generate prediction models with increased 
accuracy, to improve the early diagnosis of cancer in primary care. 
Although a clear association between inflammatory markers and one-year 
mortality was identified, the clinical utility of this finding is less clear-cut. It 
seems unlikely that clinicians would test inflammatory markers for the purpose 
of mortality prediction as this would be likely to cause worry and anxiety to 
patients, particularly as there is a lack of evidence-based interventions available 
to target those identified at high risk.(272) However, general practitioners are 
already required to identify patients who are frail,(273) and inflammatory 
marker tests are commonly performed for many other reasons.  Inflammatory 
marker test results, when available, may therefore add useful information to 
improve prediction of mortality and assessment of frailty in primary care. 
General practitioners should interpret raised inflammatory markers within the 
wider clinical context; where the cause of inflammation is identifiable and 
treatable, mortality risks should not cause undue alarm. However, clinicians 
should consider whether older patients with persistently raised inflammatory 
markers are reaching the end of life.  
 
 Qualitative study 
The qualitative research findings have important implications for clinical 
practice, and are relevant, not only for inflammatory marker testing but blood 
testing more widely. The lack of shared understanding is important, not only for 
the ideals of shared decision-making, but also for the more fundamental 
principles of informed consent. The General Medical Council (GMC) duties of a 
doctor state ‘you must give patients the information they want or need about the 
purpose of any proposed investigation’.(173) The fact that less than half of the 
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patients interviewed (11 out of 28) perceived that they knew the reason for 
testing is at odds with this.  
Shared understanding is not only important for informed consent, but also for 
doctors and patients to create meaning from the test results. Shared 
understanding and explanation are important, not only for patients with 
abnormal test results; patients in this study with normal test results also needed 
explanation and understanding of their test results. There are several potential 
harms from a lack of shared understanding. Firstly, if patients are offered a false 
promise of certainty from tests, they can feel frustrated, or even delegitimised by 
normal test results. Secondly by imbuing test results with too much weight, 
patients may be falsely reassured by normal results (exemplified by the 
statement from one patient that ‘obviously there’s no cancers going on’). If normal 
results are not accompanied with appropriate safety netting this could 
potentially delay appropriate health seeking. Future research into diagnostic 
tests should measure not only the diagnostic value of tests but also consider 
patient reported outcomes including cognitive, emotional, social and behavioural 
outcomes of testing.(274) 
Although doctors were concerned that sharing too much information could 
generate anxiety, patient interviews did not show any evidence for this; there 
was, however, evidence that a lack of information sharing could cause anxiety. 
Patients did not want to be overloaded with technical information or medical 
terminology about their tests, but they did want information in lay terms about 
why tests were being done, and what the results would mean for their health. 
Clinicians who proactively shared their expectations of tests before the results 
were available, were able to improve shared understanding of tests.  
Multiple barriers to shared understanding were identified. One of these was a 
perception from doctors that sharing information about tests was low priority 
and that patients did not want this information. The findings of this research 
challenge this assumption.  
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Systems of testing were a barrier to effective communication, and a lack of clear 
protocols for sharing test results made it challenging for patients to navigate 
these systems. These findings highlight the risks of clinicians assuming patients 
will proactively seek out their test results by making contact with the GP 
surgery. This is important because failures in test result communication, which 
are identified in this thesis, are a potential area for patient harm and litigation. 
Further research and quality improvement for systems of blood test 
communication is needed. This should engage key stakeholders including 
patients, doctors, and the wider healthcare team. Co-production methods could 
be used to collaboratively develop and improve test communication. This should 
include fail-safe mechanisms to ensure results are returned to patients to prevent 
harms.(275) It should also consider the importance of improving the experience 
of patients whose test results are normal. Whilst new opportunities such as text 
message systems, and online access to test results have potential to enhance 
communication, patients’ perspectives should be sought and potential for 
causing anxiety should be carefully considered.  
A lack of resources for information sharing was another barrier to 
communication. Future research is needed to generate resources and 
interventions to improve shared understanding of tests; these should be 
designed with input from both clinicians and patients.  
Time pressures within 10-minute GP consultation and GP workload were 
perceived to be barriers to improved communication. Although this is a potential 
challenge, previous studies have found that improved patient centred 
communication is associated with lower rates of diagnostic testing.(250) 
Improving the communication and shared understanding could therefore be 
important not only for patient satisfaction but could also potentially reduce 




 Synthesis and reflections 
The quantitative results from my thesis illustrate and quantify the complexity 
and uncertainty inherent in inflammatory marker testing. Far from providing the 
clear-cut answers which patients expect, these tests have modest diagnostic 
accuracy which can neither be used to rule-in nor rule-out, yet may offer ‘clues’ 
to possible serious diagnoses. This is very different to patients’ expectations and 
understanding of these tests as revealed by the qualitative component of this 
thesis. GPs are aware of the limitations of tests yet seem to be reluctant to share 
this with patients, with multiple barriers to shared understanding identified. 
Patients needed to understand the meaning of their results, in the context of their 
symptoms; without this ‘normal’ results did not always provide the reassurance 
that GPs were expecting. This is particularly important given that inflammatory 
markers are frequently used as a tool for ruling-out disease and reassuring 
patients.(2) The findings of this thesis contradict this - inflammatory markers do 
not have the necessary properties for a ‘rule-out’ test, nor do these tests, in 
themselves, provide reassurance to patients, without explanation and 
understanding. Inflammatory marker testing therefore has limited diagnostic 
utility and limited non-medical benefits for patients. Yet highlighting the 
limitations of tests does not mean that the tests have no place in clinical practice. 
My interviews with patients and GPs highlighted cases where doctors made 
carefully balanced clinical decisions to test and shared this with patients, 
consequently the test results helped clarify the diagnosis and provide patient 
satisfaction and reassurance. This demonstrates the importance of triangulation 
of qualitative and quantitative methodologies, to uncover the stories within the 
data, and the underlying meanings created from tests.  
The contradictions between patients’ expectation of tests and the reality of test 
result interpretation raise many unanswered questions. Given this complexity for 
a single test, to what extent is shared decision-making, for a battery of blood 
tests, possible? Can these uncertainties be meaningfully shared with patients 
within a 10-minute consultation, and ‘should’ they? Is shared decision-making 
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the ‘right’ model for decisions on testing, or is a different approach warranted? 
There is a tendency to assume that all shared decision-making is ‘good’, and all 
paternalism is ‘bad’, yet in my view the reality is more nuanced. Doctors have 
expertise and make decisions using clinical experience and intuition in the face of 
diagnostic ambiguity and uncertainty. Patients speak about ‘trusting’ their 
doctor to make the right decisions, and do not perceive blood testing to be an 
area where options are open to them. Shared decision-making requires sharing 
uncertainty, whereas patients generally perceive tests as a solution to resolving 
uncertainty.  
I had an opportunity to begin to explore some of these issues through meetings 
with my PPI group where I shared the findings of my quantitative and 
qualitative research. I summarised my quantitative results in a single infographic 
in the form of a modified cates plot, to demonstrate the outcomes of 
inflammatory marker testing outcomes in natural frequencies (see Figure 10). 
Participants in the meeting were surprised by the findings, which did not match 
their expectations and understandings of tests. Whilst they felt strongly that 
communication about testing should be improved, they were not strongly 
supportive of the principles of shared decision-making for blood tests and were 
unsure whether sharing information on the limitations of tests would be helpful 
for patients. In general, the PPI panel felt that they would value more 
information after their blood tests were done, rather than before. This highlights 
the risks of assuming that sharing decision-making is the ‘right’ thing to do, 
without exploring the consequences and patients’ perspectives.  
A range of different ideas for improving understanding of tests were explored: 
one suggestion from the PPI group was that posters in GP practices, similar to 
the ‘ask three questions’ campaign,(276) could help empower patients to find out 
about their blood tests. Patient information leaflets on blood tests were 
discussed; the PPI group highlighted that because these provide general 
information, they were unlikely to answer patients’ questions about the meaning 
of test results for their health, in the context of their symptoms. The PPI group 
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were much more interested in the idea of providing personalised written 
information at the end of a consultation, summarising briefly which tests had 
been requested and why, and how to obtain test results. I am currently engaging 
with colleagues in Bristol to explore how this could be incorporated into the 
Consultation Open And Closed (COAC) Study.(277)  
My own experiences as a clinician have been influenced strongly by my research 
into inflammatory marker testing, and I now only use these tests in a limited 
number of circumstances – most commonly for suspected polymyalgia. My 
communication with patients has also been strongly influenced by my qualitative 
research, yet despite my desire to improve communication of tests, I often find it 
challenging to achieve a shared understanding. I also often find myself reluctant 
to disabuse patients of the expectation that tests will provide clear-cut ‘answers’. 
I find myself using easy phrases when arranging tests like “we’ll make sure 
we’re not missing anything”, even though I know that this is over-optimistic. 
Changing the nature of these conversations is challenging, and further research 
and education is needed to try to improve communication and promote a shared 
understanding. I have made significant changes to the ways in which I share test 
results, and I make an effort to contact patients to discuss the meaning of their 
test results in the context of their symptoms.  
Overall, management of uncertainty seems to be the overarching theme 
highlighted by the interplay between the qualitative and quantitative aspects of 
this thesis; uncertainty as a reason for testing, uncertainty in interpreting test 
results, patient uncertainty as to why tests were done and how to get results 
back. Some of this uncertainty can be reduced by research and quality 
improvement, for example improving systems of test result communication 
could reduce patient uncertainty around test results. However, if patients are 
accustomed to the perception that blood tests will provide clear cut answers, 
then this research could also increase uncertainty for patients, by demonstrating 
that inflammatory markers, like all tests, lead to false positives and false 
negatives. Communicating this uncertainty is a fundamental challenge which has 
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relevance beyond the realm of diagnostic testing, indeed tolerating uncertainty 
was suggested by Simpkin and Schwartzstein as being ‘the next medical 
revolution’.(255) In the article they state ‘although physicians are rationally aware 
when uncertainty exists, the culture of medicine evinces a deep-rooted unwillingness to 
acknowledge and embrace it’.(255) This culture of medicine may in part underlie 




Since publication, the research presented in this thesis has generated significant 
interest and impact; with two papers(278, 279) published in the British Journal of 
General Practice (BJGP) reaching 5th and 3rd place respectively in the BJGP top-
10 research papers of 2019. Two GP education providers, NB Medical Education 
and Red Whale, included these papers in their popular GP Update courses and 
in the Red Whale’s ‘best of 2019’ webinar. Locally this was written up by the 
Applied Research Collaborative (ARC) West as a ‘BITE’ summary.(280) This 
generated significant interest from Bristol North Somerset and South 
Gloucestershire (BNSSG) Clinical Commissioning Group (CCG). I was invited to 
join the CCGs Clinical Pathology Group and as part of this group I developed an 
intervention to optimise inflammatory marker testing locally, using guidelines, 
educational outreach and popups built into the electronic test ordering systems. 
This allowed me to gain experience of implementation before my PhD had 
finished and build collaborations and networks with clinicians and 
commissioners. The intervention was iteratively developed following 
presentations and feedback at BNSSG GP membership forums, and nurse 
practitioner forums and was endorsed at CCG Locality Leadership Groups. A 
guideline for inflammatory marker testing was developed in collaboration with 
GPs from the Clinical Pathology Group and secondary care physicians from 
gastroenterology, haematology, care of the elderly and rheumatology across the 
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three local hospital trusts (see Appendix E). Pop-ups were implemented in the 
GP electronic test ordering systems with links to these guidelines on the CCG 
website (see Appendix F). Plasma viscosity and ESR were removed from the 
‘front screen’ of the electronic blood test ordering system, and a popup requiring 
clinicians to choose a valid indication for testing for PV and ESR was introduced, 
based on feedback from secondary care clinicians. If a valid indication was not 
chosen, the blood test automatically defaulted to CRP as first line test.  
These popups were implemented in January 2020, with a plan to use an 
interrupted time series analysis to measure the impact on rates of inflammatory 
marker testing. Unfortunately, the Covid-19 pandemic in March 2020 led to a 
near complete cessation of all primary care blood testing, which meant that the 
planned interrupted time series analysis was no longer possible, and a simple 
descriptive analysis showing rates of testing over time was presented to the CCG 
instead. However, the pandemic made my research on diagnostic testing very 
topical, leading to opportunities for dissemination and impact (see Box 1).   
 
Box 1: Wider impact - reflections on diagnostic research 
in the era of Covid-19 
During the final year of my Doctoral Research Fellowship the Covid-19 
pandemic hit the UK, and my interest in diagnostic test accuracy suddenly 
became highly topical. Very early in the Covid-19 pandemic I was concerned 
that the government and media portrayed Covid-19 PCR tests as offering clear-
cut binary answers, and that there was lack of clinical interpretation of test 
results. I discussed this with colleagues in the Royal College of General 
Practitioners (RCGP) Overdiagnosis Group, who shared my view that a 
Bayesian interpretation of tests was important. At this time, during the peak of 
the first wave, testing was very limited and was reserved for people in hospital 
with a high pre-test probability of disease, increasing the likelihood of false 
negative test results. I wrote a paper on interpreting a Covid-19 test in the 
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BMJ.(281) This paper has an Altmetric score of 4244 (17th highest Altmetric 
score for a BMJ article ever). I also wrote a companion piece for The 
Conversation,(282) recorded two podcasts on Covid-19 testing for the BMJ(283) 
and the RCGP,(284) and was interviewed for BBC Radio 4’s More or Less.(285) 
This led to a significant amount of media interest including coverage in BBC 
News, New Scientist, World Economic Forum, the Guardian and the Mail 
Online. The BMJ article has also been adapted for Science in School, the 
European journal for science teachers. I was subsequently asked by the BMJ to 
write a second follow up article on interpreting SARS-CoV-2 antibody 
tests.(286) More recently I have been invited to co-author an article on 
interpreting a lateral flow SARS-CoV-2 antigen test, which has been submitted 
to the BMJ and is currently under review.(287)  
The Covid-19 pandemic illustrated just how important and challenging it is to 
communicate the uncertainty inherent in all tests with patients and public. This 
has been particularly challenging within a social media culture which tends to 
polarise debates. I hope that the infographics and interactive tools which I 
helped develop for the BMJ articles are helpful for clinicians and researchers to 
communicate evidence on test accuracy to a lay audience, not only for COVID-
19 testing but also diagnostic testing more generally. I have adapted these 
infographics for this thesis to summarise evidence on inflammatory marker 
test accuracy (see Figure 10). This experience has helped me to move beyond 
my limited sphere as a researcher with expertise in inflammatory marker 
testing and develop my expertise in broader primary care diagnostic test 
accuracy research.  
 
 Conclusions 
The overall aim of this thesis was to explore the diagnostic utility and clinical 
practice of inflammatory marker testing in primary care, including how results 
are shared with patients.  
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My clinical experience and previous qualitative research helped me to frame 
research objectives of relevance to routine clinical practice, by examining the 
outcome of ‘any relevant disease’.  
The findings in this thesis will be of interest to primary care clinicians wanting to 
know when (and when not) to use inflammatory markers, how to interpret the 
results and how to communicate this with patients. I have shown that, contrary 
to GPs’ perceptions, these tests are not a useful ‘rule-out’ test, in fact they miss 
around half of relevant disease in primary care. Testing more than one 
inflammatory marker simultaneously does not increase diagnostic accuracy. 
Whilst not a useful rule-out test, a raised inflammatory marker should trigger 
consideration of a possible underlying malignancy. Although the tests are often 
used for reassurance, patients with ongoing symptoms perceived that normal 
results were unhelpful.  
As well as having important implications for primary care clinicians, the findings 
in this thesis will also be of interest to commissioners wanting to reduce 
unwarranted variation in testing. Whilst the costs of individual inflammatory 
marker tests are low, the additional follow up blood tests, GP appointments and 
referrals are costly. Simple measures such as avoiding using inflammatory 
markers as a non-specific rule-out, and avoiding the use of two simultaneous 
inflammatory markers, could reduce unnecessary testing. Authors of guidelines 
for investigating irritable bowel syndrome, tiredness and dementia should 
reconsider their recommendations to use inflammatory marker testing to ‘rule-
out’ any relevant disease.  
Finally, and most importantly, the findings in this thesis are significant for 
patients. The quantitative results of this thesis are important to help ensure 
patients get inflammatory marker tests done when they need them (and avoid 
them when they don’t). The qualitative results in this thesis identify barriers to 
communication and shared understanding of tests which is important for 
patients having blood testing in primary care. Further work is needed to move 
beyond identifying problems with test communication, towards developing 
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solutions. The issues raised in the qualitative component of this thesis are 
relevant not only to inflammatory marker tests, but to the wider context of blood 
test communication and shared understanding between health professionals and 
patients.  
At a more philosophical level, this work raises unanswered questions about 
shared decision-making and sharing uncertainty. Shared decision-making might 
be accepted as best practice, but it did not reflect the reality of doctors’ and 
patients’ accounts of testing. Patients expressed a desire, not for shared decision-
making, but for a shared understanding of tests. Uncertainty is a core part of 
medicine, and is especially relevant in primary care, yet this uncertainty is rarely 
shared openly with patients.  
My experience over the past five years of generating and exploring my own 
research questions has cemented my enthusiasm for a career in academic 
primary care. The methods used in this thesis will be relevant for exploring the 
use of other blood tests in primary care, and I hope will give me the grounding 









Inflammatory arthritis   Rheumatoid arthritis 
Seronegative arthritis, including ankylosing spondylitis, 
psoriatic arthritis and reactive arthritis 
Diseases of the endocrine system Type 1 diabetes mellitus  
Primary adrenocortical insufficiency (Addison’s disease) 
and other autoimmune polyglandular syndromes 
Polymyalgia rheumatica Including temporal arteritis, polymyalgia rheumatica 
and giant cell arteritis 
Vasculitis Including polyarteritis nodosa, Kawasaki, Churg-Strauss, 
thrombotic microangiopathy, Wegener’s 
granulomatosis, Henoch-Schoenlein purpura, allergic 
granulomatosis, Bechet’s, cryoglobulinaemic vasculitis, 
microscopic polyangiitis, granulomatosis with 
polyangiitis, eosinophilic granulomatosis with 
polyangiitis, necrotising arteritis, necrotising 
polyangiitis, chronic granulomatous arteritis, Takayasu’s 
arteritis 
Connective tissue disorders Systemic lupus erythematosus 
 Systemic sclerosis (scleroderma) 
 Polymyositis/dermatomyositis 
Sarcoidosis 
Diseases of digestive system Inflammatory bowel disease 
 Hepatobiliary diseases including primary biliary 
cirrhosis, primary sclerosing cholangitis, autoimmune 
hepatitis, autoimmune cholangitis, autoimmune 
pancreatitis.  
Diseases of the skin Including bullous skin diseases; pemphigus and 
pemphigoid  
Haematological diseases Including pernicious anaemia, autoimmune haemolytic 
anaemia, idiopathic thrombocytopenic purpura, 
antiphospholipid syndrome, immune neutropenia, 
acquired aplastic anaemia, paroxysmal nocturnal 
haemoglobinuria PNH, acquired haemophilia, 
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thrombotic thrombocytopenic purpura, cold agglutin 
disease  
Diseases of the cardiovascular system Including rheumatic heart disease, autoimmune 
cardiomyopathy, autoimmune myocarditis 
Diseases of the respiratory system Including idiopathic pulmonary fibrosis, cryptogenic 
organising pneumonia, bronchiolitis obliterans.  
Diseases of the renal system  Including nephrotic syndrome, IgA 
nephropathy/Berger’s disease, glomerulonephritis, SLE 
nephritis anti-glomerular basement membrane disease  
 
*Autoimmune thyroid disease, coeliac disease and psoriasis were excluded as it was felt to be clinically implausible 
that inflammatory markers would be used for diagnosis of these conditions, and because preliminary analysis showed 







Lower respiratory tract infections Including pneumonia, pulmonary TB, infective 
exacerbation COPD/asthma, empyema, lung abscess 
Bacterial upper respiratory Including mastoiditis, streptococcal pharyngitis, otitis media, 
tracheitis, tonsillitis, sinusitis 
Viral upper respiratory Including laryngitis, pharyngitis, influenza, common cold 
Lower urinary tract Urinary tract infections (excluding asymptomatic bacteriuria) 
Upper urinary tract Pyelonephritis 
Gastrointestinal Gastroenteritis, colitis, enteritis of likely bacterial origin 
Diverticulitis Bacterial infections of diverticular disease, diverticular abscess 
Peritoneal infection Including peritoneal abscess, peritonitis 
Hepatobiliary infections Hepatitis, liver abscess, cholecystitis, cholangitis, empyema of 
the gallbladder 
Bone infections Osteomyelitis, septic arthritis, pyogenic arthritis 
Muscle Including infective myositis, necrotising fasciitis, gas gangrene, 
muscle abscess 
Skin infections Cellulitis, erysipelas (excluding localised superficial infections) 
Genital infections Including pelvic inflammatory disease, salpingitis, endometritis, 
oophoritis, cervicitis, epididymitis, orchitis, prostatitis (excluding 
superficial infections e.g. vulvovaginitis, balanitis) 
Puerperal infections Including mastitis, endometritis, puerperal sepsis 
Cardiovascular infections Including endocarditis, myocarditis, pericarditis 
Neurological infections Including meningitis, encephalitis, cranial abscess 





Appendix B: ESR upper limit of normal  
 Men Women 
<40 11 14 
40-49 12 15 
50-59 14 17 
60-69 14 18 
70-79 20 22 
>80 20 23 
Derived using the CPRD mean upper limit of normal stratified by age and gender, rounded to the 




Appendix C: Topic guide 
Initial interview with patient participants 
Suggested flow / questions Suggested prompts, if needed 
1. Background. Can you tell me a bit about 
yourself? 
• Work life: What do you do for a 
living?  
• Home life: Who is at home with you? 
2. Blood test. What prompted you to book a 
blood test today? 
• Did a GP or nurse ask you to book a 
blood test?  
• Did you get a call or letter from the 
practice to book bloods? 
• Do you know why?  
2a. What prompted you to see your GP? 
(If blood tests requested following a GP 
appointment) 
• What were you expecting or hoping 
for from the GP appointment? 
• Were you hoping or expecting to 
have blood tests? 
2b. Do you know which chronic conditions 
are being monitored?  
(If blood tests being done for routine 
monitoring) 
• Do you know why? 
3: Blood tests. What do you know about the 
blood tests that your GP/nurse requested? 
• Do you know which blood tests you 
are having/have had?  
• Do you know what these blood tests 
can pick up? 
• If inflammatory markers mentioned, 
then probe further ‘what does 
‘inflammatory marker’ mean?’ 
4: Communication. What did your GP tell you 
about your blood tests? 
• Did they tell you why they wanted to 
do blood tests? 
• Did they give you any options or 
choices about testing? 
• Was the decision to test mostly your 
decision, mostly your GPs decision, or 
a shared decision?  
• Did they discuss any benefits or 
limitations of blood tests? 
• Did they tell you what the test results 
might show? 
• Did they explain how to get the 
results? 
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• Was there anything else about your 
blood tests that you wanted to 
know?  
• Any sources of information you use 
to get information about tests? 
5: Expectations. What do you expect will 
happen next? 
• Do you know how to get your test 
results? 
• Do you know when to get your test 
results? 
• How would you like to get your 
results? 
• What do you think your test results 
will tell you? 
• Do you think the test results will 
change anything for you? 
6: Phlebotomy appointment (if relevant). 
What was your experience of having your 
blood test done? 
• How easy or difficult was it for you to 
book an appointment? 
• How easy or difficult was it for you to 
have your blood test taken? 
• Did you discuss your blood tests with 
the phlebotomist/nurse who took the 
blood? 
7: Suggestions for improvement. Is there 
anything about your experience of blood 
testing which could be improved? 
• Any suggestions to help doctors and 
nurses communicate? 
• Any suggestions to help improve the 
systems? 
• Any suggestions for patients? 
8: Is there anything else about your blood 
tests you would like to say that we haven’t 
mentioned yet?  
 
Second interview with patients after blood test results available 
1. Have you received your test results? If no test results received: 
• How do you feel about that? 
• Do you know what happens next? 
• Would you be happy to reschedule a 
follow up interview? 
2. What was your experience of getting your 
test results? 
• How did you get your test results? 
(telephone, internet, face-to-face?) 
• Did the practice contact you, or did 
you call them?  
• Who gave you the test results? (GP, 
nurse, receptionist?) 
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• Do you know which blood tests you 
have had?  
• Were you given the test results in 
numbers or just told that they were 
raised or normal? 
• What explanation of the meaning of 
the test results did you receive? 
• If test results were abnormal – what 
further instructions were you given? 
(e.g., book appointment with GP, 
book repeat blood test) 
• Did you use any other sources of 
information to find out about your 
tests? (ego websites, discussions with 
friends or family) 
3. What did your blood test results mean for 
you? 
• Did the results change anything for 
you? 
• Do you know what the results mean 
for your health? 
• Do you know what happens next? 
4. Do you have any suggestions for how 
communication about testing could be 
improved? 
• What do you want to know about 
tests?   
• How do you want to receive 
information about tests? 
• Are there any resources you use to 
find out about tests? 
• Are there any resources you would 
like to have about tests? 
5. Is there anything else about your blood 




1. Background. Can you tell me a bit about 
yourself? 
• Years’ experience 
• Type of practice 
• Role in the practice 
(partner/salaried/locum) 
2. Patient background. Can you tell me 
what you remember about your 
consultation with patient X? 
• Why did they come to the doctors? 
• What do you think they were expecting? 
• What do you think they were worried 
about? 
3. Choice of test. What prompted you to • Why did you choose to check 
inflammatory markers? 
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check bloods on this patient? • What were you looking for? 
• How do you decide which bloods to 
check? 
4. What were your expectations of the 
tests? 
• What did you think the results would 
show? 
5. Test results. What did the test results 
show you? 
• Did they change your management? 
• What will you do next? 
6. Patient perspectives. What do you think 
the patient understands about testing? 
• Do you think that patient wanted tests 
done? 
• Was the decision to do tests mostly your 
decision, mostly the patients’ decision, or 
a shared decision? 
• Do you think the patient knows which 
tests were done? 
• What do you think the patient 
understands about the tests? 
• What do you think the patient expected 
from the tests? 
7. Communication around testing. What did 
you explain to the patient?  
• What did you explain to the patient 
about the blood tests you were doing and 
why? 
• How will/did you explain the test result? 
• How do you decide how much 
information to share with patients? 
• Are there any resources you use to 
explain tests to patients? 
• Is there anything which you would find 
useful to improve communication around 
blood testing?  
8. Systems of testing. How do systems of 
testing help or hinder communication 
with patients? 
• Any issues around how the test results 
are communicated to patients? 
(text/email/phone calls) 
• Any issues with communication between 
hospital/laboratory and primary care of 
test results? 
• Any suggestions for improvement to the 
systems of testing? 
9. Is there anything you would like to say 
that we haven’t mentioned yet? 
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Appendix D: Coding framework 
Number Name Description 
1 Background Background information about the patient or 
GP 
1.1 Personal Background information about the person 
being interviewed 
1.2 GP practice Information about the GP practice or practice 
area 
 
2 Why? Reasons for testing and expectations of tests 
2.1 Symptoms Where doctors or patients describe the 
symptoms which triggered testing, but not the 
diagnostic reasoning 
2.2 Co-morbidities Where doctors or patients describe the other 
pre-existing conditions, which might be linked 
to testing 
2.3 Diagnosis – specific Tests being done to check for a specific 
condition 
2.4 Diagnosis – general To check for a number of conditions or more 
general range of conditions (e.g., ‘infections’ 
or ‘autoimmune’) 
2.5 Screening or ‘fishing’ Tests done as a general ‘screen’ or ‘fishing’ 
without any particular diagnostic rationale  
2.6 Avoiding ‘missing 
something’ 
When doctors or patients express that they 
are testing to avoid ‘missing something’ (might 
be specific or general) or as a ‘rule-out’ or to 
make sure ‘everything’s ok’ 
2.7 Answers Expectations that tests will provide answers 
2.8 Magic Perceptions that tests are powerful, 
mysterious, or can ‘reveal’ something special 
2.9 Monitoring To monitor a known diagnosis or drug 
monitoring 
2.10 Secondary care driven Requests or perceived requests from 
secondary care 
2.11 Patient pressure Patient requests or perceived pressure from 
patients including where patient has had 
pressure from other sources (family/media for 
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example) 
2.12 Unknown/unsure If patient or doctor does not know or is not 
sure why the bloods have been requested or 
what to expect 
 
 
3 Which tests  
3.1 ‘Everything’ When patient express an expectation that 
bloods will provide a broad ‘screen’/’MOT’ or 
check most things.  
3.2 Inflammatory markers When inflammatory markers, CRP, plasma 
viscosity or ESR are mentioned specifically  
3.3 Other specific tests Include all specific named tests such as blood 
count, cholesterol, liver, kidney, vit D etc. 
3.4 ‘Batteries’ When doctors or patients mention groups of 
tests done together (differs from ‘everything’ 
as includes a combination of specific tests 
tailored to symptoms e.g., ‘tiredness screen’) 
3.5 Unknown/unsure When participants are not sure which tests are 
being done 
4 Phlebotomy 




Any description of the communication at the 
time of blood taking 
5 Test results  
5.1 All clear / normal Results described as ‘normal’ ‘satisfactory’ 
‘fine’ ‘OK’ 
5.2 Stable Results described as ‘stable’ or ‘unchanged’  
5.3 Borderline Results described as ‘slightly’ raised or 
‘borderline’ 
5.4 Abnormal Results described as ‘high’, ‘low’, ‘abnormal’  
5.5 Numbers Results described as actual numbers 
5.6 Written results When test results are printed or given in 
writing 
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5.7 Unknown/uncertain Results not known or unclear/uncertain 
5.8 Unexpected results Incidental or unexpected abnormalities in test 
results 
5.9 Meaning Explanations of what results mean in terms of 
a persons’ health 
 
6 Next steps:  
6.1 Repeat testing Repeating the same test(s) again 
6.2 Further testing Doing new/extra tests as follow on (either 
bloods or x-rays/scans etc.) 
6.3 Follow up GP appointment Seeing the GP for a face to face or telephone 
follow up 
6.4 Treatment Starting a new tablet/treatment/change in 
management 
6.5 Referral Referring onwards to hospital/another 
doctor/clinician 
6.6 Watchful waiting ‘keeping an eye’ on things, with an active plan 
of follow up 
6.7 No change in management When there are no planned next steps, or 
patient is continuing as before 
6.8  Unknown/uncertain Where doctor or patient is unclear, unsure or 
does not know what is supposed to happen 
next  
7 Knowledge/understanding 
7.1 Knowledge around testing Code under this heading what patients and 
doctors know about tests generally  
7.2 Lack of knowledge When doctors or patients discuss their lack of 
knowledge about tests 
7.3 Guesswork/tacit knowledge ‘I guess’ ‘I imagine’. Knowledge that people 
have ‘picked up’ through experience but not 
been taught 
7.4 Misinformation Any examples where patients make incorrect 
statements of knowledge or fact 
7.5 Inflammation Capture patient descriptions of what 
knowledge and understanding they have of 
the term ‘inflammation’ or ‘inflammatory 
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markers’ here 
7.6 Limitations of tests Where GPs or patients describe knowledge or 
understanding of the limitations of blood tests 
8 Communication   
8.1 Information sharing Discussions or descriptions of how doctors 
share information with patients 
8.2 Decision-making Discussions about how decisions are made – 
either shared decision-making or paternalistic 
or patient centered decisions 
8.3 Openness Perceived ‘openness’ of communication – how 
willing doctors are to communicate freely and 
openly with patients or perceived lack of open 
communication – including withholding 
information in order to ‘protect’ patients 
8.4 Medical jargon Use of medical jargon or medical terminology 
rather than using lay language 
8.5 Asking questions Where patients ask questions, or conversely 
where they describe finding it difficult to ask 
questions when communicating with doctors 
8.6 Information overload Where doctors or patients discuss challenges 
of getting too much information or getting 
confused or overloaded by information 
8.7 Not enough information Where doctors or patients discuss challenges 
of not receiving enough information from 
medical professionals about tests 
8.8 Retaining information Where doctors or patients discuss challenges 
of remembering what was said during a 
consultation or forget what they have been 
told 
   
Information 
9.1 Sources of information Where doctors or patients get information 
about tests, or where they would like to get 
information from 
9.2 Websites When people discuss using online sources of 
information  
9.3 Leaflets When people discuss using leaflets or written 
sources of information 
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9.4 Family/friends When people ask family or friends for 
information about testing 
9.5 Experience When people gain information about tests 
from previous experience 
   
10 Psychology of testing 
10.1 Anxiety Patient or doctor feelings of anxiety/worry or 
concern about testing or test results 
10.2 Reassurance Patient or doctor feelings of reassurance  
10.3 Uncertainty People expressing a feeling of uncertainty 
10.4 Trust Feeling of trust in doctor patient relationships 
10.5 Frustration Feeling of frustration, annoyance or even 
anger 
10.6 Guilt, internalised 
responsibility, blame 
Feelings of guilt or blame or feeling 
responsible or that you ‘should have’ done 
something 
10.7 Disappointment Feelings of disappointment, for example that 
tests have not fulfilled expectations 
   
11 Systems of testing – How? Any discussion of the systems around test 
ordering and methods test communication 
11.1 Text messages Any discussion of the use of texts as a system 
for communicating results 
11.2 Online results Any discussion of patient access to results 
online or via email 
11.3 Phone calls Any discussion of using telephone calls as a 
system for communicating 
11.4 Face to face When a patient gets test results face to face 
from a clinician 
11.4 Unclear systems Discussions where there seems to be a lack of 
clarity or uncertainty about how to get test 
results 
11.5 Assumptions Systems which assume that things will happen, 
or assume that someone else is taking 
responsibility for test communication 
11.6 Patient records How discussions are recorded in the patient 
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records/GPs relationship with the patient 
records 
11.7 Electronic test ordering 
systems 
Any discussions of the electronic (‘ICE’) test 
ordering systems 
   
12 Who? Discussion about who communicates test 
results or information about testing 
12.1 Doctors When doctors communicate results to 
patients 
12.2 Receptionists When results are communicated via 
receptionists or admin staff 
12.3 Nurses/AHPs When test results or information about tests 
comes from nurses, health care assistants or 
any other members of the health care team 
12.4 Practice initiated 
communication 
Where the practice or clinical team proactively 
contact the patient to inform them of the test 
results 
12.5 Patient initiated 
communication 
Where the patient contacts the GP practice to 
obtain their results 
   
13 Wider system issues Discussions about systems issues which are 
not specific to testing 
13.1 Time pressure Discussions about consultation length or time 
pressures  
13.2 Access When challenges with accessing primary care 
are mentioned (e.g., difficulty getting an 
appointment or getting through on telephone) 
13.3 Primary-secondary care 
interface 
Systems of interface between primary and 
secondary care 
13.4 Continuity Discussions about continuity of care – seeing 
the same GP or same clinician 
13.5 Other? Need to see if other systems issues are arising 
in other interviews? 
   
14 Patient engagement  
14.1 Active/engaged Patients who are active, engaged, want to 
understand and be involved in decisions about 
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their care 
14.2 Passive Patients who are passive, prefer to trust their 
doctor, don’t feel that they can be involved in 
decisions about their care 
   
Other  Assorted – these were added in an iterative 
way during the course of the analysis as 
frequently occurring themes which were not 
adequately covered elsewhere 
15.1 Unanswered questions Where patients have unanswered questions 
about their tests or about their medical issues 
which have not been addressed 
15.2 Ongoing symptoms Where patients describe ongoing symptoms, 
which persist after testing 
15.3 Waiting  Discussions of the experience of waiting for 
test results to come back 
15.4 Study impact Any examples where patient or GPs seem to 
have been influenced by their participation in 
the study 
15.5 Imagery Use this code to capture any interesting 
imagery/metaphors/powerful quotes that 




Appendix E: BNSSG Inflammatory Marker Testing Guideline 
Available at:  https://remedy.bnssgccg.nhs.uk/adults/investigations/inflammatory-marker-
testing/  
 
Inflammatory markers are not useful in primary care as ‘rule-out’ tests.(1)  For every 1000 
inflammatory marker tests done there are 236 false positives, which leads to 710 GP 
appointments, 229 blood test appointments and 24 referrals in the following six months.  
 
What do we recommend?  
• Usually only one inflammatory marker test should be used.  
• CRP should be the first line test in most circumstances (see table).  
• Second line inflammatory markers differ across BNSSG; ESR is offered in Weston 
and UHBristol, plasma viscosity (PV) is offered by NBT. These should only be used 
for suspected temporal arteritis, as a second line test for polymyalgia rheumatica, for 
persistent bone pain in the over 60s or following secondary care request (see table 
below). 
• Avoid using inflammatory markers for screening or as a rule-out for patients with non-
specific symptoms. 
 
Which test should be used?  
Clinical question CRP ESR* PV* Comments 
Screening 
asymptomatic patients 
   Unlikely to be useful. False positives 
common and may generate 
increased workload.  
To ‘rule-out’ significant 
underlying disease in 
patients with non-
specific symptoms e.g. 
tiredness 
   Inflammatory markers have low 
sensitivity and are therefore 
unsuitable as a rule-out test. False 
positives are common and may 
generate increased workload. (1) A 
small minority of patients with 
persistent tiredness will require 
referral to secondary care chronic 
fatigue/ME services and 
inflammatory markers are currently 
recommended prior to referral. 
Could this patient have 
a significant infection? 
   May be useful although not always 
necessary if symptoms and signs are 
clear cut. Point of care testing (if 
available) may reduce antibiotic 
prescribing in respiratory tract 
infections.(48)  
Is this infection 
responding to antibiotic 
Little 
use 
  For the vast majority of infections, 
repeat CRP testing is not indicated 
and assessment should be made on 
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Clinical question CRP ESR* PV* Comments 
treatment? clinical grounds. Monitoring of CRP 
may be useful is some chronic 
infections (e.g. osteomyelitis (4)) 






CRP recommended first line. If CRP 
is normal and symptoms highly 
suggestive ESR or PV* should be 
added as a second line test.  
Does this patient have 
giant cell arteritis? 
   Both CRP and ESR/PV* are 
warranted – due to risks of serious 
complications if diagnosis is delayed.  





  A normal inflammatory marker is not 
a rule-out test. Calprotectin should 
be used first line if inflammatory 
bowel disease is suspected. 
What is the cause of 
this/these inflamed 
joints? 
    CRP is useful for secondary care 
triage of rheumatology referrals. 
However, normal inflammatory 
markers are not a rule-out; if clinical 
suspicion of inflammatory arthritis 
refer regardless of CRP results.  
What is the cause of 
this patients raised 
platelets? 
   British Society for Haematology 
recommends peripheral blood smear, 
CRP and iron studies as first line 
tests to investigate thrombocytosis. 
Raised CRP suggests reactive 
thrombocytosis, due to underlying 
inflammatory or malignant cause.(5) 
Could this patient aged 
>60 with persistent 




   NICE recommend FBC, calcium and 
PV or ESR, to screen for potential 
underlying pathology including 
myeloma.(6, 7) If a raised 
inflammatory marker is detected then 
request a myeloma screen (see 
below).  
Does this patient have 
myeloma? 
     If you suspect myeloma please order 
serum protein electrophoresis and 
urinary free light chains (Bence 
Jones protein) or serum free light 
chains, plus FBC, U+E, creatinine 
and calcium.  
Monitoring of 
polymyalgia rheumatica 
   Inflammatory markers are useful 
when tapering steroids. CRP is 
generally more sensitive than ESR or 
PV. No need to routinely test both 
simultaneously. 
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Clinical question CRP ESR* PV* Comments 
Monitoring DMARDs    Inflammatory markers are not part of 
shared care protocols for DMARDs. 
Ask patients at each DMARD review 
if a) if they have a specialist out-
patient appointment before the next 
routine blood test b) if their 
symptoms have flared such that they 
are needing to contact their GP or 
specialist team. Only do a CRP if the 
answer is yes to either one. 
Blood tests prior to 
rheumatology 
secondary care review 
   CRPs are useful in monitoring 
disease activity, and are needed to 
allow the specialists to calculate the 
disease activity score. They are 
therefore needed before each 
specialist review, but are 
unnecessary to monitor safety of 
medication on routine reviews, 
whether or not the dose has recently 
been changed. 
Is this symptomatic 
patient with 
inflammatory arthritis or 
inflammatory bowel 
disease experiencing a 
flare?  
   Raised inflammatory markers may be 
useful in confirming a disease flare 
and guiding appropriate 
management. 
(*Weston and UHBristol offer ESR as a second line test; NBT offers plasma viscosity 
(PV)) 
 
How do I interpret a raised inflammatory marker in primary care?  
Interpretation should be relatively straightforward if there is a clear pretest hypothesis against which 
the test result can be evaluated. The difficulty lies in the interpretation of an ‘incidental’ abnormality, 
when no specific disease is suspected. A systems inquiry, focusing on infection, autoimmune 
conditions, and malignancy, plus examination of the patient should generally point towards specific 
investigations.(8) If no obvious source can be found the test should be repeated. Men over 50 and 
women over 60 with persistently raised inflammatory markers have a cancer risk which exceeds the 
3% NICE threshold for urgent investigation.(9) However inflammatory markers have a low sensitivity 
at <50%, so they are not recommended as a test to rule in or out the possibility of cancer in those 
with non-specific symptoms. 
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Appendix F: Popups implemented in BNSSG electronic test 
ordering systems 
 
ESR GP popup 
Please select an indication for the ESR. A CRP will be requested where these indications are not 
met. For further details see: 
<https://remedy.bnssgccg.nhs.uk/adults/investigations/inflammatory-marker-testing/> 
GP ESR Indications 
Please select an indication from the list below: 
(drop down) 
Temporal arteritis/giant cell arteritis 
Polymyalgia rheumatica (second line testing) 
Persistent bone pain/unexplained fracture in >60yo 
Requirement from secondary care 
None of the above. A CRP will be requested 
 
Plasma viscosity GP popup 
Please select an indication for the plasma viscosity. A CRP will be requested where these 
indications are not met. For further details see: 
<https://remedy.bnssgccg.nhs.uk/adults/investigations/inflammatory-marker-testing/> 
GP plasma viscosity Indications 
Please select an indication from the list below: 
(drop down) 
Temporal arteritis/giant cell arteritis 
Polymyalgia rheumatica (second line testing) 
Persistent bone pain/unexplained fracture in >60yo 
Requirement from secondary care 
None of the above. A CRP will be requested 
 
GP CRP popup 
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